6	STRIBILD.xml:S1:4:1	O
ADVERSE	STRIBILD.xml:S1:6:7	O
REACTIONS	STRIBILD.xml:S1:14:9	O

The	STRIBILD.xml:S1:27:3	O
following	STRIBILD.xml:S1:31:9	O
adverse	STRIBILD.xml:S1:41:7	O
drug	STRIBILD.xml:S1:49:4	O
reactions	STRIBILD.xml:S1:54:9	O
are	STRIBILD.xml:S1:64:3	O
discussed	STRIBILD.xml:S1:68:9	O
in	STRIBILD.xml:S1:78:2	O
other	STRIBILD.xml:S1:81:5	O
sections	STRIBILD.xml:S1:87:8	O
of	STRIBILD.xml:S1:96:2	O
the	STRIBILD.xml:S1:99:3	O
labeling	STRIBILD.xml:S1:103:8	O
:	STRIBILD.xml:S1:111:1	O

Lactic	STRIBILD.xml:S1:120:6	B-AdverseReaction
Acidosis	STRIBILD.xml:S1:127:8	I-AdverseReaction
Severe	STRIBILD.xml:S1:136:6	B-Severity
Hepatomegaly	STRIBILD.xml:S1:143:12	B-AdverseReaction
with	STRIBILD.xml:S1:156:4	O
Steatosis	STRIBILD.xml:S1:161:9	B-AdverseReaction
[	STRIBILD.xml:S1:171:1	O
see	STRIBILD.xml:S1:172:3	O
Boxed	STRIBILD.xml:S1:177:5	O
Warning	STRIBILD.xml:S1:183:7	O
,	STRIBILD.xml:S1:192:1	O
Warnings	STRIBILD.xml:S1:195:8	O
and	STRIBILD.xml:S1:204:3	O
Precautions	STRIBILD.xml:S1:208:11	O
(	STRIBILD.xml:S1:220:1	O
5.1	STRIBILD.xml:S1:221:3	O
)	STRIBILD.xml:S1:224:1	O
]	STRIBILD.xml:S1:227:1	O
.	STRIBILD.xml:S1:229:1	O

Severe	STRIBILD.xml:S1:236:6	B-Severity
Acute	STRIBILD.xml:S1:243:5	B-AdverseReaction
Exacerbations	STRIBILD.xml:S1:249:13	I-AdverseReaction
of	STRIBILD.xml:S1:263:2	I-AdverseReaction
Hepatitis	STRIBILD.xml:S1:266:9	I-AdverseReaction
B	STRIBILD.xml:S1:276:1	I-AdverseReaction
[	STRIBILD.xml:S1:278:1	O
see	STRIBILD.xml:S1:279:3	O
Boxed	STRIBILD.xml:S1:284:5	O
Warning	STRIBILD.xml:S1:290:7	O
,	STRIBILD.xml:S1:299:1	O
Warnings	STRIBILD.xml:S1:302:8	O
and	STRIBILD.xml:S1:311:3	O
Precautions	STRIBILD.xml:S1:315:11	O
(	STRIBILD.xml:S1:327:1	O
5.2	STRIBILD.xml:S1:328:3	O
)	STRIBILD.xml:S1:331:1	O
]	STRIBILD.xml:S1:334:1	O
.	STRIBILD.xml:S1:336:1	O

New	STRIBILD.xml:S1:343:3	B-AdverseReaction
Onset	STRIBILD.xml:S1:347:5	I-AdverseReaction
or	STRIBILD.xml:S1:353:2	O
Worsening	STRIBILD.xml:S1:356:9	B-AdverseReaction
Renal	STRIBILD.xml:S1:366:5	I-AdverseReaction
Impairment	STRIBILD.xml:S1:372:10	I-AdverseReaction
[	STRIBILD.xml:S1:383:1	O
see	STRIBILD.xml:S1:384:3	O
Warnings	STRIBILD.xml:S1:389:8	O
and	STRIBILD.xml:S1:398:3	O
Precautions	STRIBILD.xml:S1:402:11	O
(	STRIBILD.xml:S1:414:1	O
5.3	STRIBILD.xml:S1:415:3	O
)	STRIBILD.xml:S1:418:1	O
]	STRIBILD.xml:S1:421:1	O
.	STRIBILD.xml:S1:423:1	O

Bone	STRIBILD.xml:S1:430:4	B-AdverseReaction
Effects	STRIBILD.xml:S1:435:7	I-AdverseReaction
of	STRIBILD.xml:S1:443:2	O
Tenofovir	STRIBILD.xml:S1:446:9	O
DF	STRIBILD.xml:S1:456:2	O
[	STRIBILD.xml:S1:459:1	O
see	STRIBILD.xml:S1:460:3	O
Warnings	STRIBILD.xml:S1:465:8	O
and	STRIBILD.xml:S1:474:3	O
Precautions	STRIBILD.xml:S1:478:11	O
(	STRIBILD.xml:S1:490:1	O
5.6	STRIBILD.xml:S1:491:3	O
)	STRIBILD.xml:S1:494:1	O
]	STRIBILD.xml:S1:497:1	O
.	STRIBILD.xml:S1:499:1	O

Immune	STRIBILD.xml:S1:506:6	B-AdverseReaction
Reconstitution	STRIBILD.xml:S1:513:14	I-AdverseReaction
Syndrome	STRIBILD.xml:S1:528:8	I-AdverseReaction
[	STRIBILD.xml:S1:537:1	O
see	STRIBILD.xml:S1:538:3	O
Warnings	STRIBILD.xml:S1:543:8	O
and	STRIBILD.xml:S1:552:3	O
Precautions	STRIBILD.xml:S1:556:11	O
(	STRIBILD.xml:S1:568:1	O
5.8	STRIBILD.xml:S1:569:3	O
)	STRIBILD.xml:S1:572:1	O
]	STRIBILD.xml:S1:575:1	O
.	STRIBILD.xml:S1:577:1	O

EXCERPT	STRIBILD.xml:S1:586:7	O
:	STRIBILD.xml:S1:593:1	O
Most	STRIBILD.xml:S1:597:4	O
common	STRIBILD.xml:S1:602:6	O
adverse	STRIBILD.xml:S1:609:7	O
drug	STRIBILD.xml:S1:617:4	O
reactions	STRIBILD.xml:S1:622:9	O
to	STRIBILD.xml:S1:632:2	O
STRIBILD	STRIBILD.xml:S1:635:8	O
(	STRIBILD.xml:S1:644:1	O
incidence	STRIBILD.xml:S1:645:9	O
greater	STRIBILD.xml:S1:655:7	O
than	STRIBILD.xml:S1:663:4	O
or	STRIBILD.xml:S1:668:2	O
equal	STRIBILD.xml:S1:671:5	O
to	STRIBILD.xml:S1:677:2	O
10%	STRIBILD.xml:S1:680:3	O
,	STRIBILD.xml:S1:683:1	O
all	STRIBILD.xml:S1:685:3	O
grades	STRIBILD.xml:S1:689:6	O
)	STRIBILD.xml:S1:695:1	O
are	STRIBILD.xml:S1:697:3	O
nausea	STRIBILD.xml:S1:701:6	B-AdverseReaction
and	STRIBILD.xml:S1:708:3	O
diarrhea	STRIBILD.xml:S1:712:8	B-AdverseReaction
.	STRIBILD.xml:S1:720:1	O

(	STRIBILD.xml:S1:722:1	O
6.1	STRIBILD.xml:S1:725:3	O
)	STRIBILD.xml:S1:730:1	O

To	STRIBILD.xml:S1:738:2	O

report	STRIBILD.xml:S1:741:6	O
SUSPECTED	STRIBILD.xml:S1:748:9	O
ADVERSE	STRIBILD.xml:S1:758:7	O
REACTIONS	STRIBILD.xml:S1:766:9	O
,	STRIBILD.xml:S1:775:1	O
contact	STRIBILD.xml:S1:777:7	O
Gilead	STRIBILD.xml:S1:785:6	O
Sciences	STRIBILD.xml:S1:792:8	O
,	STRIBILD.xml:S1:800:1	O
Inc	STRIBILD.xml:S1:802:3	O
.	STRIBILD.xml:S1:805:1	O

at	STRIBILD.xml:S1:807:2	O
1	STRIBILD.xml:S1:810:1	O
-	STRIBILD.xml:S1:811:1	O
800	STRIBILD.xml:S1:812:3	O
-	STRIBILD.xml:S1:815:1	O
GILEAD	STRIBILD.xml:S1:816:6	O
-	STRIBILD.xml:S1:822:1	O
5	STRIBILD.xml:S1:823:1	O
or	STRIBILD.xml:S1:825:2	O
FDA	STRIBILD.xml:S1:828:3	O
at	STRIBILD.xml:S1:832:2	O
1	STRIBILD.xml:S1:835:1	O
-	STRIBILD.xml:S1:836:1	O
800	STRIBILD.xml:S1:837:3	O
-	STRIBILD.xml:S1:840:1	O
FDA	STRIBILD.xml:S1:841:3	O
-	STRIBILD.xml:S1:844:1	O
1088	STRIBILD.xml:S1:845:4	O
or	STRIBILD.xml:S1:850:2	O
www	STRIBILD.xml:S1:853:3	O
.	STRIBILD.xml:S1:856:1	O
fda	STRIBILD.xml:S1:857:3	O
.	STRIBILD.xml:S1:860:1	O
gov	STRIBILD.xml:S1:861:3	O
medwatch	STRIBILD.xml:S1:865:8	O
.	STRIBILD.xml:S1:873:1	O

6.1	STRIBILD.xml:S1:885:3	O

Adverse	STRIBILD.xml:S1:889:7	O
Reactions	STRIBILD.xml:S1:897:9	O
from	STRIBILD.xml:S1:907:4	O
Clinical	STRIBILD.xml:S1:912:8	O
Trials	STRIBILD.xml:S1:921:6	O
Experience	STRIBILD.xml:S1:928:10	O

Because	STRIBILD.xml:S1:942:7	O
clinical	STRIBILD.xml:S1:950:8	O
trials	STRIBILD.xml:S1:959:6	O
are	STRIBILD.xml:S1:966:3	O
conducted	STRIBILD.xml:S1:970:9	O
under	STRIBILD.xml:S1:980:5	O
widely	STRIBILD.xml:S1:986:6	O
varying	STRIBILD.xml:S1:993:7	O
conditions	STRIBILD.xml:S1:1001:10	O
,	STRIBILD.xml:S1:1011:1	O
adverse	STRIBILD.xml:S1:1013:7	O
reaction	STRIBILD.xml:S1:1021:8	O
rates	STRIBILD.xml:S1:1030:5	O
observed	STRIBILD.xml:S1:1036:8	O
in	STRIBILD.xml:S1:1045:2	O
the	STRIBILD.xml:S1:1048:3	O
clinical	STRIBILD.xml:S1:1052:8	O
trials	STRIBILD.xml:S1:1061:6	O
of	STRIBILD.xml:S1:1068:2	O
a	STRIBILD.xml:S1:1071:1	O
drug	STRIBILD.xml:S1:1073:4	O
cannot	STRIBILD.xml:S1:1078:6	O
be	STRIBILD.xml:S1:1085:2	O
directly	STRIBILD.xml:S1:1088:8	O
compared	STRIBILD.xml:S1:1097:8	O
to	STRIBILD.xml:S1:1106:2	O
rates	STRIBILD.xml:S1:1109:5	O
in	STRIBILD.xml:S1:1115:2	O
the	STRIBILD.xml:S1:1118:3	O
clinical	STRIBILD.xml:S1:1122:8	O
trials	STRIBILD.xml:S1:1131:6	O
of	STRIBILD.xml:S1:1138:2	O
another	STRIBILD.xml:S1:1141:7	O
drug	STRIBILD.xml:S1:1149:4	O
and	STRIBILD.xml:S1:1154:3	O
may	STRIBILD.xml:S1:1158:3	O
not	STRIBILD.xml:S1:1162:3	O
reflect	STRIBILD.xml:S1:1166:7	O
the	STRIBILD.xml:S1:1174:3	O
rates	STRIBILD.xml:S1:1178:5	O
observed	STRIBILD.xml:S1:1184:8	O
in	STRIBILD.xml:S1:1193:2	O
practice	STRIBILD.xml:S1:1196:8	O
.	STRIBILD.xml:S1:1204:1	O

In	STRIBILD.xml:S1:1214:2	O
HIV	STRIBILD.xml:S1:1217:3	O
-	STRIBILD.xml:S1:1220:1	O
1	STRIBILD.xml:S1:1221:1	O
-	STRIBILD.xml:S1:1222:1	O
Infected	STRIBILD.xml:S1:1223:8	O
Subjects	STRIBILD.xml:S1:1232:8	O
With	STRIBILD.xml:S1:1241:4	O
No	STRIBILD.xml:S1:1246:2	O
Antiretroviral	STRIBILD.xml:S1:1249:14	O
Treatment	STRIBILD.xml:S1:1264:9	O
History	STRIBILD.xml:S1:1274:7	O

The	STRIBILD.xml:S1:1288:3	O
safety	STRIBILD.xml:S1:1292:6	O
assessment	STRIBILD.xml:S1:1299:10	O
of	STRIBILD.xml:S1:1310:2	O
STRIBILD	STRIBILD.xml:S1:1313:8	O
is	STRIBILD.xml:S1:1322:2	O
based	STRIBILD.xml:S1:1325:5	O
on	STRIBILD.xml:S1:1331:2	O
the	STRIBILD.xml:S1:1334:3	O
Week	STRIBILD.xml:S1:1338:4	O
144	STRIBILD.xml:S1:1343:3	O
pooled	STRIBILD.xml:S1:1347:6	O
data	STRIBILD.xml:S1:1354:4	O
from	STRIBILD.xml:S1:1359:4	O
1408	STRIBILD.xml:S1:1364:4	O
subjects	STRIBILD.xml:S1:1369:8	O
in	STRIBILD.xml:S1:1378:2	O
two	STRIBILD.xml:S1:1381:3	O
randomized	STRIBILD.xml:S1:1385:10	O
,	STRIBILD.xml:S1:1395:1	O
double	STRIBILD.xml:S1:1397:6	O
-	STRIBILD.xml:S1:1403:1	O
blind	STRIBILD.xml:S1:1404:5	O
,	STRIBILD.xml:S1:1409:1	O
active	STRIBILD.xml:S1:1411:6	O
-	STRIBILD.xml:S1:1417:1	O
controlled	STRIBILD.xml:S1:1418:10	O
clinical	STRIBILD.xml:S1:1429:8	O
trials	STRIBILD.xml:S1:1438:6	O
,	STRIBILD.xml:S1:1444:1	O
Study	STRIBILD.xml:S1:1446:5	O
102	STRIBILD.xml:S1:1452:3	O
and	STRIBILD.xml:S1:1456:3	O
Study	STRIBILD.xml:S1:1460:5	O
103	STRIBILD.xml:S1:1466:3	O
,	STRIBILD.xml:S1:1469:1	O
in	STRIBILD.xml:S1:1471:2	O
antiretroviral	STRIBILD.xml:S1:1474:14	O
treatment	STRIBILD.xml:S1:1489:9	O
-	STRIBILD.xml:S1:1498:1	O
naive	STRIBILD.xml:S1:1499:5	O
HIV	STRIBILD.xml:S1:1505:3	O
-	STRIBILD.xml:S1:1508:1	O
1	STRIBILD.xml:S1:1509:1	O
infected	STRIBILD.xml:S1:1511:8	O
adult	STRIBILD.xml:S1:1520:5	O
subjects	STRIBILD.xml:S1:1526:8	O
[	STRIBILD.xml:S1:1536:1	O
see	STRIBILD.xml:S1:1537:3	O
Clinical	STRIBILD.xml:S1:1542:8	O
Studies	STRIBILD.xml:S1:1551:7	O
(	STRIBILD.xml:S1:1559:1	O
14	STRIBILD.xml:S1:1560:2	O
)	STRIBILD.xml:S1:1562:1	O
]	STRIBILD.xml:S1:1565:1	O
.	STRIBILD.xml:S1:1566:1	O

A	STRIBILD.xml:S1:1569:1	O
total	STRIBILD.xml:S1:1571:5	O
of	STRIBILD.xml:S1:1577:2	O
701	STRIBILD.xml:S1:1580:3	O
subjects	STRIBILD.xml:S1:1584:8	O
received	STRIBILD.xml:S1:1593:8	O
STRIBILD	STRIBILD.xml:S1:1602:8	O
once	STRIBILD.xml:S1:1611:4	O
daily	STRIBILD.xml:S1:1616:5	O
in	STRIBILD.xml:S1:1622:2	O
these	STRIBILD.xml:S1:1625:5	O
two	STRIBILD.xml:S1:1631:3	O
studies	STRIBILD.xml:S1:1635:7	O
.	STRIBILD.xml:S1:1642:1	O

The	STRIBILD.xml:S1:1648:3	O
proportion	STRIBILD.xml:S1:1652:10	O
of	STRIBILD.xml:S1:1663:2	O
subjects	STRIBILD.xml:S1:1666:8	O
who	STRIBILD.xml:S1:1675:3	O
discontinued	STRIBILD.xml:S1:1679:12	O
treatment	STRIBILD.xml:S1:1692:9	O
with	STRIBILD.xml:S1:1702:4	O
STRIBILD	STRIBILD.xml:S1:1707:8	O
(	STRIBILD.xml:S1:1716:1	O
elvitegravir	STRIBILD.xml:S1:1717:12	O
150	STRIBILD.xml:S1:1730:3	O
mg	STRIBILD.xml:S1:1734:2	O
cobicistat	STRIBILD.xml:S1:1737:10	O
150	STRIBILD.xml:S1:1748:3	O
mg	STRIBILD.xml:S1:1752:2	O
emtricitabine	STRIBILD.xml:S1:1755:13	O
200	STRIBILD.xml:S1:1769:3	O
mg	STRIBILD.xml:S1:1773:2	O
tenofovir	STRIBILD.xml:S1:1776:9	O
DF	STRIBILD.xml:S1:1786:2	O
300	STRIBILD.xml:S1:1789:3	O
mg	STRIBILD.xml:S1:1793:2	O
)	STRIBILD.xml:S1:1795:1	O
;	STRIBILD.xml:S1:1796:1	O
ATRIPLA	STRIBILD.xml:S1:1798:7	O
(	STRIBILD.xml:S1:1806:1	O
efavirenz	STRIBILD.xml:S1:1807:9	O
600	STRIBILD.xml:S1:1817:3	O
mg	STRIBILD.xml:S1:1821:2	O
emtricitabine	STRIBILD.xml:S1:1824:13	O
200	STRIBILD.xml:S1:1838:3	O
mg	STRIBILD.xml:S1:1842:2	O
tenofovir	STRIBILD.xml:S1:1845:9	O
DF	STRIBILD.xml:S1:1855:2	O
300	STRIBILD.xml:S1:1858:3	O
mg	STRIBILD.xml:S1:1862:2	O
)	STRIBILD.xml:S1:1864:1	O
;	STRIBILD.xml:S1:1865:1	O
or	STRIBILD.xml:S1:1867:2	O
atazanavir	STRIBILD.xml:S1:1870:10	O
(	STRIBILD.xml:S1:1881:1	O
ATV	STRIBILD.xml:S1:1882:3	O
)	STRIBILD.xml:S1:1885:1	O
ritonavir	STRIBILD.xml:S1:1889:9	O
(	STRIBILD.xml:S1:1899:1	O
RTV	STRIBILD.xml:S1:1900:3	O
)	STRIBILD.xml:S1:1903:1	O
TRUVADA	STRIBILD.xml:S1:1907:7	O
(	STRIBILD.xml:S1:1915:1	O
emtricitabine	STRIBILD.xml:S1:1916:13	O
200	STRIBILD.xml:S1:1930:3	O
mg	STRIBILD.xml:S1:1934:2	O
tenofovir	STRIBILD.xml:S1:1937:9	O
DF	STRIBILD.xml:S1:1947:2	O
300	STRIBILD.xml:S1:1950:3	O
mg	STRIBILD.xml:S1:1954:2	O
)	STRIBILD.xml:S1:1956:1	O
due	STRIBILD.xml:S1:1958:3	O
to	STRIBILD.xml:S1:1962:2	O
adverse	STRIBILD.xml:S1:1965:7	O
events	STRIBILD.xml:S1:1973:6	O
,	STRIBILD.xml:S1:1979:1	O
regardless	STRIBILD.xml:S1:1981:10	O
of	STRIBILD.xml:S1:1992:2	O
severity	STRIBILD.xml:S1:1995:8	O
,	STRIBILD.xml:S1:2003:1	O
was	STRIBILD.xml:S1:2005:3	O
6.0%	STRIBILD.xml:S1:2009:4	O
,	STRIBILD.xml:S1:2013:1	O
7.4%	STRIBILD.xml:S1:2015:4	O
and	STRIBILD.xml:S1:2020:3	O
8.5%	STRIBILD.xml:S1:2024:4	O
,	STRIBILD.xml:S1:2028:1	O
respectively	STRIBILD.xml:S1:2030:12	O
.	STRIBILD.xml:S1:2042:1	O

Table	STRIBILD.xml:S1:2044:5	O
2	STRIBILD.xml:S1:2050:1	O
displays	STRIBILD.xml:S1:2052:8	O
the	STRIBILD.xml:S1:2061:3	O
frequency	STRIBILD.xml:S1:2065:9	O
of	STRIBILD.xml:S1:2075:2	O
adverse	STRIBILD.xml:S1:2078:7	O
drug	STRIBILD.xml:S1:2086:4	O
reactions	STRIBILD.xml:S1:2091:9	O
greater	STRIBILD.xml:S1:2101:7	O
than	STRIBILD.xml:S1:2109:4	O
or	STRIBILD.xml:S1:2114:2	O
equal	STRIBILD.xml:S1:2117:5	O
to	STRIBILD.xml:S1:2123:2	O
5%	STRIBILD.xml:S1:2126:2	O
of	STRIBILD.xml:S1:2129:2	O
subjects	STRIBILD.xml:S1:2132:8	O
in	STRIBILD.xml:S1:2141:2	O
any	STRIBILD.xml:S1:2144:3	O
treatment	STRIBILD.xml:S1:2148:9	O
arm	STRIBILD.xml:S1:2158:3	O
.	STRIBILD.xml:S1:2161:1	O

Table	STRIBILD.xml:S1:2167:5	O
2	STRIBILD.xml:S1:2173:1	O
Adverse	STRIBILD.xml:S1:2175:7	O
Drug	STRIBILD.xml:S1:2183:4	O
ReactionsFrequencies	STRIBILD.xml:S1:2188:20	O
of	STRIBILD.xml:S1:2209:2	O
adverse	STRIBILD.xml:S1:2212:7	O
reactions	STRIBILD.xml:S1:2220:9	O
are	STRIBILD.xml:S1:2230:3	O
based	STRIBILD.xml:S1:2234:5	O
on	STRIBILD.xml:S1:2240:2	O
all	STRIBILD.xml:S1:2243:3	O
treatment	STRIBILD.xml:S1:2247:9	O
-	STRIBILD.xml:S1:2256:1	O
emergent	STRIBILD.xml:S1:2257:8	O
adverse	STRIBILD.xml:S1:2266:7	O
events	STRIBILD.xml:S1:2274:6	O
,	STRIBILD.xml:S1:2280:1	O
attributed	STRIBILD.xml:S1:2282:10	O
to	STRIBILD.xml:S1:2293:2	O
study	STRIBILD.xml:S1:2296:5	O
drugs	STRIBILD.xml:S1:2302:5	O
.	STRIBILD.xml:S1:2307:1	O

(	STRIBILD.xml:S1:2309:1	O
all	STRIBILD.xml:S1:2310:3	O
grades	STRIBILD.xml:S1:2314:6	O
)	STRIBILD.xml:S1:2320:1	O
Reported	STRIBILD.xml:S1:2322:8	O
in	STRIBILD.xml:S1:2331:2	O
5%	STRIBILD.xml:S1:2337:2	O
of	STRIBILD.xml:S1:2340:2	O
Subjects	STRIBILD.xml:S1:2343:8	O
in	STRIBILD.xml:S1:2352:2	O
Any	STRIBILD.xml:S1:2355:3	O
Treatment	STRIBILD.xml:S1:2359:9	O
Arm	STRIBILD.xml:S1:2369:3	O
in	STRIBILD.xml:S1:2373:2	O
Studies	STRIBILD.xml:S1:2376:7	O
102	STRIBILD.xml:S1:2384:3	O
and	STRIBILD.xml:S1:2388:3	O
103	STRIBILD.xml:S1:2392:3	O
(	STRIBILD.xml:S1:2396:1	O
Week	STRIBILD.xml:S1:2397:4	O
144	STRIBILD.xml:S1:2402:3	O
analysis	STRIBILD.xml:S1:2406:8	O
)	STRIBILD.xml:S1:2414:1	O
.	STRIBILD.xml:S1:2415:1	O

STRIBILDN	STRIBILD.xml:S1:2472:9	O
701	STRIBILD.xml:S1:2482:3	O
ATRIPLAN	STRIBILD.xml:S1:2491:8	O
352	STRIBILD.xml:S1:2500:3	O
ATV	STRIBILD.xml:S1:2508:3	O
RTV	STRIBILD.xml:S1:2514:3	O
TRUVADAN	STRIBILD.xml:S1:2520:8	O
355	STRIBILD.xml:S1:2529:3	O

EYE	STRIBILD.xml:S1:2540:3	O

DISORDERS	STRIBILD.xml:S1:2544:9	O

Ocular	STRIBILD.xml:S1:2653:6	B-AdverseReaction
icterus	STRIBILD.xml:S1:2660:7	I-AdverseReaction
1%	STRIBILD.xml:S1:2710:2	O
0%	STRIBILD.xml:S1:2728:2	O
13%	STRIBILD.xml:S1:2747:3	O

GASTROINTESTINAL	STRIBILD.xml:S1:2762:16	O
DISORDERS	STRIBILD.xml:S1:2779:9	O

Diarrhea	STRIBILD.xml:S1:2875:8	B-AdverseReaction
12%	STRIBILD.xml:S1:2931:3	O
11%	STRIBILD.xml:S1:2950:3	O
17%	STRIBILD.xml:S1:2969:3	O

Flatulence	STRIBILD.xml:S1:2986:10	B-AdverseReaction
2%	STRIBILD.xml:S1:3042:2	O
1%	STRIBILD.xml:S1:3062:2	O
8%	STRIBILD.xml:S1:3080:2	O

Nausea	STRIBILD.xml:S1:3097:6	B-AdverseReaction
16%	STRIBILD.xml:S1:3153:3	O
9%	STRIBILD.xml:S1:3172:2	O
14%	STRIBILD.xml:S1:3191:3	O

GENERAL	STRIBILD.xml:S1:3206:7	O
DISORDERS	STRIBILD.xml:S1:3214:9	O
AND	STRIBILD.xml:S1:3224:3	O
ADMINISTRATION	STRIBILD.xml:S1:3228:14	O
SITE	STRIBILD.xml:S1:3243:4	O
CONDITIONS	STRIBILD.xml:S1:3248:10	O

Fatigue	STRIBILD.xml:S1:3322:7	B-AdverseReaction
4%	STRIBILD.xml:S1:3378:2	O
8%	STRIBILD.xml:S1:3397:2	O
6%	STRIBILD.xml:S1:3416:2	O

HEPATOBILIARY	STRIBILD.xml:S1:3431:13	O
DISORDERS	STRIBILD.xml:S1:3445:9	O

Jaundice	STRIBILD.xml:S1:3544:8	B-AdverseReaction
0%	STRIBILD.xml:S1:3600:2	O
1%	STRIBILD.xml:S1:3620:2	O
9%	STRIBILD.xml:S1:3638:2	O

NERVOUS	STRIBILD.xml:S1:3653:7	O
SYSTEM	STRIBILD.xml:S1:3661:6	O
DISORDERS	STRIBILD.xml:S1:3668:9	O

Somnolence	STRIBILD.xml:S1:3766:10	B-AdverseReaction
1%	STRIBILD.xml:S1:3822:2	O
7%	STRIBILD.xml:S1:3841:2	O
1%	STRIBILD.xml:S1:3860:2	O

Headache	STRIBILD.xml:S1:3877:8	B-AdverseReaction
7%	STRIBILD.xml:S1:3933:2	O
4%	STRIBILD.xml:S1:3952:2	O
6%	STRIBILD.xml:S1:3971:2	O

Dizziness	STRIBILD.xml:S1:3988:9	B-AdverseReaction
3%	STRIBILD.xml:S1:4044:2	O
21%	STRIBILD.xml:S1:4063:3	O
5%	STRIBILD.xml:S1:4082:2	O

PSYCHIATRIC	STRIBILD.xml:S1:4097:11	O
DISORDERS	STRIBILD.xml:S1:4109:9	O

Insomnia	STRIBILD.xml:S1:4210:8	B-AdverseReaction
3%	STRIBILD.xml:S1:4266:2	O
9%	STRIBILD.xml:S1:4285:2	O
1%	STRIBILD.xml:S1:4304:2	O

Abnormal	STRIBILD.xml:S1:4321:8	B-AdverseReaction
dreams	STRIBILD.xml:S1:4330:6	I-AdverseReaction
9%	STRIBILD.xml:S1:4377:2	O
27%	STRIBILD.xml:S1:4396:3	O
4%	STRIBILD.xml:S1:4415:2	O

SKIN	STRIBILD.xml:S1:4430:4	O
AND	STRIBILD.xml:S1:4435:3	O
SUBCUTANEOUS	STRIBILD.xml:S1:4439:12	O
TISSUE	STRIBILD.xml:S1:4452:6	O
DISORDERS	STRIBILD.xml:S1:4459:9	O

Rash	STRIBILD.xml:S1:4543:4	B-AdverseReaction
4%	STRIBILD.xml:S1:4599:2	O
15%	STRIBILD.xml:S1:4618:3	O
6%	STRIBILD.xml:S1:4637:2	O

See	STRIBILD.xml:S1:4661:3	O
Warnings	STRIBILD.xml:S1:4668:8	O
and	STRIBILD.xml:S1:4677:3	O
Precautions	STRIBILD.xml:S1:4681:11	O
(	STRIBILD.xml:S1:4693:1	O
5.3	STRIBILD.xml:S1:4694:3	O
)	STRIBILD.xml:S1:4697:1	O
,	STRIBILD.xml:S1:4702:1	O
for	STRIBILD.xml:S1:4704:3	O
a	STRIBILD.xml:S1:4708:1	O
discussion	STRIBILD.xml:S1:4710:10	O
of	STRIBILD.xml:S1:4721:2	O
renal	STRIBILD.xml:S1:4724:5	B-AdverseReaction
adverse	STRIBILD.xml:S1:4730:7	I-AdverseReaction
reactions	STRIBILD.xml:S1:4738:9	I-AdverseReaction
from	STRIBILD.xml:S1:4748:4	O
clinical	STRIBILD.xml:S1:4753:8	O
trials	STRIBILD.xml:S1:4762:6	O
experience	STRIBILD.xml:S1:4769:10	O
with	STRIBILD.xml:S1:4780:4	O
STRIBILD	STRIBILD.xml:S1:4785:8	O
.	STRIBILD.xml:S1:4793:1	O

Additional	STRIBILD.xml:S1:4799:10	O

adverse	STRIBILD.xml:S1:4810:7	O
drug	STRIBILD.xml:S1:4818:4	O
reactions	STRIBILD.xml:S1:4823:9	O
observed	STRIBILD.xml:S1:4833:8	O
with	STRIBILD.xml:S1:4842:4	O
STRIBILD	STRIBILD.xml:S1:4847:8	O
included	STRIBILD.xml:S1:4856:8	O
suicidal	STRIBILD.xml:S1:4865:8	B-AdverseReaction
ideation	STRIBILD.xml:S1:4874:8	I-AdverseReaction
and	STRIBILD.xml:S1:4883:3	O
suicide	STRIBILD.xml:S1:4887:7	B-AdverseReaction
attempt	STRIBILD.xml:S1:4895:7	I-AdverseReaction
(	STRIBILD.xml:S1:4903:1	O
0.3%	STRIBILD.xml:S1:4904:4	O
)	STRIBILD.xml:S1:4908:1	O
,	STRIBILD.xml:S1:4909:1	O
all	STRIBILD.xml:S1:4911:3	O
in	STRIBILD.xml:S1:4915:2	O
subjects	STRIBILD.xml:S1:4918:8	O
with	STRIBILD.xml:S1:4927:4	O
a	STRIBILD.xml:S1:4932:1	O
pre	STRIBILD.xml:S1:4934:3	O
-	STRIBILD.xml:S1:4937:1	O
existing	STRIBILD.xml:S1:4938:8	O
history	STRIBILD.xml:S1:4947:7	O
of	STRIBILD.xml:S1:4955:2	O
depression	STRIBILD.xml:S1:4958:10	O
or	STRIBILD.xml:S1:4969:2	O
psychiatric	STRIBILD.xml:S1:4972:11	O
illness	STRIBILD.xml:S1:4984:7	O
.	STRIBILD.xml:S1:4991:1	O

In	STRIBILD.xml:S1:5001:2	O
Virologically	STRIBILD.xml:S1:5004:13	O
-	STRIBILD.xml:S1:5017:1	O
Suppressed	STRIBILD.xml:S1:5018:10	O
HIV	STRIBILD.xml:S1:5029:3	O
-	STRIBILD.xml:S1:5032:1	O
1	STRIBILD.xml:S1:5033:1	O
-	STRIBILD.xml:S1:5034:1	O
Infected	STRIBILD.xml:S1:5035:8	O
Subjects	STRIBILD.xml:S1:5044:8	O

No	STRIBILD.xml:S1:5059:2	O
new	STRIBILD.xml:S1:5062:3	O
adverse	STRIBILD.xml:S1:5066:7	O
reactions	STRIBILD.xml:S1:5074:9	O
to	STRIBILD.xml:S1:5084:2	O
STRIBILD	STRIBILD.xml:S1:5087:8	O
through	STRIBILD.xml:S1:5096:7	O
Week	STRIBILD.xml:S1:5104:4	O
48	STRIBILD.xml:S1:5109:2	O
were	STRIBILD.xml:S1:5112:4	O
identified	STRIBILD.xml:S1:5117:10	O
in	STRIBILD.xml:S1:5128:2	O
584	STRIBILD.xml:S1:5131:3	O
virologically	STRIBILD.xml:S1:5135:13	O
stably	STRIBILD.xml:S1:5149:6	O
suppressed	STRIBILD.xml:S1:5156:10	O
subjects	STRIBILD.xml:S1:5167:8	O
switching	STRIBILD.xml:S1:5176:9	O
to	STRIBILD.xml:S1:5186:2	O
STRIBILD	STRIBILD.xml:S1:5189:8	O
from	STRIBILD.xml:S1:5198:4	O
a	STRIBILD.xml:S1:5203:1	O
regimen	STRIBILD.xml:S1:5205:7	O
containing	STRIBILD.xml:S1:5213:10	O
a	STRIBILD.xml:S1:5224:1	O
RTV	STRIBILD.xml:S1:5226:3	O
-	STRIBILD.xml:S1:5229:1	O
boosted	STRIBILD.xml:S1:5230:7	O
protease	STRIBILD.xml:S1:5238:8	O
inhibitor	STRIBILD.xml:S1:5247:9	O
(	STRIBILD.xml:S1:5257:1	O
PI	STRIBILD.xml:S1:5258:2	O
)	STRIBILD.xml:S1:5260:1	O
or	STRIBILD.xml:S1:5262:2	O
a	STRIBILD.xml:S1:5265:1	O
non	STRIBILD.xml:S1:5267:3	O
-	STRIBILD.xml:S1:5270:1	O
nucleoside	STRIBILD.xml:S1:5271:10	O
reverse	STRIBILD.xml:S1:5282:7	O
transcriptase	STRIBILD.xml:S1:5290:13	O
inhibitor	STRIBILD.xml:S1:5304:9	O
(	STRIBILD.xml:S1:5314:1	O
NNRTI	STRIBILD.xml:S1:5315:5	O
)	STRIBILD.xml:S1:5320:1	O
.	STRIBILD.xml:S1:5321:1	O

In	STRIBILD.xml:S1:5323:2	O
a	STRIBILD.xml:S1:5326:1	O
combined	STRIBILD.xml:S1:5328:8	O
analysis	STRIBILD.xml:S1:5337:8	O
of	STRIBILD.xml:S1:5346:2	O
Studies	STRIBILD.xml:S1:5349:7	O
115	STRIBILD.xml:S1:5357:3	O
and	STRIBILD.xml:S1:5361:3	O
121	STRIBILD.xml:S1:5365:3	O
,	STRIBILD.xml:S1:5368:1	O
the	STRIBILD.xml:S1:5370:3	O
frequency	STRIBILD.xml:S1:5374:9	O
of	STRIBILD.xml:S1:5384:2	O
adverse	STRIBILD.xml:S1:5387:7	O
reactions	STRIBILD.xml:S1:5395:9	O
(	STRIBILD.xml:S1:5405:1	O
all	STRIBILD.xml:S1:5406:3	O
grades	STRIBILD.xml:S1:5410:6	O
)	STRIBILD.xml:S1:5416:1	O
was	STRIBILD.xml:S1:5418:3	O
24%	STRIBILD.xml:S1:5422:3	O
in	STRIBILD.xml:S1:5426:2	O
subjects	STRIBILD.xml:S1:5429:8	O
switching	STRIBILD.xml:S1:5438:9	O
to	STRIBILD.xml:S1:5448:2	O
STRIBILD	STRIBILD.xml:S1:5451:8	O
compared	STRIBILD.xml:S1:5460:8	O
to	STRIBILD.xml:S1:5469:2	O
6%	STRIBILD.xml:S1:5472:2	O
of	STRIBILD.xml:S1:5475:2	O
subjects	STRIBILD.xml:S1:5478:8	O
in	STRIBILD.xml:S1:5487:2	O
either	STRIBILD.xml:S1:5490:6	O
group	STRIBILD.xml:S1:5497:5	O
who	STRIBILD.xml:S1:5503:3	O
stayed	STRIBILD.xml:S1:5507:6	O
on	STRIBILD.xml:S1:5514:2	O
their	STRIBILD.xml:S1:5517:5	O
baseline	STRIBILD.xml:S1:5523:8	O
antiretroviral	STRIBILD.xml:S1:5532:14	O
regimen	STRIBILD.xml:S1:5547:7	O
,	STRIBILD.xml:S1:5554:1	O
RTV	STRIBILD.xml:S1:5556:3	O
-	STRIBILD.xml:S1:5559:1	O
boosted	STRIBILD.xml:S1:5560:7	O
PI	STRIBILD.xml:S1:5568:2	O
TRUVADA	STRIBILD.xml:S1:5573:7	O
or	STRIBILD.xml:S1:5581:2	O
NNRTI	STRIBILD.xml:S1:5584:5	O
TRUVADA	STRIBILD.xml:S1:5592:7	O
.	STRIBILD.xml:S1:5599:1	O

Common	STRIBILD.xml:S1:5601:6	O
adverse	STRIBILD.xml:S1:5608:7	O
reactions	STRIBILD.xml:S1:5616:9	O
that	STRIBILD.xml:S1:5626:4	O
occurred	STRIBILD.xml:S1:5631:8	O
in	STRIBILD.xml:S1:5640:2	O
greater	STRIBILD.xml:S1:5643:7	O
than	STRIBILD.xml:S1:5651:4	O
or	STRIBILD.xml:S1:5656:2	O
equal	STRIBILD.xml:S1:5659:5	O
to	STRIBILD.xml:S1:5665:2	O
2%	STRIBILD.xml:S1:5668:2	O
of	STRIBILD.xml:S1:5671:2	O
subjects	STRIBILD.xml:S1:5674:8	O
switching	STRIBILD.xml:S1:5683:9	O
to	STRIBILD.xml:S1:5693:2	O
STRIBILD	STRIBILD.xml:S1:5696:8	O
were	STRIBILD.xml:S1:5705:4	O
nausea	STRIBILD.xml:S1:5710:6	B-AdverseReaction
(	STRIBILD.xml:S1:5717:1	O
4%	STRIBILD.xml:S1:5718:2	O
)	STRIBILD.xml:S1:5720:1	O
,	STRIBILD.xml:S1:5721:1	O
flatulence	STRIBILD.xml:S1:5723:10	B-AdverseReaction
(	STRIBILD.xml:S1:5734:1	O
2%	STRIBILD.xml:S1:5735:2	O
)	STRIBILD.xml:S1:5737:1	O
,	STRIBILD.xml:S1:5738:1	O
and	STRIBILD.xml:S1:5740:3	O
headache	STRIBILD.xml:S1:5744:8	B-AdverseReaction
(	STRIBILD.xml:S1:5753:1	O
2%	STRIBILD.xml:S1:5754:2	O
)	STRIBILD.xml:S1:5756:1	O
.	STRIBILD.xml:S1:5757:1	O

The	STRIBILD.xml:S1:5759:3	O
proportion	STRIBILD.xml:S1:5763:10	O
of	STRIBILD.xml:S1:5774:2	O
subjects	STRIBILD.xml:S1:5777:8	O
who	STRIBILD.xml:S1:5786:3	O
discontinued	STRIBILD.xml:S1:5790:12	O
treatment	STRIBILD.xml:S1:5803:9	O
with	STRIBILD.xml:S1:5813:4	O
STRIBILD	STRIBILD.xml:S1:5818:8	O
,	STRIBILD.xml:S1:5826:1	O
the	STRIBILD.xml:S1:5828:3	O
RTV	STRIBILD.xml:S1:5832:3	O
-	STRIBILD.xml:S1:5835:1	O
boosted	STRIBILD.xml:S1:5836:7	O
PI	STRIBILD.xml:S1:5844:2	O
,	STRIBILD.xml:S1:5846:1	O
or	STRIBILD.xml:S1:5848:2	O
the	STRIBILD.xml:S1:5851:3	O
NNRTI	STRIBILD.xml:S1:5855:5	O
due	STRIBILD.xml:S1:5861:3	O
to	STRIBILD.xml:S1:5865:2	O
adverse	STRIBILD.xml:S1:5868:7	O
events	STRIBILD.xml:S1:5876:6	O
,	STRIBILD.xml:S1:5882:1	O
was	STRIBILD.xml:S1:5884:3	O
2%	STRIBILD.xml:S1:5888:2	O
,	STRIBILD.xml:S1:5890:1	O
3%	STRIBILD.xml:S1:5892:2	O
and	STRIBILD.xml:S1:5895:3	O
1%	STRIBILD.xml:S1:5899:2	O
,	STRIBILD.xml:S1:5901:1	O
respectively	STRIBILD.xml:S1:5903:12	O
.	STRIBILD.xml:S1:5915:1	O

Adverse	STRIBILD.xml:S1:5925:7	O
Reactions	STRIBILD.xml:S1:5933:9	O
from	STRIBILD.xml:S1:5943:4	O
Clinical	STRIBILD.xml:S1:5948:8	O
Trials	STRIBILD.xml:S1:5957:6	O
of	STRIBILD.xml:S1:5964:2	O
the	STRIBILD.xml:S1:5967:3	O
Components	STRIBILD.xml:S1:5971:10	O
of	STRIBILD.xml:S1:5982:2	O
STRIBILD	STRIBILD.xml:S1:5985:8	O

Emtricitabine	STRIBILD.xml:S1:6004:13	O
and	STRIBILD.xml:S1:6018:3	O
Tenofovir	STRIBILD.xml:S1:6022:9	O
Disoproxil	STRIBILD.xml:S1:6032:10	O
Fumarate	STRIBILD.xml:S1:6043:8	O
:	STRIBILD.xml:S1:6051:1	O
In	STRIBILD.xml:S1:6054:2	O
addition	STRIBILD.xml:S1:6057:8	O
to	STRIBILD.xml:S1:6066:2	O
the	STRIBILD.xml:S1:6069:3	O
adverse	STRIBILD.xml:S1:6073:7	O
reactions	STRIBILD.xml:S1:6081:9	O
observed	STRIBILD.xml:S1:6091:8	O
with	STRIBILD.xml:S1:6100:4	O
STRIBILD	STRIBILD.xml:S1:6105:8	O
,	STRIBILD.xml:S1:6113:1	O
the	STRIBILD.xml:S1:6115:3	O
following	STRIBILD.xml:S1:6119:9	O
adverse	STRIBILD.xml:S1:6129:7	O
reactions	STRIBILD.xml:S1:6137:9	O
occurred	STRIBILD.xml:S1:6147:8	O
in	STRIBILD.xml:S1:6156:2	O
at	STRIBILD.xml:S1:6159:2	O
least	STRIBILD.xml:S1:6162:5	O
5%	STRIBILD.xml:S1:6168:2	O
of	STRIBILD.xml:S1:6171:2	O
treatment	STRIBILD.xml:S1:6174:9	O
-	STRIBILD.xml:S1:6183:1	O
experienced	STRIBILD.xml:S1:6184:11	O
or	STRIBILD.xml:S1:6196:2	O
treatment	STRIBILD.xml:S1:6199:9	O
-	STRIBILD.xml:S1:6208:1	O
naive	STRIBILD.xml:S1:6209:5	O
subjects	STRIBILD.xml:S1:6215:8	O
receiving	STRIBILD.xml:S1:6224:9	O
emtricitabine	STRIBILD.xml:S1:6234:13	O
or	STRIBILD.xml:S1:6248:2	O
tenofovir	STRIBILD.xml:S1:6251:9	O
DF	STRIBILD.xml:S1:6261:2	O
with	STRIBILD.xml:S1:6264:4	O
other	STRIBILD.xml:S1:6269:5	O
antiretroviral	STRIBILD.xml:S1:6275:14	O
agents	STRIBILD.xml:S1:6290:6	O
in	STRIBILD.xml:S1:6297:2	O
other	STRIBILD.xml:S1:6300:5	O
clinical	STRIBILD.xml:S1:6306:8	O
trials	STRIBILD.xml:S1:6315:6	O
:	STRIBILD.xml:S1:6321:1	O
depression	STRIBILD.xml:S1:6323:10	B-AdverseReaction
,	STRIBILD.xml:S1:6333:1	O
abdominal	STRIBILD.xml:S1:6335:9	B-AdverseReaction
pain	STRIBILD.xml:S1:6345:4	I-AdverseReaction
,	STRIBILD.xml:S1:6349:1	O
dyspepsia	STRIBILD.xml:S1:6351:9	B-AdverseReaction
,	STRIBILD.xml:S1:6360:1	O
vomiting	STRIBILD.xml:S1:6362:8	B-AdverseReaction
,	STRIBILD.xml:S1:6370:1	O
fever	STRIBILD.xml:S1:6372:5	B-AdverseReaction
,	STRIBILD.xml:S1:6377:1	O
pain	STRIBILD.xml:S1:6379:4	B-AdverseReaction
,	STRIBILD.xml:S1:6383:1	O
nasopharyngitis	STRIBILD.xml:S1:6385:15	B-AdverseReaction
,	STRIBILD.xml:S1:6400:1	O
pneumonia	STRIBILD.xml:S1:6402:9	B-AdverseReaction
,	STRIBILD.xml:S1:6411:1	O
sinusitis	STRIBILD.xml:S1:6413:9	B-AdverseReaction
,	STRIBILD.xml:S1:6422:1	O
upper	STRIBILD.xml:S1:6424:5	B-AdverseReaction
respiratory	STRIBILD.xml:S1:6430:11	I-AdverseReaction
tract	STRIBILD.xml:S1:6442:5	I-AdverseReaction
infection	STRIBILD.xml:S1:6448:9	I-AdverseReaction
,	STRIBILD.xml:S1:6457:1	O
arthralgia	STRIBILD.xml:S1:6459:10	B-AdverseReaction
,	STRIBILD.xml:S1:6469:1	O
back	STRIBILD.xml:S1:6471:4	B-AdverseReaction
pain	STRIBILD.xml:S1:6476:4	I-AdverseReaction
,	STRIBILD.xml:S1:6480:1	O
myalgia	STRIBILD.xml:S1:6482:7	B-AdverseReaction
,	STRIBILD.xml:S1:6489:1	O
paresthesia	STRIBILD.xml:S1:6491:11	B-AdverseReaction
,	STRIBILD.xml:S1:6502:1	O
peripheral	STRIBILD.xml:S1:6504:10	B-AdverseReaction
neuropathy	STRIBILD.xml:S1:6515:10	I-AdverseReaction
(	STRIBILD.xml:S1:6526:1	O
including	STRIBILD.xml:S1:6527:9	O
peripheral	STRIBILD.xml:S1:6537:10	B-AdverseReaction
neuritis	STRIBILD.xml:S1:6548:8	I-AdverseReaction
and	STRIBILD.xml:S1:6557:3	O
neuropathy	STRIBILD.xml:S1:6561:10	I-AdverseReaction
)	STRIBILD.xml:S1:6571:1	O
,	STRIBILD.xml:S1:6572:1	O
anxiety	STRIBILD.xml:S1:6574:7	B-AdverseReaction
,	STRIBILD.xml:S1:6581:1	O
increased	STRIBILD.xml:S1:6583:9	B-AdverseReaction
cough	STRIBILD.xml:S1:6593:5	I-AdverseReaction
,	STRIBILD.xml:S1:6598:1	O
and	STRIBILD.xml:S1:6600:3	O
rhinitis	STRIBILD.xml:S1:6604:8	B-AdverseReaction
.	STRIBILD.xml:S1:6612:1	O

Skin	STRIBILD.xml:S1:6618:4	B-AdverseReaction
discoloration	STRIBILD.xml:S1:6623:13	I-AdverseReaction
has	STRIBILD.xml:S1:6637:3	O
been	STRIBILD.xml:S1:6641:4	O
reported	STRIBILD.xml:S1:6646:8	O
with	STRIBILD.xml:S1:6655:4	O
higher	STRIBILD.xml:S1:6660:6	O
frequency	STRIBILD.xml:S1:6667:9	O
among	STRIBILD.xml:S1:6677:5	O
emtricitabine	STRIBILD.xml:S1:6683:13	O
-	STRIBILD.xml:S1:6696:1	O
treated	STRIBILD.xml:S1:6697:7	O
subjects	STRIBILD.xml:S1:6705:8	O
;	STRIBILD.xml:S1:6713:1	O
it	STRIBILD.xml:S1:6715:2	O
was	STRIBILD.xml:S1:6718:3	O
manifested	STRIBILD.xml:S1:6722:10	O
by	STRIBILD.xml:S1:6733:2	O
hyperpigmentation	STRIBILD.xml:S1:6736:17	B-AdverseReaction
on	STRIBILD.xml:S1:6754:2	I-AdverseReaction
the	STRIBILD.xml:S1:6757:3	I-AdverseReaction
palms	STRIBILD.xml:S1:6761:5	I-AdverseReaction
and	STRIBILD.xml:S1:6767:3	O
or	STRIBILD.xml:S1:6771:2	O
soles	STRIBILD.xml:S1:6774:5	I-AdverseReaction
and	STRIBILD.xml:S1:6780:3	O
was	STRIBILD.xml:S1:6784:3	O
generally	STRIBILD.xml:S1:6788:9	O
mild	STRIBILD.xml:S1:6798:4	B-Severity
and	STRIBILD.xml:S1:6803:3	O
asymptomatic	STRIBILD.xml:S1:6807:12	O
.	STRIBILD.xml:S1:6819:1	O

The	STRIBILD.xml:S1:6821:3	O
mechanism	STRIBILD.xml:S1:6825:9	O
and	STRIBILD.xml:S1:6835:3	O
clinical	STRIBILD.xml:S1:6839:8	O
significance	STRIBILD.xml:S1:6848:12	O
are	STRIBILD.xml:S1:6861:3	O
unknown	STRIBILD.xml:S1:6865:7	O
.	STRIBILD.xml:S1:6872:1	O

Laboratory	STRIBILD.xml:S1:6882:10	O
Abnormalities	STRIBILD.xml:S1:6893:13	O

The	STRIBILD.xml:S1:6913:3	O
frequency	STRIBILD.xml:S1:6917:9	O
of	STRIBILD.xml:S1:6927:2	O
laboratory	STRIBILD.xml:S1:6930:10	O
abnormalities	STRIBILD.xml:S1:6941:13	O
(	STRIBILD.xml:S1:6955:1	O
Grades	STRIBILD.xml:S1:6956:6	O
3	STRIBILD.xml:S1:6963:1	O
-	STRIBILD.xml:S1:6964:1	O
4	STRIBILD.xml:S1:6965:1	O
)	STRIBILD.xml:S1:6966:1	O
occurring	STRIBILD.xml:S1:6968:9	O
in	STRIBILD.xml:S1:6978:2	O
at	STRIBILD.xml:S1:6981:2	O
least	STRIBILD.xml:S1:6984:5	O
2%	STRIBILD.xml:S1:6990:2	O
of	STRIBILD.xml:S1:6993:2	O
subjects	STRIBILD.xml:S1:6996:8	O
receiving	STRIBILD.xml:S1:7005:9	O
STRIBILD	STRIBILD.xml:S1:7015:8	O
in	STRIBILD.xml:S1:7024:2	O
Studies	STRIBILD.xml:S1:7027:7	O
102	STRIBILD.xml:S1:7035:3	O
and	STRIBILD.xml:S1:7039:3	O
103	STRIBILD.xml:S1:7043:3	O
are	STRIBILD.xml:S1:7047:3	O
presented	STRIBILD.xml:S1:7051:9	O
in	STRIBILD.xml:S1:7061:2	O
Table	STRIBILD.xml:S1:7064:5	O
3	STRIBILD.xml:S1:7070:1	O
.	STRIBILD.xml:S1:7071:1	O

Table	STRIBILD.xml:S1:7077:5	O
3	STRIBILD.xml:S1:7083:1	O
Laboratory	STRIBILD.xml:S1:7085:10	O
Abnormalities	STRIBILD.xml:S1:7096:13	O
(	STRIBILD.xml:S1:7110:1	O
Grades	STRIBILD.xml:S1:7111:6	O
3	STRIBILD.xml:S1:7118:1	O
-	STRIBILD.xml:S1:7119:1	O
4	STRIBILD.xml:S1:7120:1	O
)	STRIBILD.xml:S1:7121:1	O
Reported	STRIBILD.xml:S1:7123:8	O
in	STRIBILD.xml:S1:7132:2	O
2%	STRIBILD.xml:S1:7138:2	O
of	STRIBILD.xml:S1:7141:2	O
Subjects	STRIBILD.xml:S1:7144:8	O
Receiving	STRIBILD.xml:S1:7153:9	O
STRIBILD	STRIBILD.xml:S1:7163:8	O
in	STRIBILD.xml:S1:7172:2	O
Studies	STRIBILD.xml:S1:7175:7	O
102	STRIBILD.xml:S1:7183:3	O
and	STRIBILD.xml:S1:7187:3	O
103	STRIBILD.xml:S1:7191:3	O
(	STRIBILD.xml:S1:7195:1	O
Week	STRIBILD.xml:S1:7196:4	O
144	STRIBILD.xml:S1:7201:3	O
analysis	STRIBILD.xml:S1:7205:8	O
)	STRIBILD.xml:S1:7213:1	O

STRIBILD	STRIBILD.xml:S1:7267:8	O
ATRIPLA	STRIBILD.xml:S1:7287:7	O
ATV	STRIBILD.xml:S1:7303:3	O
RTV	STRIBILD.xml:S1:7309:3	O
TRUVADA	STRIBILD.xml:S1:7315:7	O

Laboratory	STRIBILD.xml:S1:7333:10	O

Parameter	STRIBILD.xml:S1:7344:9	O
Abnormality	STRIBILD.xml:S1:7354:11	O
,	STRIBILD.xml:S1:7369:1	O
N	STRIBILD.xml:S1:7382:1	O
701	STRIBILD.xml:S1:7384:3	O
N	STRIBILD.xml:S1:7402:1	O
352	STRIBILD.xml:S1:7404:3	O
N	STRIBILD.xml:S1:7424:1	O
355	STRIBILD.xml:S1:7426:3	O

AST	STRIBILD.xml:S1:7442:3	B-AdverseReaction
(	STRIBILD.xml:S1:7446:1	O
5.0	STRIBILD.xml:S1:7448:3	I-AdverseReaction
ULN	STRIBILD.xml:S1:7454:3	I-AdverseReaction
)	STRIBILD.xml:S1:7457:1	O
3%	STRIBILD.xml:S1:7495:2	O
6%	STRIBILD.xml:S1:7515:2	O
6%	STRIBILD.xml:S1:7536:2	O

ALT	STRIBILD.xml:S1:7553:3	B-AdverseReaction
(	STRIBILD.xml:S1:7557:1	O
3.0	STRIBILD.xml:S1:7559:3	I-AdverseReaction
ULN	STRIBILD.xml:S1:7565:3	I-AdverseReaction
)	STRIBILD.xml:S1:7568:1	O
2%	STRIBILD.xml:S1:7606:2	O
5%	STRIBILD.xml:S1:7626:2	O
4%	STRIBILD.xml:S1:7647:2	O

Amylase	STRIBILD.xml:S1:7664:7	B-AdverseReaction
(	STRIBILD.xml:S1:7671:1	O
2.0	STRIBILD.xml:S1:7673:3	I-AdverseReaction
ULN	STRIBILD.xml:S1:7679:3	I-AdverseReaction
)	STRIBILD.xml:S1:7682:1	O
3%	STRIBILD.xml:S1:7717:2	O
3%	STRIBILD.xml:S1:7737:2	O
5%	STRIBILD.xml:S1:7758:2	O

Creatine	STRIBILD.xml:S1:7775:8	B-AdverseReaction
Kinase	STRIBILD.xml:S1:7784:6	I-AdverseReaction
(	STRIBILD.xml:S1:7791:1	O
10.0	STRIBILD.xml:S1:7795:4	I-AdverseReaction
ULN	STRIBILD.xml:S1:7802:3	I-AdverseReaction
)	STRIBILD.xml:S1:7805:1	O
8%	STRIBILD.xml:S1:7828:2	O
15%	STRIBILD.xml:S1:7847:3	O
11%	STRIBILD.xml:S1:7869:3	O

Urine	STRIBILD.xml:S1:7886:5	B-AdverseReaction
RBC	STRIBILD.xml:S1:7892:3	I-AdverseReaction
(	STRIBILD.xml:S1:7896:1	O
Hematuria	STRIBILD.xml:S1:7897:9	B-AdverseReaction
)	STRIBILD.xml:S1:7906:1	O
(	STRIBILD.xml:S1:7908:1	O
75	STRIBILD.xml:S1:7911:2	O
RBC	STRIBILD.xml:S1:7914:3	O
HPF	STRIBILD.xml:S1:7918:3	O
)	STRIBILD.xml:S1:7921:1	O
4%	STRIBILD.xml:S1:7939:2	O
2%	STRIBILD.xml:S1:7959:2	O
4%	STRIBILD.xml:S1:7980:2	O

In	STRIBILD.xml:S1:8006:2	O
Study	STRIBILD.xml:S1:8009:5	O
103	STRIBILD.xml:S1:8015:3	O
,	STRIBILD.xml:S1:8018:1	O
BMD	STRIBILD.xml:S1:8020:3	O
was	STRIBILD.xml:S1:8024:3	O
assessed	STRIBILD.xml:S1:8028:8	O
by	STRIBILD.xml:S1:8037:2	O
DEXA	STRIBILD.xml:S1:8040:4	O
in	STRIBILD.xml:S1:8045:2	O
a	STRIBILD.xml:S1:8048:1	O
non	STRIBILD.xml:S1:8050:3	O
-	STRIBILD.xml:S1:8053:1	O
random	STRIBILD.xml:S1:8054:6	O
subset	STRIBILD.xml:S1:8061:6	O
of	STRIBILD.xml:S1:8068:2	O
120	STRIBILD.xml:S1:8071:3	O
subjects	STRIBILD.xml:S1:8075:8	O
(	STRIBILD.xml:S1:8084:1	O
STRIBILD	STRIBILD.xml:S1:8085:8	O
group	STRIBILD.xml:S1:8094:5	O
N	STRIBILD.xml:S1:8100:1	O
54	STRIBILD.xml:S1:8104:2	O
;	STRIBILD.xml:S1:8106:1	O
ATV	STRIBILD.xml:S1:8108:3	O
RTV	STRIBILD.xml:S1:8114:3	O
TRUVADA	STRIBILD.xml:S1:8120:7	O
group	STRIBILD.xml:S1:8128:5	O
N	STRIBILD.xml:S1:8134:1	O
66	STRIBILD.xml:S1:8138:2	O
)	STRIBILD.xml:S1:8140:1	O
.	STRIBILD.xml:S1:8141:1	O

Mean	STRIBILD.xml:S1:8143:4	O
percentage	STRIBILD.xml:S1:8148:10	O
decreases	STRIBILD.xml:S1:8159:9	B-AdverseReaction
in	STRIBILD.xml:S1:8169:2	I-AdverseReaction
BMD	STRIBILD.xml:S1:8172:3	I-AdverseReaction
from	STRIBILD.xml:S1:8176:4	O
baseline	STRIBILD.xml:S1:8181:8	O
to	STRIBILD.xml:S1:8190:2	O
Week	STRIBILD.xml:S1:8193:4	O
144	STRIBILD.xml:S1:8198:3	O
in	STRIBILD.xml:S1:8202:2	O
the	STRIBILD.xml:S1:8205:3	O
STRIBILD	STRIBILD.xml:S1:8209:8	O
group	STRIBILD.xml:S1:8218:5	O
were	STRIBILD.xml:S1:8224:4	O
comparable	STRIBILD.xml:S1:8229:10	O
to	STRIBILD.xml:S1:8240:2	O
the	STRIBILD.xml:S1:8243:3	O
ATV	STRIBILD.xml:S1:8247:3	O
RTV	STRIBILD.xml:S1:8253:3	O
TRUVADA	STRIBILD.xml:S1:8259:7	O
group	STRIBILD.xml:S1:8267:5	O
at	STRIBILD.xml:S1:8273:2	O
the	STRIBILD.xml:S1:8276:3	O
lumbar	STRIBILD.xml:S1:8280:6	O
spine	STRIBILD.xml:S1:8287:5	O
(-	STRIBILD.xml:S1:8293:2	O
1.43%	STRIBILD.xml:S1:8295:5	O
versus	STRIBILD.xml:S1:8301:6	O
-	STRIBILD.xml:S1:8308:1	O
3.68%	STRIBILD.xml:S1:8309:5	O
,	STRIBILD.xml:S1:8314:1	O
respectively	STRIBILD.xml:S1:8316:12	O
)	STRIBILD.xml:S1:8328:1	O
and	STRIBILD.xml:S1:8330:3	O
at	STRIBILD.xml:S1:8334:2	O
the	STRIBILD.xml:S1:8337:3	O
hip	STRIBILD.xml:S1:8341:3	O
(-	STRIBILD.xml:S1:8345:2	O
2.83%	STRIBILD.xml:S1:8347:5	O
versus	STRIBILD.xml:S1:8353:6	O
-	STRIBILD.xml:S1:8360:1	O
3.77%	STRIBILD.xml:S1:8361:5	O
,	STRIBILD.xml:S1:8366:1	O
respectively	STRIBILD.xml:S1:8368:12	O
)	STRIBILD.xml:S1:8380:1	O
.	STRIBILD.xml:S1:8381:1	O

In	STRIBILD.xml:S1:8383:2	O
Studies	STRIBILD.xml:S1:8386:7	O
102	STRIBILD.xml:S1:8394:3	O
and	STRIBILD.xml:S1:8398:3	O
103	STRIBILD.xml:S1:8402:3	O
,	STRIBILD.xml:S1:8405:1	O
bone	STRIBILD.xml:S1:8407:4	B-AdverseReaction
fractures	STRIBILD.xml:S1:8412:9	I-AdverseReaction
occurred	STRIBILD.xml:S1:8422:8	O
in	STRIBILD.xml:S1:8431:2	O
27	STRIBILD.xml:S1:8434:2	O
subjects	STRIBILD.xml:S1:8437:8	O
(	STRIBILD.xml:S1:8446:1	O
3.9%	STRIBILD.xml:S1:8447:4	O
)	STRIBILD.xml:S1:8451:1	O
in	STRIBILD.xml:S1:8453:2	O
the	STRIBILD.xml:S1:8456:3	O
STRIBILD	STRIBILD.xml:S1:8460:8	O
group	STRIBILD.xml:S1:8469:5	O
,	STRIBILD.xml:S1:8474:1	O
8	STRIBILD.xml:S1:8476:1	O
subjects	STRIBILD.xml:S1:8478:8	O
(	STRIBILD.xml:S1:8487:1	O
2.3%	STRIBILD.xml:S1:8488:4	O
)	STRIBILD.xml:S1:8492:1	O
in	STRIBILD.xml:S1:8494:2	O
the	STRIBILD.xml:S1:8497:3	O
ATRIPLA	STRIBILD.xml:S1:8501:7	O
group	STRIBILD.xml:S1:8509:5	O
,	STRIBILD.xml:S1:8514:1	O
and	STRIBILD.xml:S1:8516:3	O
19	STRIBILD.xml:S1:8520:2	O
subjects	STRIBILD.xml:S1:8523:8	O
(	STRIBILD.xml:S1:8532:1	O
5.4%	STRIBILD.xml:S1:8533:4	O
)	STRIBILD.xml:S1:8537:1	O
in	STRIBILD.xml:S1:8539:2	O
the	STRIBILD.xml:S1:8542:3	O
ATV	STRIBILD.xml:S1:8546:3	O
RTV	STRIBILD.xml:S1:8552:3	O
TRUVADA	STRIBILD.xml:S1:8558:7	O
group	STRIBILD.xml:S1:8566:5	O
.	STRIBILD.xml:S1:8571:1	O

These	STRIBILD.xml:S1:8573:5	O
findings	STRIBILD.xml:S1:8579:8	O
were	STRIBILD.xml:S1:8588:4	O
consistent	STRIBILD.xml:S1:8593:10	O
with	STRIBILD.xml:S1:8604:4	O
data	STRIBILD.xml:S1:8609:4	O
from	STRIBILD.xml:S1:8614:4	O
an	STRIBILD.xml:S1:8619:2	O
earlier	STRIBILD.xml:S1:8622:7	O
144	STRIBILD.xml:S1:8630:3	O
-	STRIBILD.xml:S1:8633:1	O
week	STRIBILD.xml:S1:8634:4	O
trial	STRIBILD.xml:S1:8639:5	O
of	STRIBILD.xml:S1:8645:2	O
treatment	STRIBILD.xml:S1:8648:9	O
-	STRIBILD.xml:S1:8657:1	O
naive	STRIBILD.xml:S1:8658:5	O
subjects	STRIBILD.xml:S1:8664:8	O
receiving	STRIBILD.xml:S1:8673:9	O
tenofovir	STRIBILD.xml:S1:8683:9	O
DF	STRIBILD.xml:S1:8693:2	O
lamivudine	STRIBILD.xml:S1:8698:10	O
efavirenz	STRIBILD.xml:S1:8711:9	O
.	STRIBILD.xml:S1:8720:1	O

Proteinuria	STRIBILD.xml:S1:8726:11	B-AdverseReaction

(	STRIBILD.xml:S1:8738:1	O
all	STRIBILD.xml:S1:8739:3	O
grades	STRIBILD.xml:S1:8743:6	O
)	STRIBILD.xml:S1:8749:1	O
occurred	STRIBILD.xml:S1:8751:8	O
in	STRIBILD.xml:S1:8760:2	O
52%	STRIBILD.xml:S1:8763:3	O
of	STRIBILD.xml:S1:8767:2	O
subjects	STRIBILD.xml:S1:8770:8	O
receiving	STRIBILD.xml:S1:8779:9	O
STRIBILD	STRIBILD.xml:S1:8789:8	O
,	STRIBILD.xml:S1:8797:1	O
41%	STRIBILD.xml:S1:8799:3	O
of	STRIBILD.xml:S1:8803:2	O
subjects	STRIBILD.xml:S1:8806:8	O
receiving	STRIBILD.xml:S1:8815:9	O
ATRIPLA	STRIBILD.xml:S1:8825:7	O
,	STRIBILD.xml:S1:8832:1	O
and	STRIBILD.xml:S1:8834:3	O
42%	STRIBILD.xml:S1:8838:3	O
of	STRIBILD.xml:S1:8842:2	O
subjects	STRIBILD.xml:S1:8845:8	O
receiving	STRIBILD.xml:S1:8854:9	O
ATV	STRIBILD.xml:S1:8864:3	O
RTV	STRIBILD.xml:S1:8870:3	O
TRUVADA	STRIBILD.xml:S1:8876:7	O
.	STRIBILD.xml:S1:8883:1	O

The	STRIBILD.xml:S1:8889:3	O
cobicistat	STRIBILD.xml:S1:8893:10	O
component	STRIBILD.xml:S1:8904:9	O
of	STRIBILD.xml:S1:8914:2	O
STRIBILD	STRIBILD.xml:S1:8917:8	O
has	STRIBILD.xml:S1:8926:3	O
been	STRIBILD.xml:S1:8930:4	O
shown	STRIBILD.xml:S1:8935:5	O
to	STRIBILD.xml:S1:8941:2	O
increase	STRIBILD.xml:S1:8944:8	B-AdverseReaction
serum	STRIBILD.xml:S1:8953:5	I-AdverseReaction
creatinine	STRIBILD.xml:S1:8959:10	I-AdverseReaction
and	STRIBILD.xml:S1:8970:3	O
decrease	STRIBILD.xml:S1:8974:8	B-AdverseReaction
estimated	STRIBILD.xml:S1:8983:9	I-AdverseReaction
creatinine	STRIBILD.xml:S1:8993:10	I-AdverseReaction
clearance	STRIBILD.xml:S1:9004:9	I-AdverseReaction
due	STRIBILD.xml:S1:9014:3	O
to	STRIBILD.xml:S1:9018:2	O
inhibition	STRIBILD.xml:S1:9021:10	O
of	STRIBILD.xml:S1:9032:2	O
tubular	STRIBILD.xml:S1:9035:7	O
secretion	STRIBILD.xml:S1:9043:9	O
of	STRIBILD.xml:S1:9053:2	O
creatinine	STRIBILD.xml:S1:9056:10	O
without	STRIBILD.xml:S1:9067:7	B-Negation
affecting	STRIBILD.xml:S1:9075:9	B-AdverseReaction
renal	STRIBILD.xml:S1:9085:5	I-AdverseReaction
glomerular	STRIBILD.xml:S1:9091:10	I-AdverseReaction
function	STRIBILD.xml:S1:9102:8	I-AdverseReaction
.	STRIBILD.xml:S1:9110:1	O

In	STRIBILD.xml:S1:9112:2	O
Studies	STRIBILD.xml:S1:9115:7	O
102	STRIBILD.xml:S1:9123:3	O
and	STRIBILD.xml:S1:9127:3	O
103	STRIBILD.xml:S1:9131:3	O
,	STRIBILD.xml:S1:9134:1	O
increases	STRIBILD.xml:S1:9136:9	B-AdverseReaction
in	STRIBILD.xml:S1:9146:2	I-AdverseReaction
serum	STRIBILD.xml:S1:9149:5	I-AdverseReaction
creatinine	STRIBILD.xml:S1:9155:10	I-AdverseReaction
and	STRIBILD.xml:S1:9166:3	O
decreases	STRIBILD.xml:S1:9170:9	B-AdverseReaction
in	STRIBILD.xml:S1:9180:2	I-AdverseReaction
estimated	STRIBILD.xml:S1:9183:9	I-AdverseReaction
creatinine	STRIBILD.xml:S1:9193:10	I-AdverseReaction
clearance	STRIBILD.xml:S1:9204:9	I-AdverseReaction
occurred	STRIBILD.xml:S1:9214:8	O
early	STRIBILD.xml:S1:9223:5	O
in	STRIBILD.xml:S1:9229:2	O
treatment	STRIBILD.xml:S1:9232:9	O
with	STRIBILD.xml:S1:9242:4	O
STRIBILD	STRIBILD.xml:S1:9247:8	O
,	STRIBILD.xml:S1:9255:1	O
after	STRIBILD.xml:S1:9257:5	O
which	STRIBILD.xml:S1:9263:5	O
they	STRIBILD.xml:S1:9269:4	O
stabilized	STRIBILD.xml:S1:9274:10	O
.	STRIBILD.xml:S1:9284:1	O

Table	STRIBILD.xml:S1:9286:5	O
4	STRIBILD.xml:S1:9292:1	O
displays	STRIBILD.xml:S1:9294:8	O
the	STRIBILD.xml:S1:9303:3	O
mean	STRIBILD.xml:S1:9307:4	O
changes	STRIBILD.xml:S1:9312:7	O
in	STRIBILD.xml:S1:9320:2	O
serum	STRIBILD.xml:S1:9323:5	O
creatinine	STRIBILD.xml:S1:9329:10	O
and	STRIBILD.xml:S1:9340:3	O
eGFR	STRIBILD.xml:S1:9344:4	O
levels	STRIBILD.xml:S1:9349:6	O
at	STRIBILD.xml:S1:9356:2	O
Week	STRIBILD.xml:S1:9359:4	O
144	STRIBILD.xml:S1:9364:3	O
and	STRIBILD.xml:S1:9368:3	O
the	STRIBILD.xml:S1:9372:3	O
percentage	STRIBILD.xml:S1:9376:10	O
of	STRIBILD.xml:S1:9387:2	O
subjects	STRIBILD.xml:S1:9390:8	O
with	STRIBILD.xml:S1:9399:4	O
elevations	STRIBILD.xml:S1:9404:10	B-AdverseReaction
in	STRIBILD.xml:S1:9415:2	I-AdverseReaction
serum	STRIBILD.xml:S1:9418:5	I-AdverseReaction
creatinine	STRIBILD.xml:S1:9424:10	I-AdverseReaction
(	STRIBILD.xml:S1:9435:1	O
All	STRIBILD.xml:S1:9436:3	O
Grades	STRIBILD.xml:S1:9440:6	O
)	STRIBILD.xml:S1:9446:1	O
.	STRIBILD.xml:S1:9447:1	O

Table	STRIBILD.xml:S1:9453:5	O
4	STRIBILD.xml:S1:9459:1	O
Change	STRIBILD.xml:S1:9461:6	O
from	STRIBILD.xml:S1:9468:4	O
Baseline	STRIBILD.xml:S1:9473:8	O
in	STRIBILD.xml:S1:9482:2	O
Serum	STRIBILD.xml:S1:9485:5	O
Creatinine	STRIBILD.xml:S1:9491:10	O
and	STRIBILD.xml:S1:9502:3	O
eGFR	STRIBILD.xml:S1:9506:4	O
and	STRIBILD.xml:S1:9511:3	O
Incidence	STRIBILD.xml:S1:9515:9	O
of	STRIBILD.xml:S1:9525:2	O
Elevated	STRIBILD.xml:S1:9528:8	B-AdverseReaction
Serum	STRIBILD.xml:S1:9537:5	I-AdverseReaction
Creatinine	STRIBILD.xml:S1:9543:10	I-AdverseReaction
(	STRIBILD.xml:S1:9554:1	O
All	STRIBILD.xml:S1:9555:3	O
Grades	STRIBILD.xml:S1:9559:6	O
)	STRIBILD.xml:S1:9565:1	O
in	STRIBILD.xml:S1:9567:2	O
Studies	STRIBILD.xml:S1:9570:7	O
102	STRIBILD.xml:S1:9578:3	O
and	STRIBILD.xml:S1:9582:3	O
103	STRIBILD.xml:S1:9586:3	O
at	STRIBILD.xml:S1:9590:2	O
Week	STRIBILD.xml:S1:9593:4	O
144	STRIBILD.xml:S1:9598:3	O

STRIBILD	STRIBILD.xml:S1:9650:8	O
(	STRIBILD.xml:S1:9658:1	O
N	STRIBILD.xml:S1:9659:1	O
701	STRIBILD.xml:S1:9661:3	O
)	STRIBILD.xml:S1:9664:1	O
ATRIPLA	STRIBILD.xml:S1:9671:7	O
(	STRIBILD.xml:S1:9678:1	O
N	STRIBILD.xml:S1:9679:1	O
352	STRIBILD.xml:S1:9681:3	O
)	STRIBILD.xml:S1:9684:1	O
ATV	STRIBILD.xml:S1:9689:3	O
RTV	STRIBILD.xml:S1:9695:3	O
TRUVADA	STRIBILD.xml:S1:9701:7	O
(	STRIBILD.xml:S1:9708:1	O
N	STRIBILD.xml:S1:9709:1	O
355	STRIBILD.xml:S1:9711:3	O
)	STRIBILD.xml:S1:9714:1	O

Serum	STRIBILD.xml:S1:9723:5	O

Creatinine	STRIBILD.xml:S1:9729:10	O
(	STRIBILD.xml:S1:9740:1	O
mg	STRIBILD.xml:S1:9741:2	O
dL	STRIBILD.xml:S1:9744:2	O
)	STRIBILD.xml:S1:9746:1	O
0.14	STRIBILD.xml:S1:9770:4	O
(	STRIBILD.xml:S1:9775:1	O
-	STRIBILD.xml:S1:9778:1	O
0.14	STRIBILD.xml:S1:9779:4	O
)	STRIBILD.xml:S1:9783:1	O
0.01	STRIBILD.xml:S1:9790:4	O
(	STRIBILD.xml:S1:9795:1	O
-	STRIBILD.xml:S1:9798:1	O
0.12	STRIBILD.xml:S1:9799:4	O
)	STRIBILD.xml:S1:9803:1	O
0.09	STRIBILD.xml:S1:9811:4	O
(	STRIBILD.xml:S1:9816:1	O
-	STRIBILD.xml:S1:9819:1	O
0.15	STRIBILD.xml:S1:9820:4	O
)	STRIBILD.xml:S1:9824:1	O

eGFR	STRIBILD.xml:S1:9834:4	O
by	STRIBILD.xml:S1:9839:2	O
Cockcroft	STRIBILD.xml:S1:9842:9	O
-	STRIBILD.xml:S1:9851:1	O
Gault	STRIBILD.xml:S1:9852:5	O
(	STRIBILD.xml:S1:9858:1	O
mL	STRIBILD.xml:S1:9859:2	O
minute	STRIBILD.xml:S1:9862:6	O
)	STRIBILD.xml:S1:9868:1	O
-	STRIBILD.xml:S1:9880:1	O
14.0	STRIBILD.xml:S1:9881:4	O
(	STRIBILD.xml:S1:9886:1	O
-	STRIBILD.xml:S1:9889:1	O
16.6	STRIBILD.xml:S1:9890:4	O
)	STRIBILD.xml:S1:9894:1	O
-	STRIBILD.xml:S1:9901:1	O
1.9	STRIBILD.xml:S1:9902:3	O
(	STRIBILD.xml:S1:9906:1	O
-	STRIBILD.xml:S1:9909:1	O
17.9	STRIBILD.xml:S1:9910:4	O
)	STRIBILD.xml:S1:9914:1	O
-	STRIBILD.xml:S1:9922:1	O
9.8	STRIBILD.xml:S1:9923:3	O
(	STRIBILD.xml:S1:9927:1	O
-	STRIBILD.xml:S1:9930:1	O
19.4	STRIBILD.xml:S1:9931:4	O
)	STRIBILD.xml:S1:9935:1	O

Subjects	STRIBILD.xml:S1:9945:8	O
with	STRIBILD.xml:S1:9954:4	O
Elevations	STRIBILD.xml:S1:9959:10	B-AdverseReaction
in	STRIBILD.xml:S1:9970:2	I-AdverseReaction
Serum	STRIBILD.xml:S1:9973:5	I-AdverseReaction
Creatinine	STRIBILD.xml:S1:9979:10	I-AdverseReaction
(	STRIBILD.xml:S1:9990:1	O
All	STRIBILD.xml:S1:9991:3	O
Grades	STRIBILD.xml:S1:9995:6	O
)(	STRIBILD.xml:S1:10001:2	O
)	STRIBILD.xml:S1:10004:1	O
12	STRIBILD.xml:S1:10015:2	O
2	STRIBILD.xml:S1:10035:1	O
6	STRIBILD.xml:S1:10057:1	O

Emtricitabine	STRIBILD.xml:S1:10086:13	O
or	STRIBILD.xml:S1:10100:2	O
Tenofovir	STRIBILD.xml:S1:10103:9	O
DF	STRIBILD.xml:S1:10113:2	O
:	STRIBILD.xml:S1:10115:1	O
In	STRIBILD.xml:S1:10118:2	O
addition	STRIBILD.xml:S1:10121:8	O
to	STRIBILD.xml:S1:10130:2	O
the	STRIBILD.xml:S1:10133:3	O
laboratory	STRIBILD.xml:S1:10137:10	O
abnormalities	STRIBILD.xml:S1:10148:13	O
observed	STRIBILD.xml:S1:10162:8	O
with	STRIBILD.xml:S1:10171:4	O
STRIBILD	STRIBILD.xml:S1:10176:8	O
,	STRIBILD.xml:S1:10184:1	O
the	STRIBILD.xml:S1:10186:3	O
following	STRIBILD.xml:S1:10190:9	O
laboratory	STRIBILD.xml:S1:10200:10	O
abnormalities	STRIBILD.xml:S1:10211:13	O
have	STRIBILD.xml:S1:10225:4	O
been	STRIBILD.xml:S1:10230:4	O
previously	STRIBILD.xml:S1:10235:10	O
reported	STRIBILD.xml:S1:10246:8	O
in	STRIBILD.xml:S1:10255:2	O
subjects	STRIBILD.xml:S1:10258:8	O
treated	STRIBILD.xml:S1:10267:7	O
with	STRIBILD.xml:S1:10275:4	O
emtricitabine	STRIBILD.xml:S1:10280:13	O
or	STRIBILD.xml:S1:10294:2	O
tenofovir	STRIBILD.xml:S1:10297:9	O
DF	STRIBILD.xml:S1:10307:2	O
with	STRIBILD.xml:S1:10310:4	O
other	STRIBILD.xml:S1:10315:5	O
antiretroviral	STRIBILD.xml:S1:10321:14	O
agents	STRIBILD.xml:S1:10336:6	O
in	STRIBILD.xml:S1:10343:2	O
other	STRIBILD.xml:S1:10346:5	O
clinical	STRIBILD.xml:S1:10352:8	O
trials	STRIBILD.xml:S1:10361:6	O
:	STRIBILD.xml:S1:10367:1	O
Grade	STRIBILD.xml:S1:10369:5	B-Severity
3	STRIBILD.xml:S1:10375:1	I-Severity
or	STRIBILD.xml:S1:10377:2	O
4	STRIBILD.xml:S1:10380:1	I-Severity
laboratory	STRIBILD.xml:S1:10382:10	O
abnormalities	STRIBILD.xml:S1:10393:13	B-AdverseReaction
of	STRIBILD.xml:S1:10407:2	I-AdverseReaction
ALT	STRIBILD.xml:S1:10410:3	I-AdverseReaction
(	STRIBILD.xml:S1:10414:1	O
M	STRIBILD.xml:S1:10415:1	O
:	STRIBILD.xml:S1:10416:1	O
greater	STRIBILD.xml:S1:10418:7	O
than	STRIBILD.xml:S1:10426:4	O
215	STRIBILD.xml:S1:10431:3	B-Severity
U	STRIBILD.xml:S1:10435:1	I-Severity
per	STRIBILD.xml:S1:10437:3	I-Severity
L	STRIBILD.xml:S1:10441:1	I-Severity
;	STRIBILD.xml:S1:10442:1	O
F	STRIBILD.xml:S1:10444:1	O
:	STRIBILD.xml:S1:10445:1	O
greater	STRIBILD.xml:S1:10447:7	O
than	STRIBILD.xml:S1:10455:4	O
170	STRIBILD.xml:S1:10460:3	B-Severity
U	STRIBILD.xml:S1:10464:1	I-Severity
per	STRIBILD.xml:S1:10466:3	I-Severity
L	STRIBILD.xml:S1:10470:1	I-Severity
)	STRIBILD.xml:S1:10471:1	O
,	STRIBILD.xml:S1:10472:1	O
alkaline	STRIBILD.xml:S1:10474:8	I-AdverseReaction
phosphatase	STRIBILD.xml:S1:10483:11	I-AdverseReaction
(	STRIBILD.xml:S1:10495:1	O
greater	STRIBILD.xml:S1:10496:7	O
than	STRIBILD.xml:S1:10504:4	O
550	STRIBILD.xml:S1:10509:3	B-Severity
U	STRIBILD.xml:S1:10513:1	I-Severity
per	STRIBILD.xml:S1:10515:3	I-Severity
L	STRIBILD.xml:S1:10519:1	I-Severity
)	STRIBILD.xml:S1:10520:1	O
,	STRIBILD.xml:S1:10521:1	O
bilirubin	STRIBILD.xml:S1:10523:9	I-AdverseReaction
(	STRIBILD.xml:S1:10533:1	O
greater	STRIBILD.xml:S1:10534:7	O
than	STRIBILD.xml:S1:10542:4	O
2.5	STRIBILD.xml:S1:10547:3	B-Severity
ULN	STRIBILD.xml:S1:10553:3	I-Severity
)	STRIBILD.xml:S1:10556:1	O
,	STRIBILD.xml:S1:10557:1	O
serum	STRIBILD.xml:S1:10559:5	I-AdverseReaction
glucose	STRIBILD.xml:S1:10565:7	I-AdverseReaction
(	STRIBILD.xml:S1:10573:1	O
less	STRIBILD.xml:S1:10574:4	O
than	STRIBILD.xml:S1:10579:4	O
40	STRIBILD.xml:S1:10584:2	B-Severity
or	STRIBILD.xml:S1:10587:2	O
greater	STRIBILD.xml:S1:10590:7	O
than	STRIBILD.xml:S1:10598:4	O
250	STRIBILD.xml:S1:10603:3	B-Severity
mg	STRIBILD.xml:S1:10607:2	I-Severity
per	STRIBILD.xml:S1:10610:3	I-Severity
dL	STRIBILD.xml:S1:10614:2	I-Severity
)	STRIBILD.xml:S1:10616:1	O
,	STRIBILD.xml:S1:10617:1	O
glycosuria	STRIBILD.xml:S1:10619:10	I-AdverseReaction
(	STRIBILD.xml:S1:10630:1	O
greater	STRIBILD.xml:S1:10631:7	O
than	STRIBILD.xml:S1:10639:4	O
or	STRIBILD.xml:S1:10644:2	O
equal	STRIBILD.xml:S1:10647:5	O
to	STRIBILD.xml:S1:10653:2	O
3	STRIBILD.xml:S1:10656:1	B-Severity
)	STRIBILD.xml:S1:10658:1	O
,	STRIBILD.xml:S1:10659:1	O
neutrophils	STRIBILD.xml:S1:10661:11	I-AdverseReaction
(	STRIBILD.xml:S1:10673:1	O
less	STRIBILD.xml:S1:10674:4	O
than	STRIBILD.xml:S1:10679:4	O
750	STRIBILD.xml:S1:10684:3	B-Severity
per	STRIBILD.xml:S1:10688:3	I-Severity
mm	STRIBILD.xml:S1:10692:2	I-Severity
3	STRIBILD.xml:S1:10696:1	I-Severity
)	STRIBILD.xml:S1:10699:1	O
,	STRIBILD.xml:S1:10700:1	O
fasting	STRIBILD.xml:S1:10702:7	I-AdverseReaction
cholesterol	STRIBILD.xml:S1:10710:11	I-AdverseReaction
(	STRIBILD.xml:S1:10722:1	O
greater	STRIBILD.xml:S1:10723:7	O
than	STRIBILD.xml:S1:10731:4	O
240	STRIBILD.xml:S1:10736:3	B-Severity
mg	STRIBILD.xml:S1:10740:2	I-Severity
per	STRIBILD.xml:S1:10743:3	I-Severity
dL	STRIBILD.xml:S1:10747:2	I-Severity
)	STRIBILD.xml:S1:10749:1	O
,	STRIBILD.xml:S1:10750:1	O
and	STRIBILD.xml:S1:10752:3	O
fasting	STRIBILD.xml:S1:10756:7	I-AdverseReaction
triglycerides	STRIBILD.xml:S1:10764:13	I-AdverseReaction
(	STRIBILD.xml:S1:10778:1	O
greater	STRIBILD.xml:S1:10779:7	O
than	STRIBILD.xml:S1:10787:4	O
750	STRIBILD.xml:S1:10792:3	B-Severity
mg	STRIBILD.xml:S1:10796:2	I-Severity
per	STRIBILD.xml:S1:10799:3	I-Severity
dL	STRIBILD.xml:S1:10803:2	I-Severity
)	STRIBILD.xml:S1:10805:1	O
.	STRIBILD.xml:S1:10806:1	O

Serum	STRIBILD.xml:S1:10816:5	O

Lipids	STRIBILD.xml:S1:10822:6	O
:	STRIBILD.xml:S1:10828:1	O
In	STRIBILD.xml:S1:10831:2	O
the	STRIBILD.xml:S1:10834:3	O
clinical	STRIBILD.xml:S1:10838:8	O
trials	STRIBILD.xml:S1:10847:6	O
of	STRIBILD.xml:S1:10854:2	O
STRIBILD	STRIBILD.xml:S1:10857:8	O
,	STRIBILD.xml:S1:10865:1	O
a	STRIBILD.xml:S1:10867:1	O
similar	STRIBILD.xml:S1:10869:7	O
percentage	STRIBILD.xml:S1:10877:10	O
of	STRIBILD.xml:S1:10888:2	O
subjects	STRIBILD.xml:S1:10891:8	O
receiving	STRIBILD.xml:S1:10900:9	O
STRIBILD	STRIBILD.xml:S1:10910:8	O
,	STRIBILD.xml:S1:10918:1	O
ATRIPLA	STRIBILD.xml:S1:10920:7	O
,	STRIBILD.xml:S1:10927:1	O
and	STRIBILD.xml:S1:10929:3	O
ATV	STRIBILD.xml:S1:10933:3	O
RTV	STRIBILD.xml:S1:10939:3	O
TRUVADA	STRIBILD.xml:S1:10945:7	O
were	STRIBILD.xml:S1:10953:4	O
on	STRIBILD.xml:S1:10958:2	O
lipid	STRIBILD.xml:S1:10961:5	O
lowering	STRIBILD.xml:S1:10967:8	O
agents	STRIBILD.xml:S1:10976:6	O
at	STRIBILD.xml:S1:10983:2	O
baseline	STRIBILD.xml:S1:10986:8	O
(	STRIBILD.xml:S1:10995:1	O
12%	STRIBILD.xml:S1:10996:3	O
,	STRIBILD.xml:S1:10999:1	O
12%	STRIBILD.xml:S1:11001:3	O
,	STRIBILD.xml:S1:11004:1	O
and	STRIBILD.xml:S1:11006:3	O
13%	STRIBILD.xml:S1:11010:3	O
,	STRIBILD.xml:S1:11013:1	O
respectively	STRIBILD.xml:S1:11015:12	O
)	STRIBILD.xml:S1:11027:1	O
.	STRIBILD.xml:S1:11028:1	O

While	STRIBILD.xml:S1:11030:5	O
receiving	STRIBILD.xml:S1:11036:9	O
study	STRIBILD.xml:S1:11046:5	O
drug	STRIBILD.xml:S1:11052:4	O
through	STRIBILD.xml:S1:11057:7	O
Week	STRIBILD.xml:S1:11065:4	O
144	STRIBILD.xml:S1:11070:3	O
,	STRIBILD.xml:S1:11073:1	O
an	STRIBILD.xml:S1:11075:2	O
additional	STRIBILD.xml:S1:11078:10	O
11%	STRIBILD.xml:S1:11089:3	O
of	STRIBILD.xml:S1:11093:2	O
STRIBILD	STRIBILD.xml:S1:11096:8	O
subjects	STRIBILD.xml:S1:11105:8	O
were	STRIBILD.xml:S1:11114:4	O
started	STRIBILD.xml:S1:11119:7	O
on	STRIBILD.xml:S1:11127:2	O
lipid	STRIBILD.xml:S1:11130:5	O
lowering	STRIBILD.xml:S1:11136:8	O
agents	STRIBILD.xml:S1:11145:6	O
,	STRIBILD.xml:S1:11151:1	O
compared	STRIBILD.xml:S1:11153:8	O
to	STRIBILD.xml:S1:11162:2	O
13%	STRIBILD.xml:S1:11165:3	O
of	STRIBILD.xml:S1:11169:2	O
ATRIPLA	STRIBILD.xml:S1:11172:7	O
and	STRIBILD.xml:S1:11180:3	O
12%	STRIBILD.xml:S1:11184:3	O
of	STRIBILD.xml:S1:11188:2	O
ATV	STRIBILD.xml:S1:11191:3	O
RTV	STRIBILD.xml:S1:11197:3	O
TRUVADA	STRIBILD.xml:S1:11203:7	O
subjects	STRIBILD.xml:S1:11211:8	O
.	STRIBILD.xml:S1:11219:1	O

Changes	STRIBILD.xml:S1:11225:7	O
from	STRIBILD.xml:S1:11233:4	O
baseline	STRIBILD.xml:S1:11238:8	O
in	STRIBILD.xml:S1:11247:2	O
total	STRIBILD.xml:S1:11250:5	O
cholesterol	STRIBILD.xml:S1:11256:11	O
,	STRIBILD.xml:S1:11267:1	O
HDL	STRIBILD.xml:S1:11269:3	O
-	STRIBILD.xml:S1:11272:1	O
cholesterol	STRIBILD.xml:S1:11273:11	O
,	STRIBILD.xml:S1:11284:1	O
LDL	STRIBILD.xml:S1:11286:3	O
-	STRIBILD.xml:S1:11289:1	O
cholesterol	STRIBILD.xml:S1:11290:11	O
,	STRIBILD.xml:S1:11301:1	O
and	STRIBILD.xml:S1:11303:3	O
triglycerides	STRIBILD.xml:S1:11307:13	O
are	STRIBILD.xml:S1:11321:3	O
presented	STRIBILD.xml:S1:11325:9	O
in	STRIBILD.xml:S1:11335:2	O
Table	STRIBILD.xml:S1:11338:5	O
5	STRIBILD.xml:S1:11344:1	O
.	STRIBILD.xml:S1:11345:1	O

Table	STRIBILD.xml:S1:11351:5	O
5	STRIBILD.xml:S1:11357:1	O
Lipid	STRIBILD.xml:S1:11359:5	O
Values	STRIBILD.xml:S1:11365:6	O
,	STRIBILD.xml:S1:11371:1	O
Mean	STRIBILD.xml:S1:11373:4	O
Change	STRIBILD.xml:S1:11378:6	O
from	STRIBILD.xml:S1:11385:4	O
Baseline	STRIBILD.xml:S1:11390:8	O
at	STRIBILD.xml:S1:11399:2	O
Week	STRIBILD.xml:S1:11402:4	O
144	STRIBILD.xml:S1:11407:3	O
in	STRIBILD.xml:S1:11411:2	O
Subjects	STRIBILD.xml:S1:11414:8	O
Receiving	STRIBILD.xml:S1:11423:9	O
STRIBILD	STRIBILD.xml:S1:11433:8	O
or	STRIBILD.xml:S1:11442:2	O
Comparator	STRIBILD.xml:S1:11445:10	O
in	STRIBILD.xml:S1:11456:2	O
Studies	STRIBILD.xml:S1:11459:7	O
102	STRIBILD.xml:S1:11467:3	O
and	STRIBILD.xml:S1:11471:3	O
103	STRIBILD.xml:S1:11475:3	O

STRIBILDN	STRIBILD.xml:S1:11502:9	O
701	STRIBILD.xml:S1:11512:3	O
ATRIPLAN	STRIBILD.xml:S1:11518:8	O
352	STRIBILD.xml:S1:11527:3	O
ATV	STRIBILD.xml:S1:11533:3	O
RTV	STRIBILD.xml:S1:11539:3	O
TRUVADAN	STRIBILD.xml:S1:11545:8	O
355	STRIBILD.xml:S1:11554:3	O

Baseline	STRIBILD.xml:S1:11562:8	O
Week	STRIBILD.xml:S1:11585:4	O
144	STRIBILD.xml:S1:11590:3	O
Baseline	STRIBILD.xml:S1:11601:8	O
Week	STRIBILD.xml:S1:11616:4	O
144	STRIBILD.xml:S1:11621:3	O
Baseline	STRIBILD.xml:S1:11632:8	O
Week	STRIBILD.xml:S1:11647:4	O
144	STRIBILD.xml:S1:11652:3	O

mg	STRIBILD.xml:S1:11663:2	O
dL	STRIBILD.xml:S1:11666:2	O
Change	STRIBILD.xml:S1:11687:6	O
mg	STRIBILD.xml:S1:11703:2	O
dL	STRIBILD.xml:S1:11706:2	O
Change	STRIBILD.xml:S1:11718:6	O
mg	STRIBILD.xml:S1:11734:2	O
dL	STRIBILD.xml:S1:11737:2	O
Change	STRIBILD.xml:S1:11749:6	O

Total	STRIBILD.xml:S1:11767:5	O

Cholesterol	STRIBILD.xml:S1:11773:11	O
(	STRIBILD.xml:S1:11785:1	O
fasted	STRIBILD.xml:S1:11786:6	O
)	STRIBILD.xml:S1:11792:1	O
166	STRIBILD.xml:S1:11796:3	O
[	STRIBILD.xml:S1:11799:1	O
N	STRIBILD.xml:S1:11800:1	O
675	STRIBILD.xml:S1:11802:3	O
]	STRIBILD.xml:S1:11805:1	O
17	STRIBILD.xml:S1:11813:2	O
[	STRIBILD.xml:S1:11815:1	O
N	STRIBILD.xml:S1:11816:1	O
535	STRIBILD.xml:S1:11818:3	O
]	STRIBILD.xml:S1:11821:1	O
161	STRIBILD.xml:S1:11827:3	O
[	STRIBILD.xml:S1:11830:1	O
N	STRIBILD.xml:S1:11831:1	O
343	STRIBILD.xml:S1:11833:3	O
]	STRIBILD.xml:S1:11836:1	O
22	STRIBILD.xml:S1:11844:2	O
[	STRIBILD.xml:S1:11846:1	O
N	STRIBILD.xml:S1:11847:1	O
262	STRIBILD.xml:S1:11849:3	O
]	STRIBILD.xml:S1:11852:1	O
168	STRIBILD.xml:S1:11858:3	O
[	STRIBILD.xml:S1:11861:1	O
N	STRIBILD.xml:S1:11862:1	O
337	STRIBILD.xml:S1:11864:3	O
]	STRIBILD.xml:S1:11867:1	O
16	STRIBILD.xml:S1:11875:2	O
[	STRIBILD.xml:S1:11877:1	O
N	STRIBILD.xml:S1:11878:1	O
243	STRIBILD.xml:S1:11880:3	O
]	STRIBILD.xml:S1:11883:1	O

HDL	STRIBILD.xml:S1:11891:3	O
-	STRIBILD.xml:S1:11894:1	O
cholesterol	STRIBILD.xml:S1:11895:11	O
(	STRIBILD.xml:S1:11907:1	O
fasted	STRIBILD.xml:S1:11908:6	O
)	STRIBILD.xml:S1:11914:1	O
43	STRIBILD.xml:S1:11919:2	O
[	STRIBILD.xml:S1:11921:1	O
N	STRIBILD.xml:S1:11922:1	O
675	STRIBILD.xml:S1:11924:3	O
]	STRIBILD.xml:S1:11927:1	O
7	STRIBILD.xml:S1:11935:1	O
[	STRIBILD.xml:S1:11936:1	O
N	STRIBILD.xml:S1:11937:1	O
535	STRIBILD.xml:S1:11939:3	O
]	STRIBILD.xml:S1:11942:1	O
43	STRIBILD.xml:S1:11950:2	O
[	STRIBILD.xml:S1:11952:1	O
N	STRIBILD.xml:S1:11953:1	O
343	STRIBILD.xml:S1:11955:3	O
]	STRIBILD.xml:S1:11958:1	O
9	STRIBILD.xml:S1:11966:1	O
[	STRIBILD.xml:S1:11967:1	O
N	STRIBILD.xml:S1:11968:1	O
262	STRIBILD.xml:S1:11970:3	O
]	STRIBILD.xml:S1:11973:1	O
42	STRIBILD.xml:S1:11981:2	O
[	STRIBILD.xml:S1:11983:1	O
N	STRIBILD.xml:S1:11984:1	O
335	STRIBILD.xml:S1:11986:3	O
]	STRIBILD.xml:S1:11989:1	O
7	STRIBILD.xml:S1:11997:1	O
[	STRIBILD.xml:S1:11998:1	O
N	STRIBILD.xml:S1:11999:1	O
242	STRIBILD.xml:S1:12001:3	O
]	STRIBILD.xml:S1:12004:1	O

LDL	STRIBILD.xml:S1:12013:3	O
-	STRIBILD.xml:S1:12016:1	O
cholesterol	STRIBILD.xml:S1:12017:11	O
(	STRIBILD.xml:S1:12029:1	O
fasted	STRIBILD.xml:S1:12030:6	O
)	STRIBILD.xml:S1:12036:1	O
100	STRIBILD.xml:S1:12040:3	O
[	STRIBILD.xml:S1:12043:1	O
N	STRIBILD.xml:S1:12044:1	O
675	STRIBILD.xml:S1:12046:3	O
]	STRIBILD.xml:S1:12049:1	O
15	STRIBILD.xml:S1:12057:2	O
[	STRIBILD.xml:S1:12059:1	O
N	STRIBILD.xml:S1:12060:1	O
535	STRIBILD.xml:S1:12062:3	O
]	STRIBILD.xml:S1:12065:1	O
97	STRIBILD.xml:S1:12072:2	O
[	STRIBILD.xml:S1:12074:1	O
N	STRIBILD.xml:S1:12075:1	O
343	STRIBILD.xml:S1:12077:3	O
]	STRIBILD.xml:S1:12080:1	O
19	STRIBILD.xml:S1:12088:2	O
[	STRIBILD.xml:S1:12090:1	O
N	STRIBILD.xml:S1:12091:1	O
262	STRIBILD.xml:S1:12093:3	O
]	STRIBILD.xml:S1:12096:1	O
101	STRIBILD.xml:S1:12102:3	O
[	STRIBILD.xml:S1:12105:1	O
N	STRIBILD.xml:S1:12106:1	O
337	STRIBILD.xml:S1:12108:3	O
]	STRIBILD.xml:S1:12111:1	O
18	STRIBILD.xml:S1:12119:2	O
[	STRIBILD.xml:S1:12121:1	O
N	STRIBILD.xml:S1:12122:1	O
242	STRIBILD.xml:S1:12124:3	O
]	STRIBILD.xml:S1:12127:1	O

Triglycerides	STRIBILD.xml:S1:12135:13	O
(	STRIBILD.xml:S1:12149:1	O
fasted	STRIBILD.xml:S1:12150:6	O
)	STRIBILD.xml:S1:12156:1	O
122	STRIBILD.xml:S1:12160:3	O
[	STRIBILD.xml:S1:12163:1	O
N	STRIBILD.xml:S1:12164:1	O
675	STRIBILD.xml:S1:12166:3	O
]	STRIBILD.xml:S1:12169:1	O
12	STRIBILD.xml:S1:12177:2	O
[	STRIBILD.xml:S1:12179:1	O
N	STRIBILD.xml:S1:12180:1	O
535	STRIBILD.xml:S1:12182:3	O
]	STRIBILD.xml:S1:12185:1	O
121	STRIBILD.xml:S1:12191:3	O
[	STRIBILD.xml:S1:12194:1	O
N	STRIBILD.xml:S1:12195:1	O
343	STRIBILD.xml:S1:12197:3	O
]	STRIBILD.xml:S1:12200:1	O
5	STRIBILD.xml:S1:12208:1	O
[	STRIBILD.xml:S1:12209:1	O
N	STRIBILD.xml:S1:12210:1	O
262	STRIBILD.xml:S1:12212:3	O
]	STRIBILD.xml:S1:12215:1	O
132	STRIBILD.xml:S1:12222:3	O
[	STRIBILD.xml:S1:12225:1	O
N	STRIBILD.xml:S1:12226:1	O
337	STRIBILD.xml:S1:12228:3	O
]	STRIBILD.xml:S1:12231:1	O
22	STRIBILD.xml:S1:12239:2	O
[	STRIBILD.xml:S1:12241:1	O
N	STRIBILD.xml:S1:12242:1	O
242	STRIBILD.xml:S1:12244:3	O
]	STRIBILD.xml:S1:12247:1	O

6.2	STRIBILD.xml:S1:12269:3	O
Postmarketing	STRIBILD.xml:S1:12273:13	O
Experience	STRIBILD.xml:S1:12287:10	O

The	STRIBILD.xml:S1:12301:3	O
following	STRIBILD.xml:S1:12305:9	O
adverse	STRIBILD.xml:S1:12315:7	O
reactions	STRIBILD.xml:S1:12323:9	O
have	STRIBILD.xml:S1:12333:4	O
been	STRIBILD.xml:S1:12338:4	O
identified	STRIBILD.xml:S1:12343:10	O
during	STRIBILD.xml:S1:12354:6	O
post	STRIBILD.xml:S1:12361:4	O
approval	STRIBILD.xml:S1:12366:8	O
use	STRIBILD.xml:S1:12375:3	O
of	STRIBILD.xml:S1:12379:2	O
tenofovir	STRIBILD.xml:S1:12382:9	O
DF	STRIBILD.xml:S1:12392:2	O
.	STRIBILD.xml:S1:12394:1	O

Because	STRIBILD.xml:S1:12396:7	O
postmarketing	STRIBILD.xml:S1:12404:13	O
reactions	STRIBILD.xml:S1:12418:9	O
are	STRIBILD.xml:S1:12428:3	O
reported	STRIBILD.xml:S1:12432:8	O
voluntarily	STRIBILD.xml:S1:12441:11	O
from	STRIBILD.xml:S1:12453:4	O
a	STRIBILD.xml:S1:12458:1	O
population	STRIBILD.xml:S1:12460:10	O
of	STRIBILD.xml:S1:12471:2	O
uncertain	STRIBILD.xml:S1:12474:9	O
size	STRIBILD.xml:S1:12484:4	O
,	STRIBILD.xml:S1:12488:1	O
it	STRIBILD.xml:S1:12490:2	O
is	STRIBILD.xml:S1:12493:2	O
not	STRIBILD.xml:S1:12496:3	O
always	STRIBILD.xml:S1:12500:6	O
possible	STRIBILD.xml:S1:12507:8	O
to	STRIBILD.xml:S1:12516:2	O
reliably	STRIBILD.xml:S1:12519:8	O
estimate	STRIBILD.xml:S1:12528:8	O
their	STRIBILD.xml:S1:12537:5	O
frequency	STRIBILD.xml:S1:12543:9	O
or	STRIBILD.xml:S1:12553:2	O
establish	STRIBILD.xml:S1:12556:9	O
a	STRIBILD.xml:S1:12566:1	O
causal	STRIBILD.xml:S1:12568:6	O
relationship	STRIBILD.xml:S1:12575:12	O
to	STRIBILD.xml:S1:12588:2	O
drug	STRIBILD.xml:S1:12591:4	O
exposure	STRIBILD.xml:S1:12596:8	O
.	STRIBILD.xml:S1:12604:1	O

No	STRIBILD.xml:S1:12606:2	O
additional	STRIBILD.xml:S1:12609:10	O
postmarketing	STRIBILD.xml:S1:12620:13	O
adverse	STRIBILD.xml:S1:12634:7	O
reactions	STRIBILD.xml:S1:12642:9	O
specific	STRIBILD.xml:S1:12652:8	O
for	STRIBILD.xml:S1:12661:3	O
emtricitabine	STRIBILD.xml:S1:12665:13	O
have	STRIBILD.xml:S1:12679:4	O
been	STRIBILD.xml:S1:12684:4	O
identified	STRIBILD.xml:S1:12689:10	O
.	STRIBILD.xml:S1:12699:1	O

Immune	STRIBILD.xml:S1:12707:6	O
System	STRIBILD.xml:S1:12714:6	O
Disorders	STRIBILD.xml:S1:12721:9	O

allergic	STRIBILD.xml:S1:12737:8	B-AdverseReaction
reaction	STRIBILD.xml:S1:12746:8	I-AdverseReaction
,	STRIBILD.xml:S1:12754:1	O
including	STRIBILD.xml:S1:12756:9	O
angioedema	STRIBILD.xml:S1:12766:10	B-AdverseReaction

Metabolism	STRIBILD.xml:S1:12783:10	O
and	STRIBILD.xml:S1:12794:3	O
Nutrition	STRIBILD.xml:S1:12798:9	O
Disorders	STRIBILD.xml:S1:12808:9	O

lactic	STRIBILD.xml:S1:12824:6	B-AdverseReaction
acidosis	STRIBILD.xml:S1:12831:8	I-AdverseReaction
,	STRIBILD.xml:S1:12839:1	O
hypokalemia	STRIBILD.xml:S1:12841:11	B-AdverseReaction
,	STRIBILD.xml:S1:12852:1	O
hypophosphatemia	STRIBILD.xml:S1:12854:16	B-AdverseReaction

Respiratory	STRIBILD.xml:S1:12877:11	O
,	STRIBILD.xml:S1:12888:1	O
Thoracic	STRIBILD.xml:S1:12890:8	O
,	STRIBILD.xml:S1:12898:1	O
and	STRIBILD.xml:S1:12900:3	O
Mediastinal	STRIBILD.xml:S1:12904:11	O
Disorders	STRIBILD.xml:S1:12916:9	O

dyspnea	STRIBILD.xml:S1:12932:7	B-AdverseReaction

Gastrointestinal	STRIBILD.xml:S1:12946:16	O
Disorders	STRIBILD.xml:S1:12963:9	O

pancreatitis	STRIBILD.xml:S1:12979:12	B-AdverseReaction
,	STRIBILD.xml:S1:12991:1	O
increased	STRIBILD.xml:S1:12993:9	B-AdverseReaction
amylase	STRIBILD.xml:S1:13003:7	I-AdverseReaction
,	STRIBILD.xml:S1:13010:1	O
abdominal	STRIBILD.xml:S1:13012:9	B-AdverseReaction
pain	STRIBILD.xml:S1:13022:4	I-AdverseReaction

Hepatobiliary	STRIBILD.xml:S1:13033:13	O
Disorders	STRIBILD.xml:S1:13047:9	O

hepatic	STRIBILD.xml:S1:13063:7	B-AdverseReaction
steatosis	STRIBILD.xml:S1:13071:9	I-AdverseReaction
,	STRIBILD.xml:S1:13080:1	O
hepatitis	STRIBILD.xml:S1:13082:9	B-AdverseReaction
,	STRIBILD.xml:S1:13091:1	O
increased	STRIBILD.xml:S1:13093:9	B-AdverseReaction
liver	STRIBILD.xml:S1:13103:5	I-AdverseReaction
enzymes	STRIBILD.xml:S1:13109:7	I-AdverseReaction
(	STRIBILD.xml:S1:13117:1	O
most	STRIBILD.xml:S1:13118:4	O
commonly	STRIBILD.xml:S1:13123:8	O
AST	STRIBILD.xml:S1:13132:3	I-AdverseReaction
,	STRIBILD.xml:S1:13135:1	O
ALT	STRIBILD.xml:S1:13137:3	I-AdverseReaction
gamma	STRIBILD.xml:S1:13141:5	I-AdverseReaction
GT	STRIBILD.xml:S1:13147:2	I-AdverseReaction
)	STRIBILD.xml:S1:13149:1	O

Skin	STRIBILD.xml:S1:13157:4	O
and	STRIBILD.xml:S1:13162:3	O
Subcutaneous	STRIBILD.xml:S1:13166:12	O
Tissue	STRIBILD.xml:S1:13179:6	O
Disorders	STRIBILD.xml:S1:13186:9	O

rash	STRIBILD.xml:S1:13202:4	B-AdverseReaction

Musculoskeletal	STRIBILD.xml:S1:13213:15	O
and	STRIBILD.xml:S1:13229:3	O
Connective	STRIBILD.xml:S1:13233:10	O
Tissue	STRIBILD.xml:S1:13244:6	O
Disorders	STRIBILD.xml:S1:13251:9	O

rhabdomyolysis	STRIBILD.xml:S1:13267:14	B-AdverseReaction
,	STRIBILD.xml:S1:13281:1	O
osteomalacia	STRIBILD.xml:S1:13283:12	B-AdverseReaction
(	STRIBILD.xml:S1:13296:1	O
manifested	STRIBILD.xml:S1:13297:10	O
as	STRIBILD.xml:S1:13308:2	O
bone	STRIBILD.xml:S1:13311:4	B-AdverseReaction
pain	STRIBILD.xml:S1:13316:4	I-AdverseReaction
and	STRIBILD.xml:S1:13321:3	O
which	STRIBILD.xml:S1:13325:5	O
may	STRIBILD.xml:S1:13331:3	O
contribute	STRIBILD.xml:S1:13335:10	O
to	STRIBILD.xml:S1:13346:2	O
fractures	STRIBILD.xml:S1:13349:9	B-AdverseReaction
)	STRIBILD.xml:S1:13358:1	O
,	STRIBILD.xml:S1:13359:1	O
muscular	STRIBILD.xml:S1:13361:8	B-AdverseReaction
weakness	STRIBILD.xml:S1:13370:8	I-AdverseReaction
,	STRIBILD.xml:S1:13378:1	O
myopathy	STRIBILD.xml:S1:13380:8	B-AdverseReaction

Renal	STRIBILD.xml:S1:13395:5	O
and	STRIBILD.xml:S1:13401:3	O
Urinary	STRIBILD.xml:S1:13405:7	O
Disorders	STRIBILD.xml:S1:13413:9	O

acute	STRIBILD.xml:S1:13429:5	B-AdverseReaction
renal	STRIBILD.xml:S1:13435:5	I-AdverseReaction
failure	STRIBILD.xml:S1:13441:7	I-AdverseReaction
,	STRIBILD.xml:S1:13448:1	O
renal	STRIBILD.xml:S1:13450:5	B-AdverseReaction
failure	STRIBILD.xml:S1:13456:7	I-AdverseReaction
,	STRIBILD.xml:S1:13463:1	O
acute	STRIBILD.xml:S1:13465:5	B-AdverseReaction
tubular	STRIBILD.xml:S1:13471:7	I-AdverseReaction
necrosis	STRIBILD.xml:S1:13479:8	I-AdverseReaction
,	STRIBILD.xml:S1:13487:1	O
Fanconi	STRIBILD.xml:S1:13489:7	B-AdverseReaction
syndrome	STRIBILD.xml:S1:13497:8	I-AdverseReaction
,	STRIBILD.xml:S1:13505:1	O
proximal	STRIBILD.xml:S1:13507:8	B-AdverseReaction
renal	STRIBILD.xml:S1:13516:5	I-AdverseReaction
tubulopathy	STRIBILD.xml:S1:13522:11	I-AdverseReaction
,	STRIBILD.xml:S1:13533:1	O
interstitial	STRIBILD.xml:S1:13535:12	B-AdverseReaction
nephritis	STRIBILD.xml:S1:13548:9	I-AdverseReaction
(	STRIBILD.xml:S1:13558:1	O
including	STRIBILD.xml:S1:13559:9	O
acute	STRIBILD.xml:S1:13569:5	I-AdverseReaction
cases	STRIBILD.xml:S1:13575:5	O
)	STRIBILD.xml:S1:13580:1	O
,	STRIBILD.xml:S1:13581:1	O
nephrogenic	STRIBILD.xml:S1:13583:11	B-AdverseReaction
diabetes	STRIBILD.xml:S1:13595:8	I-AdverseReaction
insipidus	STRIBILD.xml:S1:13604:9	I-AdverseReaction
,	STRIBILD.xml:S1:13613:1	O
renal	STRIBILD.xml:S1:13615:5	B-AdverseReaction
insufficiency	STRIBILD.xml:S1:13621:13	I-AdverseReaction
,	STRIBILD.xml:S1:13634:1	O
increased	STRIBILD.xml:S1:13636:9	B-AdverseReaction
creatinine	STRIBILD.xml:S1:13646:10	I-AdverseReaction
,	STRIBILD.xml:S1:13656:1	O
proteinuria	STRIBILD.xml:S1:13658:11	B-AdverseReaction
,	STRIBILD.xml:S1:13669:1	O
polyuria	STRIBILD.xml:S1:13671:8	B-AdverseReaction

General	STRIBILD.xml:S1:13686:7	O
Disorders	STRIBILD.xml:S1:13694:9	O
and	STRIBILD.xml:S1:13704:3	O
Administration	STRIBILD.xml:S1:13708:14	O
Site	STRIBILD.xml:S1:13723:4	O
Conditions	STRIBILD.xml:S1:13728:10	O

asthenia	STRIBILD.xml:S1:13745:8	B-AdverseReaction

The	STRIBILD.xml:S1:13758:3	O
following	STRIBILD.xml:S1:13762:9	O
adverse	STRIBILD.xml:S1:13772:7	O
reactions	STRIBILD.xml:S1:13780:9	O
,	STRIBILD.xml:S1:13789:1	O
listed	STRIBILD.xml:S1:13791:6	O
under	STRIBILD.xml:S1:13798:5	O
the	STRIBILD.xml:S1:13804:3	O
body	STRIBILD.xml:S1:13808:4	O
system	STRIBILD.xml:S1:13813:6	O
headings	STRIBILD.xml:S1:13820:8	O
above	STRIBILD.xml:S1:13829:5	O
,	STRIBILD.xml:S1:13834:1	O
may	STRIBILD.xml:S1:13836:3	O
occur	STRIBILD.xml:S1:13840:5	O
as	STRIBILD.xml:S1:13846:2	O
a	STRIBILD.xml:S1:13849:1	O
consequence	STRIBILD.xml:S1:13851:11	O
of	STRIBILD.xml:S1:13863:2	O
proximal	STRIBILD.xml:S1:13866:8	B-AdverseReaction
renal	STRIBILD.xml:S1:13875:5	I-AdverseReaction
tubulopathy	STRIBILD.xml:S1:13881:11	I-AdverseReaction
:	STRIBILD.xml:S1:13892:1	O
rhabdomyolysis	STRIBILD.xml:S1:13894:14	B-AdverseReaction
,	STRIBILD.xml:S1:13908:1	O
osteomalacia	STRIBILD.xml:S1:13910:12	B-AdverseReaction
,	STRIBILD.xml:S1:13922:1	O
hypokalemia	STRIBILD.xml:S1:13924:11	B-AdverseReaction
,	STRIBILD.xml:S1:13935:1	O
muscular	STRIBILD.xml:S1:13937:8	B-AdverseReaction
weakness	STRIBILD.xml:S1:13946:8	I-AdverseReaction
,	STRIBILD.xml:S1:13954:1	O
myopathy	STRIBILD.xml:S1:13956:8	B-AdverseReaction
,	STRIBILD.xml:S1:13964:1	O
hypophosphatemia	STRIBILD.xml:S1:13966:16	B-AdverseReaction
.	STRIBILD.xml:S1:13982:1	O
\n\n	STRIBILD.xml:S2:0:2	O
BOXED	STRIBILD.xml:S2:6:5	O
WARNING	STRIBILD.xml:S2:12:7	O
:	STRIBILD.xml:S2:19:1	O
WARNING	STRIBILD.xml:S2:21:7	O
:	STRIBILD.xml:S2:28:1	O
LACTIC	STRIBILD.xml:S2:30:6	B-AdverseReaction
ACIDOSIS	STRIBILD.xml:S2:37:8	I-AdverseReaction
SEVERE	STRIBILD.xml:S2:46:6	B-Severity
HEPATOMEGALY	STRIBILD.xml:S2:53:12	B-AdverseReaction
WITH	STRIBILD.xml:S2:66:4	O
STEATOSIS	STRIBILD.xml:S2:71:9	B-AdverseReaction
and	STRIBILD.xml:S2:81:3	O
POST	STRIBILD.xml:S2:85:4	O
TREATMENT	STRIBILD.xml:S2:90:9	O
ACUTE	STRIBILD.xml:S2:100:5	B-AdverseReaction
EXACERBATION	STRIBILD.xml:S2:106:12	I-AdverseReaction
OF	STRIBILD.xml:S2:119:2	I-AdverseReaction
HEPATITIS	STRIBILD.xml:S2:122:9	I-AdverseReaction
B	STRIBILD.xml:S2:132:1	I-AdverseReaction
\n\n	STRIBILD.xml:S2:133:2	O
WARNING	STRIBILD.xml:S2:139:7	O
:	STRIBILD.xml:S2:146:1	O
LACTIC	STRIBILD.xml:S2:148:6	B-AdverseReaction
ACIDOSIS	STRIBILD.xml:S2:155:8	I-AdverseReaction
SEVERE	STRIBILD.xml:S2:164:6	B-Severity
HEPATOMEGALY	STRIBILD.xml:S2:171:12	B-AdverseReaction
WITH	STRIBILD.xml:S2:184:4	O
STEATOSIS	STRIBILD.xml:S2:189:9	B-AdverseReaction
and	STRIBILD.xml:S2:199:3	O
POST	STRIBILD.xml:S2:203:4	O
TREATMENT	STRIBILD.xml:S2:208:9	O
ACUTE	STRIBILD.xml:S2:218:5	B-AdverseReaction
EXACERBATION	STRIBILD.xml:S2:224:12	I-AdverseReaction
OF	STRIBILD.xml:S2:237:2	I-AdverseReaction
HEPATITIS	STRIBILD.xml:S2:240:9	I-AdverseReaction
B	STRIBILD.xml:S2:250:1	I-AdverseReaction
\n\n	STRIBILD.xml:S2:253:2	O
Lactic	STRIBILD.xml:S2:259:6	B-AdverseReaction
acidosis	STRIBILD.xml:S2:266:8	I-AdverseReaction
and	STRIBILD.xml:S2:275:3	O
severe	STRIBILD.xml:S2:279:6	B-Severity
hepatomegaly	STRIBILD.xml:S2:286:12	B-AdverseReaction
with	STRIBILD.xml:S2:299:4	O
steatosis	STRIBILD.xml:S2:304:9	B-AdverseReaction
,	STRIBILD.xml:S2:313:1	O
including	STRIBILD.xml:S2:315:9	O
fatal	STRIBILD.xml:S2:325:5	B-AdverseReaction
cases	STRIBILD.xml:S2:331:5	O
,	STRIBILD.xml:S2:336:1	O
have	STRIBILD.xml:S2:338:4	O
been	STRIBILD.xml:S2:343:4	O
reported	STRIBILD.xml:S2:348:8	O
with	STRIBILD.xml:S2:357:4	O
the	STRIBILD.xml:S2:362:3	O
use	STRIBILD.xml:S2:366:3	O
of	STRIBILD.xml:S2:370:2	O
nucleoside	STRIBILD.xml:S2:373:10	O
analogs	STRIBILD.xml:S2:384:7	O
,	STRIBILD.xml:S2:391:1	O
including	STRIBILD.xml:S2:393:9	O
tenofovir	STRIBILD.xml:S2:403:9	O
disoproxil	STRIBILD.xml:S2:413:10	O
fumarate	STRIBILD.xml:S2:424:8	O
,	STRIBILD.xml:S2:432:1	O
a	STRIBILD.xml:S2:434:1	O
component	STRIBILD.xml:S2:436:9	O
of	STRIBILD.xml:S2:446:2	O
STRIBILD	STRIBILD.xml:S2:449:8	O
,	STRIBILD.xml:S2:457:1	O
in	STRIBILD.xml:S2:459:2	O
combination	STRIBILD.xml:S2:462:11	O
with	STRIBILD.xml:S2:474:4	O
other	STRIBILD.xml:S2:479:5	O
antiretrovirals	STRIBILD.xml:S2:485:15	O
[	STRIBILD.xml:S2:503:1	O
see	STRIBILD.xml:S2:504:3	O
Warnings	STRIBILD.xml:S2:510:8	O
and	STRIBILD.xml:S2:519:3	O
Precautions	STRIBILD.xml:S2:523:11	O
(	STRIBILD.xml:S2:535:1	O
5.1	STRIBILD.xml:S2:536:3	O
)	STRIBILD.xml:S2:539:1	O
]	STRIBILD.xml:S2:542:1	O
.	STRIBILD.xml:S2:545:1	O

STRIBILD	STRIBILD.xml:S2:555:8	O
is	STRIBILD.xml:S2:564:2	O
not	STRIBILD.xml:S2:567:3	O
approved	STRIBILD.xml:S2:571:8	O
for	STRIBILD.xml:S2:580:3	O
the	STRIBILD.xml:S2:584:3	O
treatment	STRIBILD.xml:S2:588:9	O
of	STRIBILD.xml:S2:598:2	O
chronic	STRIBILD.xml:S2:601:7	O
hepatitis	STRIBILD.xml:S2:609:9	O
B	STRIBILD.xml:S2:619:1	O
virus	STRIBILD.xml:S2:621:5	O
(	STRIBILD.xml:S2:627:1	O
HBV	STRIBILD.xml:S2:628:3	O
)	STRIBILD.xml:S2:631:1	O
infection	STRIBILD.xml:S2:633:9	O
and	STRIBILD.xml:S2:643:3	O
the	STRIBILD.xml:S2:647:3	O
safety	STRIBILD.xml:S2:651:6	O
and	STRIBILD.xml:S2:658:3	O
efficacy	STRIBILD.xml:S2:662:8	O
of	STRIBILD.xml:S2:671:2	O
STRIBILD	STRIBILD.xml:S2:674:8	O
have	STRIBILD.xml:S2:683:4	O
not	STRIBILD.xml:S2:688:3	O
been	STRIBILD.xml:S2:692:4	O
established	STRIBILD.xml:S2:697:11	O
in	STRIBILD.xml:S2:709:2	O
patients	STRIBILD.xml:S2:712:8	O
coinfected	STRIBILD.xml:S2:721:10	O
with	STRIBILD.xml:S2:732:4	O
HBV	STRIBILD.xml:S2:737:3	O
and	STRIBILD.xml:S2:741:3	O
HIV	STRIBILD.xml:S2:745:3	O
-	STRIBILD.xml:S2:748:1	O
1	STRIBILD.xml:S2:749:1	O
.	STRIBILD.xml:S2:750:1	O

Severe	STRIBILD.xml:S2:752:6	B-Severity
acute	STRIBILD.xml:S2:759:5	B-AdverseReaction
exacerbations	STRIBILD.xml:S2:765:13	I-AdverseReaction
of	STRIBILD.xml:S2:779:2	I-AdverseReaction
hepatitis	STRIBILD.xml:S2:782:9	I-AdverseReaction
B	STRIBILD.xml:S2:792:1	I-AdverseReaction
have	STRIBILD.xml:S2:794:4	O
been	STRIBILD.xml:S2:799:4	O
reported	STRIBILD.xml:S2:804:8	O
in	STRIBILD.xml:S2:813:2	O
patients	STRIBILD.xml:S2:816:8	O
who	STRIBILD.xml:S2:825:3	O
are	STRIBILD.xml:S2:829:3	O
coinfected	STRIBILD.xml:S2:833:10	O
with	STRIBILD.xml:S2:844:4	O
HBV	STRIBILD.xml:S2:849:3	O
and	STRIBILD.xml:S2:853:3	O
human	STRIBILD.xml:S2:857:5	O
immunodeficiency	STRIBILD.xml:S2:863:16	O
virus	STRIBILD.xml:S2:880:5	O
-	STRIBILD.xml:S2:885:1	O
1	STRIBILD.xml:S2:886:1	O
(	STRIBILD.xml:S2:888:1	O
HIV	STRIBILD.xml:S2:889:3	O
-	STRIBILD.xml:S2:892:1	O
1	STRIBILD.xml:S2:893:1	O
)	STRIBILD.xml:S2:894:1	O
and	STRIBILD.xml:S2:896:3	O
have	STRIBILD.xml:S2:900:4	O
discontinued	STRIBILD.xml:S2:905:12	O
EMTRIVA	STRIBILD.xml:S2:918:7	O
or	STRIBILD.xml:S2:926:2	O
VIREAD	STRIBILD.xml:S2:929:6	O
,	STRIBILD.xml:S2:935:1	O
which	STRIBILD.xml:S2:937:5	O
are	STRIBILD.xml:S2:943:3	O
components	STRIBILD.xml:S2:947:10	O
of	STRIBILD.xml:S2:958:2	O
STRIBILD	STRIBILD.xml:S2:961:8	O
.	STRIBILD.xml:S2:969:1	O

Hepatic	STRIBILD.xml:S2:971:7	O
function	STRIBILD.xml:S2:979:8	O
should	STRIBILD.xml:S2:988:6	O
be	STRIBILD.xml:S2:995:2	O
monitored	STRIBILD.xml:S2:998:9	O
closely	STRIBILD.xml:S2:1008:7	O
with	STRIBILD.xml:S2:1016:4	O
both	STRIBILD.xml:S2:1021:4	O
clinical	STRIBILD.xml:S2:1026:8	O
and	STRIBILD.xml:S2:1035:3	O
laboratory	STRIBILD.xml:S2:1039:10	O
follow	STRIBILD.xml:S2:1050:6	O
-	STRIBILD.xml:S2:1056:1	O
up	STRIBILD.xml:S2:1057:2	O
for	STRIBILD.xml:S2:1060:3	O
at	STRIBILD.xml:S2:1064:2	O
least	STRIBILD.xml:S2:1067:5	O
several	STRIBILD.xml:S2:1073:7	O
months	STRIBILD.xml:S2:1081:6	O
in	STRIBILD.xml:S2:1088:2	O
patients	STRIBILD.xml:S2:1091:8	O
who	STRIBILD.xml:S2:1100:3	O
are	STRIBILD.xml:S2:1104:3	O
coinfected	STRIBILD.xml:S2:1108:10	O
with	STRIBILD.xml:S2:1119:4	O
HIV	STRIBILD.xml:S2:1124:3	O
-	STRIBILD.xml:S2:1127:1	O
1	STRIBILD.xml:S2:1128:1	O
and	STRIBILD.xml:S2:1130:3	O
HBV	STRIBILD.xml:S2:1134:3	O
and	STRIBILD.xml:S2:1138:3	O
discontinue	STRIBILD.xml:S2:1142:11	O
STRIBILD	STRIBILD.xml:S2:1154:8	O
.	STRIBILD.xml:S2:1162:1	O

If	STRIBILD.xml:S2:1164:2	O
appropriate	STRIBILD.xml:S2:1167:11	O
,	STRIBILD.xml:S2:1178:1	O
initiation	STRIBILD.xml:S2:1180:10	O
of	STRIBILD.xml:S2:1191:2	O
anti	STRIBILD.xml:S2:1194:4	O
-	STRIBILD.xml:S2:1198:1	O
hepatitis	STRIBILD.xml:S2:1199:9	O
B	STRIBILD.xml:S2:1209:1	O
therapy	STRIBILD.xml:S2:1211:7	O
may	STRIBILD.xml:S2:1219:3	O
be	STRIBILD.xml:S2:1223:2	O
warranted	STRIBILD.xml:S2:1226:9	O
[	STRIBILD.xml:S2:1238:1	O
see	STRIBILD.xml:S2:1239:3	O
Warnings	STRIBILD.xml:S2:1245:8	O
and	STRIBILD.xml:S2:1254:3	O
Precautions	STRIBILD.xml:S2:1258:11	O
(	STRIBILD.xml:S2:1270:1	O
5.2	STRIBILD.xml:S2:1271:3	O
)	STRIBILD.xml:S2:1274:1	O
]	STRIBILD.xml:S2:1277:1	O
.	STRIBILD.xml:S2:1280:1	O

EXCERPT	STRIBILD.xml:S2:1290:7	O
:	STRIBILD.xml:S2:1297:1	O
WARNING	STRIBILD.xml:S2:1301:7	O
:	STRIBILD.xml:S2:1308:1	O
LACTIC	STRIBILD.xml:S2:1310:6	B-AdverseReaction
ACIDOSIS	STRIBILD.xml:S2:1317:8	I-AdverseReaction
SEVERE	STRIBILD.xml:S2:1326:6	B-Severity
HEPATOMEGALY	STRIBILD.xml:S2:1333:12	B-AdverseReaction
WITH	STRIBILD.xml:S2:1346:4	O
STEATOSIS	STRIBILD.xml:S2:1351:9	B-AdverseReaction
and	STRIBILD.xml:S2:1361:3	O
POST	STRIBILD.xml:S2:1365:4	O
TREATMENT	STRIBILD.xml:S2:1370:9	O
ACUTE	STRIBILD.xml:S2:1380:5	B-AdverseReaction
EXACERBATION	STRIBILD.xml:S2:1386:12	I-AdverseReaction
OF	STRIBILD.xml:S2:1399:2	I-AdverseReaction
HEPATITIS	STRIBILD.xml:S2:1402:9	I-AdverseReaction
B	STRIBILD.xml:S2:1412:1	I-AdverseReaction
\n\n\n\n	STRIBILD.xml:S2:1413:4	O
See	STRIBILD.xml:S2:1420:3	O
full	STRIBILD.xml:S2:1424:4	O
prescribing	STRIBILD.xml:S2:1429:11	O
information	STRIBILD.xml:S2:1441:11	O
for	STRIBILD.xml:S2:1453:3	O
complete	STRIBILD.xml:S2:1457:8	O
boxed	STRIBILD.xml:S2:1466:5	O
warning	STRIBILD.xml:S2:1472:7	O
.	STRIBILD.xml:S2:1479:1	O

Lactic	STRIBILD.xml:S2:1490:6	B-AdverseReaction
acidosis	STRIBILD.xml:S2:1497:8	I-AdverseReaction
and	STRIBILD.xml:S2:1506:3	O
severe	STRIBILD.xml:S2:1510:6	B-Severity
hepatomegaly	STRIBILD.xml:S2:1517:12	B-AdverseReaction
with	STRIBILD.xml:S2:1530:4	O
steatosis	STRIBILD.xml:S2:1535:9	B-AdverseReaction
,	STRIBILD.xml:S2:1544:1	O
including	STRIBILD.xml:S2:1546:9	O
fatal	STRIBILD.xml:S2:1556:5	B-AdverseReaction
cases	STRIBILD.xml:S2:1562:5	O
,	STRIBILD.xml:S2:1567:1	O
have	STRIBILD.xml:S2:1569:4	O
been	STRIBILD.xml:S2:1574:4	O
reported	STRIBILD.xml:S2:1579:8	O
with	STRIBILD.xml:S2:1588:4	O
the	STRIBILD.xml:S2:1593:3	O
use	STRIBILD.xml:S2:1597:3	O
of	STRIBILD.xml:S2:1601:2	O
nucleoside	STRIBILD.xml:S2:1604:10	O
analogs	STRIBILD.xml:S2:1615:7	O
,	STRIBILD.xml:S2:1622:1	O
including	STRIBILD.xml:S2:1624:9	O
tenofovir	STRIBILD.xml:S2:1634:9	O
disoproxil	STRIBILD.xml:S2:1644:10	O
fumarate	STRIBILD.xml:S2:1655:8	O
(	STRIBILD.xml:S2:1664:1	O
DF	STRIBILD.xml:S2:1665:2	O
)	STRIBILD.xml:S2:1667:1	O
,	STRIBILD.xml:S2:1668:1	O
a	STRIBILD.xml:S2:1670:1	O
component	STRIBILD.xml:S2:1672:9	O
of	STRIBILD.xml:S2:1682:2	O
STRIBILD	STRIBILD.xml:S2:1685:8	O
.	STRIBILD.xml:S2:1693:1	O

(	STRIBILD.xml:S2:1695:1	O
5.1	STRIBILD.xml:S2:1696:3	O
)	STRIBILD.xml:S2:1699:1	O
\n	STRIBILD.xml:S2:1701:1	O
STRIBILD	STRIBILD.xml:S2:1706:8	O
is	STRIBILD.xml:S2:1715:2	O
not	STRIBILD.xml:S2:1718:3	O
approved	STRIBILD.xml:S2:1722:8	O
for	STRIBILD.xml:S2:1731:3	O
the	STRIBILD.xml:S2:1735:3	O
treatment	STRIBILD.xml:S2:1739:9	O
of	STRIBILD.xml:S2:1749:2	O
chronic	STRIBILD.xml:S2:1752:7	O
hepatitis	STRIBILD.xml:S2:1760:9	O
B	STRIBILD.xml:S2:1770:1	O
virus	STRIBILD.xml:S2:1772:5	O
(	STRIBILD.xml:S2:1778:1	O
HBV	STRIBILD.xml:S2:1779:3	O
)	STRIBILD.xml:S2:1782:1	O
infection	STRIBILD.xml:S2:1784:9	O
.	STRIBILD.xml:S2:1793:1	O

Severe	STRIBILD.xml:S2:1795:6	B-Severity
acute	STRIBILD.xml:S2:1802:5	B-AdverseReaction
exacerbations	STRIBILD.xml:S2:1808:13	I-AdverseReaction
of	STRIBILD.xml:S2:1822:2	I-AdverseReaction
hepatitis	STRIBILD.xml:S2:1825:9	I-AdverseReaction
B	STRIBILD.xml:S2:1835:1	I-AdverseReaction
have	STRIBILD.xml:S2:1837:4	O
been	STRIBILD.xml:S2:1842:4	O
reported	STRIBILD.xml:S2:1847:8	O
in	STRIBILD.xml:S2:1856:2	O
patients	STRIBILD.xml:S2:1859:8	O
coinfected	STRIBILD.xml:S2:1868:10	O
with	STRIBILD.xml:S2:1879:4	O
HIV	STRIBILD.xml:S2:1884:3	O
-	STRIBILD.xml:S2:1887:1	O
1	STRIBILD.xml:S2:1888:1	O
and	STRIBILD.xml:S2:1890:3	O
HBV	STRIBILD.xml:S2:1894:3	O
who	STRIBILD.xml:S2:1898:3	O
have	STRIBILD.xml:S2:1902:4	O
discontinued	STRIBILD.xml:S2:1907:12	O
EMTRIVA	STRIBILD.xml:S2:1920:7	O
or	STRIBILD.xml:S2:1928:2	O
VIREAD	STRIBILD.xml:S2:1931:6	O
,	STRIBILD.xml:S2:1937:1	O
two	STRIBILD.xml:S2:1939:3	O
of	STRIBILD.xml:S2:1943:2	O
the	STRIBILD.xml:S2:1946:3	O
components	STRIBILD.xml:S2:1950:10	O
of	STRIBILD.xml:S2:1961:2	O
STRIBILD	STRIBILD.xml:S2:1964:8	O
.	STRIBILD.xml:S2:1972:1	O

Hepatic	STRIBILD.xml:S2:1974:7	O
function	STRIBILD.xml:S2:1982:8	O
should	STRIBILD.xml:S2:1991:6	O
be	STRIBILD.xml:S2:1998:2	O
monitored	STRIBILD.xml:S2:2001:9	O
closely	STRIBILD.xml:S2:2011:7	O
in	STRIBILD.xml:S2:2019:2	O
these	STRIBILD.xml:S2:2022:5	O
patients	STRIBILD.xml:S2:2028:8	O
.	STRIBILD.xml:S2:2036:1	O

If	STRIBILD.xml:S2:2038:2	O
appropriate	STRIBILD.xml:S2:2041:11	O
,	STRIBILD.xml:S2:2052:1	O
initiation	STRIBILD.xml:S2:2054:10	O
of	STRIBILD.xml:S2:2065:2	O
anti	STRIBILD.xml:S2:2068:4	O
-	STRIBILD.xml:S2:2072:1	O
hepatitis	STRIBILD.xml:S2:2073:9	O
B	STRIBILD.xml:S2:2083:1	O
therapy	STRIBILD.xml:S2:2085:7	O
may	STRIBILD.xml:S2:2093:3	O
be	STRIBILD.xml:S2:2097:2	O
warranted	STRIBILD.xml:S2:2100:9	O
.	STRIBILD.xml:S2:2109:1	O

(	STRIBILD.xml:S2:2111:1	O
5.2	STRIBILD.xml:S2:2112:3	O
)	STRIBILD.xml:S2:2115:1	O
\n	STRIBILD.xml:S2:2117:1	O
5	STRIBILD.xml:S3:4:1	O
WARNINGS	STRIBILD.xml:S3:6:8	O
AND	STRIBILD.xml:S3:15:3	O
PRECAUTIONS	STRIBILD.xml:S3:19:11	O

EXCERPT	STRIBILD.xml:S3:37:7	O
:	STRIBILD.xml:S3:44:1	O
New	STRIBILD.xml:S3:52:3	B-AdverseReaction
onset	STRIBILD.xml:S3:56:5	I-AdverseReaction
or	STRIBILD.xml:S3:62:2	O
worsening	STRIBILD.xml:S3:65:9	B-AdverseReaction
renal	STRIBILD.xml:S3:75:5	I-AdverseReaction
impairment	STRIBILD.xml:S3:81:10	I-AdverseReaction
:	STRIBILD.xml:S3:91:1	O
Can	STRIBILD.xml:S3:93:3	B-Factor
include	STRIBILD.xml:S3:97:7	O
acute	STRIBILD.xml:S3:105:5	B-AdverseReaction
renal	STRIBILD.xml:S3:111:5	I-AdverseReaction
failure	STRIBILD.xml:S3:117:7	I-AdverseReaction
and	STRIBILD.xml:S3:125:3	O
Fanconi	STRIBILD.xml:S3:129:7	B-AdverseReaction
syndrome	STRIBILD.xml:S3:137:8	I-AdverseReaction
.	STRIBILD.xml:S3:145:1	O

Assess	STRIBILD.xml:S3:147:6	O
creatinine	STRIBILD.xml:S3:154:10	O
clearance	STRIBILD.xml:S3:165:9	O
(	STRIBILD.xml:S3:175:1	O
CLcr	STRIBILD.xml:S3:176:4	O
)	STRIBILD.xml:S3:180:1	O
,	STRIBILD.xml:S3:181:1	O
urine	STRIBILD.xml:S3:183:5	O
glucose	STRIBILD.xml:S3:189:7	O
and	STRIBILD.xml:S3:197:3	O
urine	STRIBILD.xml:S3:201:5	O
protein	STRIBILD.xml:S3:207:7	O
before	STRIBILD.xml:S3:215:6	O
initiating	STRIBILD.xml:S3:222:10	O
treatment	STRIBILD.xml:S3:233:9	O
with	STRIBILD.xml:S3:243:4	O
STRIBILD	STRIBILD.xml:S3:248:8	O
.	STRIBILD.xml:S3:256:1	O

Monitor	STRIBILD.xml:S3:258:7	O
CLcr	STRIBILD.xml:S3:266:4	O
,	STRIBILD.xml:S3:270:1	O
urine	STRIBILD.xml:S3:272:5	O
glucose	STRIBILD.xml:S3:278:7	O
,	STRIBILD.xml:S3:285:1	O
and	STRIBILD.xml:S3:287:3	O
urine	STRIBILD.xml:S3:291:5	O
protein	STRIBILD.xml:S3:297:7	O
in	STRIBILD.xml:S3:305:2	O
all	STRIBILD.xml:S3:308:3	O
patients	STRIBILD.xml:S3:312:8	O
.	STRIBILD.xml:S3:320:1	O

Monitor	STRIBILD.xml:S3:322:7	O
serum	STRIBILD.xml:S3:330:5	O
phosphorus	STRIBILD.xml:S3:336:10	O
in	STRIBILD.xml:S3:347:2	O
patients	STRIBILD.xml:S3:350:8	O
at	STRIBILD.xml:S3:359:2	O
risk	STRIBILD.xml:S3:362:4	O
for	STRIBILD.xml:S3:367:3	O
renal	STRIBILD.xml:S3:371:5	O
impairment	STRIBILD.xml:S3:377:10	O
.	STRIBILD.xml:S3:387:1	O

Avoid	STRIBILD.xml:S3:389:5	O
administering	STRIBILD.xml:S3:395:13	O
STRIBILD	STRIBILD.xml:S3:409:8	O
with	STRIBILD.xml:S3:418:4	O
concurrent	STRIBILD.xml:S3:423:10	O
or	STRIBILD.xml:S3:434:2	O
recent	STRIBILD.xml:S3:437:6	O
use	STRIBILD.xml:S3:444:3	O
of	STRIBILD.xml:S3:448:2	O
nephrotoxic	STRIBILD.xml:S3:451:11	O
drugs	STRIBILD.xml:S3:463:5	O
.	STRIBILD.xml:S3:468:1	O

(	STRIBILD.xml:S3:470:1	O
5.3	STRIBILD.xml:S3:473:3	O
)	STRIBILD.xml:S3:478:1	O

Avoid	STRIBILD.xml:S3:485:5	O
coadministration	STRIBILD.xml:S3:491:16	O
with	STRIBILD.xml:S3:508:4	O
other	STRIBILD.xml:S3:513:5	O
anti	STRIBILD.xml:S3:519:4	O
-	STRIBILD.xml:S3:523:1	O
retroviral	STRIBILD.xml:S3:524:10	O
products	STRIBILD.xml:S3:535:8	O
:	STRIBILD.xml:S3:543:1	O
Do	STRIBILD.xml:S3:545:2	O
not	STRIBILD.xml:S3:548:3	O
use	STRIBILD.xml:S3:552:3	O
with	STRIBILD.xml:S3:556:4	O
products	STRIBILD.xml:S3:561:8	O
containing	STRIBILD.xml:S3:570:10	O
any	STRIBILD.xml:S3:581:3	O
of	STRIBILD.xml:S3:585:2	O
the	STRIBILD.xml:S3:588:3	O
components	STRIBILD.xml:S3:592:10	O
of	STRIBILD.xml:S3:603:2	O
STRIBILD	STRIBILD.xml:S3:606:8	O
(	STRIBILD.xml:S3:615:1	O
cobicistat	STRIBILD.xml:S3:616:10	O
,	STRIBILD.xml:S3:626:1	O
elvitegravir	STRIBILD.xml:S3:628:12	O
,	STRIBILD.xml:S3:640:1	O
emtricitabine	STRIBILD.xml:S3:642:13	O
,	STRIBILD.xml:S3:655:1	O
and	STRIBILD.xml:S3:657:3	O
tenofovir	STRIBILD.xml:S3:661:9	O
disoproxil	STRIBILD.xml:S3:671:10	O
fumarate	STRIBILD.xml:S3:682:8	O
)	STRIBILD.xml:S3:690:1	O
,	STRIBILD.xml:S3:691:1	O
including	STRIBILD.xml:S3:693:9	O
ATRIPLA	STRIBILD.xml:S3:703:7	O
,	STRIBILD.xml:S3:710:1	O
COMPLERA	STRIBILD.xml:S3:712:8	O
,	STRIBILD.xml:S3:720:1	O
EMTRIVA	STRIBILD.xml:S3:722:7	O
,	STRIBILD.xml:S3:729:1	O
TRUVADA	STRIBILD.xml:S3:731:7	O
,	STRIBILD.xml:S3:738:1	O
TYBOST	STRIBILD.xml:S3:740:6	O
,	STRIBILD.xml:S3:746:1	O
VIREAD	STRIBILD.xml:S3:748:6	O
,	STRIBILD.xml:S3:754:1	O
or	STRIBILD.xml:S3:756:2	O
VITEKTA	STRIBILD.xml:S3:759:7	O
;	STRIBILD.xml:S3:766:1	O
with	STRIBILD.xml:S3:768:4	O
drugs	STRIBILD.xml:S3:773:5	O
containing	STRIBILD.xml:S3:779:10	O
lamivudine	STRIBILD.xml:S3:790:10	O
;	STRIBILD.xml:S3:800:1	O
or	STRIBILD.xml:S3:802:2	O
with	STRIBILD.xml:S3:805:4	O
drugs	STRIBILD.xml:S3:810:5	O
or	STRIBILD.xml:S3:816:2	O
regimens	STRIBILD.xml:S3:819:8	O
containing	STRIBILD.xml:S3:828:10	O
ritonavir	STRIBILD.xml:S3:839:9	O
.	STRIBILD.xml:S3:848:1	O

Do	STRIBILD.xml:S3:850:2	O
not	STRIBILD.xml:S3:853:3	O
administer	STRIBILD.xml:S3:857:10	O
in	STRIBILD.xml:S3:868:2	O
combination	STRIBILD.xml:S3:871:11	O
with	STRIBILD.xml:S3:883:4	O
HEPSERA	STRIBILD.xml:S3:888:7	O
.	STRIBILD.xml:S3:895:1	O

(	STRIBILD.xml:S3:897:1	O
5.4	STRIBILD.xml:S3:900:3	O
)	STRIBILD.xml:S3:905:1	O

Risk	STRIBILD.xml:S3:912:4	O
of	STRIBILD.xml:S3:917:2	O
adverse	STRIBILD.xml:S3:920:7	O
reactions	STRIBILD.xml:S3:928:9	O
or	STRIBILD.xml:S3:938:2	O
loss	STRIBILD.xml:S3:941:4	O
of	STRIBILD.xml:S3:946:2	O
virologic	STRIBILD.xml:S3:949:9	O
response	STRIBILD.xml:S3:959:8	O
due	STRIBILD.xml:S3:968:3	O
to	STRIBILD.xml:S3:972:2	O
drug	STRIBILD.xml:S3:975:4	O
interactions	STRIBILD.xml:S3:980:12	O
:	STRIBILD.xml:S3:992:1	O
The	STRIBILD.xml:S3:994:3	O
concomitant	STRIBILD.xml:S3:998:11	O
use	STRIBILD.xml:S3:1010:3	O
of	STRIBILD.xml:S3:1014:2	O
STRIBILD	STRIBILD.xml:S3:1017:8	O
and	STRIBILD.xml:S3:1026:3	O
other	STRIBILD.xml:S3:1030:5	O
drugs	STRIBILD.xml:S3:1036:5	O
may	STRIBILD.xml:S3:1042:3	O
result	STRIBILD.xml:S3:1046:6	O
in	STRIBILD.xml:S3:1053:2	O
known	STRIBILD.xml:S3:1056:5	O
or	STRIBILD.xml:S3:1062:2	O
potentially	STRIBILD.xml:S3:1065:11	O
significant	STRIBILD.xml:S3:1077:11	O
drug	STRIBILD.xml:S3:1089:4	O
interactions	STRIBILD.xml:S3:1094:12	O
,	STRIBILD.xml:S3:1106:1	O
some	STRIBILD.xml:S3:1108:4	O
of	STRIBILD.xml:S3:1113:2	O
which	STRIBILD.xml:S3:1116:5	O
may	STRIBILD.xml:S3:1122:3	O
lead	STRIBILD.xml:S3:1126:4	O
to	STRIBILD.xml:S3:1131:2	O
loss	STRIBILD.xml:S3:1134:4	O
of	STRIBILD.xml:S3:1139:2	O
therapeutic	STRIBILD.xml:S3:1142:11	O
effect	STRIBILD.xml:S3:1154:6	O
of	STRIBILD.xml:S3:1161:2	O
STRIBILD	STRIBILD.xml:S3:1164:8	O
and	STRIBILD.xml:S3:1173:3	O
possible	STRIBILD.xml:S3:1177:8	O
development	STRIBILD.xml:S3:1186:11	O
of	STRIBILD.xml:S3:1198:2	O
resistance	STRIBILD.xml:S3:1201:10	O
;	STRIBILD.xml:S3:1211:1	O
and	STRIBILD.xml:S3:1213:3	O
possible	STRIBILD.xml:S3:1217:8	O
clinically	STRIBILD.xml:S3:1226:10	O
significant	STRIBILD.xml:S3:1237:11	O
adverse	STRIBILD.xml:S3:1249:7	O
reactions	STRIBILD.xml:S3:1257:9	O
from	STRIBILD.xml:S3:1267:4	O
greater	STRIBILD.xml:S3:1272:7	O
exposures	STRIBILD.xml:S3:1280:9	O
of	STRIBILD.xml:S3:1290:2	O
concomitant	STRIBILD.xml:S3:1293:11	O
drugs	STRIBILD.xml:S3:1305:5	O
.	STRIBILD.xml:S3:1310:1	O

(	STRIBILD.xml:S3:1312:1	O
5.5	STRIBILD.xml:S3:1315:3	O
)	STRIBILD.xml:S3:1320:1	O

Decreases	STRIBILD.xml:S3:1327:9	B-AdverseReaction
in	STRIBILD.xml:S3:1337:2	I-AdverseReaction
bone	STRIBILD.xml:S3:1340:4	I-AdverseReaction
mineral	STRIBILD.xml:S3:1345:7	I-AdverseReaction
density	STRIBILD.xml:S3:1353:7	I-AdverseReaction
(	STRIBILD.xml:S3:1361:1	O
BMD	STRIBILD.xml:S3:1362:3	I-AdverseReaction
)	STRIBILD.xml:S3:1365:1	O
:	STRIBILD.xml:S3:1366:1	O
Consider	STRIBILD.xml:S3:1368:8	O
monitoring	STRIBILD.xml:S3:1377:10	O
BMD	STRIBILD.xml:S3:1388:3	O
in	STRIBILD.xml:S3:1392:2	O
patients	STRIBILD.xml:S3:1395:8	O
with	STRIBILD.xml:S3:1404:4	O
a	STRIBILD.xml:S3:1409:1	O
history	STRIBILD.xml:S3:1411:7	O
of	STRIBILD.xml:S3:1419:2	O
pathologic	STRIBILD.xml:S3:1422:10	O
fracture	STRIBILD.xml:S3:1433:8	O
or	STRIBILD.xml:S3:1442:2	O
other	STRIBILD.xml:S3:1445:5	O
risk	STRIBILD.xml:S3:1451:4	O
factors	STRIBILD.xml:S3:1456:7	O
of	STRIBILD.xml:S3:1464:2	O
osteoporosis	STRIBILD.xml:S3:1467:12	O
or	STRIBILD.xml:S3:1480:2	O
bone	STRIBILD.xml:S3:1483:4	O
loss	STRIBILD.xml:S3:1488:4	O
.	STRIBILD.xml:S3:1492:1	O

(	STRIBILD.xml:S3:1494:1	O
5.6	STRIBILD.xml:S3:1497:3	O
)	STRIBILD.xml:S3:1502:1	O

Redistribution	STRIBILD.xml:S3:1509:14	B-AdverseReaction
accumulation	STRIBILD.xml:S3:1524:12	B-AdverseReaction
of	STRIBILD.xml:S3:1537:2	I-AdverseReaction
body	STRIBILD.xml:S3:1540:4	I-AdverseReaction
fat	STRIBILD.xml:S3:1545:3	I-AdverseReaction
:	STRIBILD.xml:S3:1548:1	O
Observed	STRIBILD.xml:S3:1550:8	O
in	STRIBILD.xml:S3:1559:2	O
patients	STRIBILD.xml:S3:1562:8	O
receiving	STRIBILD.xml:S3:1571:9	O
antiretroviral	STRIBILD.xml:S3:1581:14	O
therapy	STRIBILD.xml:S3:1596:7	O
.	STRIBILD.xml:S3:1603:1	O

(	STRIBILD.xml:S3:1605:1	O
5.7	STRIBILD.xml:S3:1608:3	O
)	STRIBILD.xml:S3:1613:1	O

Immune	STRIBILD.xml:S3:1620:6	B-AdverseReaction
reconstitution	STRIBILD.xml:S3:1627:14	I-AdverseReaction
syndrome	STRIBILD.xml:S3:1642:8	I-AdverseReaction
:	STRIBILD.xml:S3:1650:1	O
May	STRIBILD.xml:S3:1652:3	O
necessitate	STRIBILD.xml:S3:1656:11	O
further	STRIBILD.xml:S3:1668:7	O
evaluation	STRIBILD.xml:S3:1676:10	O
and	STRIBILD.xml:S3:1687:3	O
treatment	STRIBILD.xml:S3:1691:9	O
.	STRIBILD.xml:S3:1700:1	O

(	STRIBILD.xml:S3:1702:1	O
5.8	STRIBILD.xml:S3:1705:3	O
)	STRIBILD.xml:S3:1710:1	O

5.1	STRIBILD.xml:S3:1724:3	O

Lactic	STRIBILD.xml:S3:1728:6	O

Acidosis	STRIBILD.xml:S3:1735:8	O
Severe	STRIBILD.xml:S3:1744:6	O
Hepatomegaly	STRIBILD.xml:S3:1751:12	O
with	STRIBILD.xml:S3:1764:4	O
Steatosis	STRIBILD.xml:S3:1769:9	O

Lactic	STRIBILD.xml:S3:1784:6	B-AdverseReaction
acidosis	STRIBILD.xml:S3:1791:8	I-AdverseReaction
and	STRIBILD.xml:S3:1800:3	O
severe	STRIBILD.xml:S3:1804:6	B-Severity
hepatomegaly	STRIBILD.xml:S3:1811:12	B-AdverseReaction
with	STRIBILD.xml:S3:1824:4	O
steatosis	STRIBILD.xml:S3:1829:9	B-AdverseReaction
,	STRIBILD.xml:S3:1838:1	O
including	STRIBILD.xml:S3:1840:9	O
fatal	STRIBILD.xml:S3:1850:5	B-AdverseReaction
cases	STRIBILD.xml:S3:1856:5	O
,	STRIBILD.xml:S3:1861:1	O
have	STRIBILD.xml:S3:1863:4	O
been	STRIBILD.xml:S3:1868:4	O
reported	STRIBILD.xml:S3:1873:8	O
with	STRIBILD.xml:S3:1882:4	O
the	STRIBILD.xml:S3:1887:3	O
use	STRIBILD.xml:S3:1891:3	O
of	STRIBILD.xml:S3:1895:2	O
nucleoside	STRIBILD.xml:S3:1898:10	O
analogs	STRIBILD.xml:S3:1909:7	O
,	STRIBILD.xml:S3:1916:1	O
including	STRIBILD.xml:S3:1918:9	O
tenofovir	STRIBILD.xml:S3:1928:9	O
DF	STRIBILD.xml:S3:1938:2	O
,	STRIBILD.xml:S3:1940:1	O
a	STRIBILD.xml:S3:1942:1	O
component	STRIBILD.xml:S3:1944:9	O
of	STRIBILD.xml:S3:1954:2	O
STRIBILD	STRIBILD.xml:S3:1957:8	O
,	STRIBILD.xml:S3:1965:1	O
in	STRIBILD.xml:S3:1967:2	O
combination	STRIBILD.xml:S3:1970:11	O
with	STRIBILD.xml:S3:1982:4	O
other	STRIBILD.xml:S3:1987:5	O
antiretrovirals	STRIBILD.xml:S3:1993:15	O
.	STRIBILD.xml:S3:2008:1	O

A	STRIBILD.xml:S3:2010:1	O
majority	STRIBILD.xml:S3:2012:8	O
of	STRIBILD.xml:S3:2021:2	O
these	STRIBILD.xml:S3:2024:5	O
cases	STRIBILD.xml:S3:2030:5	O
have	STRIBILD.xml:S3:2036:4	O
been	STRIBILD.xml:S3:2041:4	O
in	STRIBILD.xml:S3:2046:2	O
women	STRIBILD.xml:S3:2049:5	O
.	STRIBILD.xml:S3:2054:1	O

Obesity	STRIBILD.xml:S3:2056:7	O
and	STRIBILD.xml:S3:2064:3	O
prolonged	STRIBILD.xml:S3:2068:9	O
nucleoside	STRIBILD.xml:S3:2078:10	O
exposure	STRIBILD.xml:S3:2089:8	O
may	STRIBILD.xml:S3:2098:3	O
be	STRIBILD.xml:S3:2102:2	O
risk	STRIBILD.xml:S3:2105:4	O
factors	STRIBILD.xml:S3:2110:7	O
.	STRIBILD.xml:S3:2117:1	O

Particular	STRIBILD.xml:S3:2119:10	O
caution	STRIBILD.xml:S3:2130:7	O
should	STRIBILD.xml:S3:2138:6	O
be	STRIBILD.xml:S3:2145:2	O
exercised	STRIBILD.xml:S3:2148:9	O
when	STRIBILD.xml:S3:2158:4	O
administering	STRIBILD.xml:S3:2163:13	O
nucleoside	STRIBILD.xml:S3:2177:10	O
analogs	STRIBILD.xml:S3:2188:7	O
to	STRIBILD.xml:S3:2196:2	O
any	STRIBILD.xml:S3:2199:3	O
patient	STRIBILD.xml:S3:2203:7	O
with	STRIBILD.xml:S3:2211:4	O
known	STRIBILD.xml:S3:2216:5	O
risk	STRIBILD.xml:S3:2222:4	O
factors	STRIBILD.xml:S3:2227:7	O
for	STRIBILD.xml:S3:2235:3	O
liver	STRIBILD.xml:S3:2239:5	O
disease	STRIBILD.xml:S3:2245:7	O
;	STRIBILD.xml:S3:2252:1	O
however	STRIBILD.xml:S3:2254:7	O
,	STRIBILD.xml:S3:2261:1	O
cases	STRIBILD.xml:S3:2263:5	O
have	STRIBILD.xml:S3:2269:4	O
also	STRIBILD.xml:S3:2274:4	O
been	STRIBILD.xml:S3:2279:4	O
reported	STRIBILD.xml:S3:2284:8	O
in	STRIBILD.xml:S3:2293:2	O
patients	STRIBILD.xml:S3:2296:8	O
with	STRIBILD.xml:S3:2305:4	O
no	STRIBILD.xml:S3:2310:2	O
known	STRIBILD.xml:S3:2313:5	O
risk	STRIBILD.xml:S3:2319:4	O
factors	STRIBILD.xml:S3:2324:7	O
.	STRIBILD.xml:S3:2331:1	O

Treatment	STRIBILD.xml:S3:2333:9	O
with	STRIBILD.xml:S3:2343:4	O
STRIBILD	STRIBILD.xml:S3:2348:8	O
should	STRIBILD.xml:S3:2357:6	O
be	STRIBILD.xml:S3:2364:2	O
suspended	STRIBILD.xml:S3:2367:9	O
in	STRIBILD.xml:S3:2377:2	O
any	STRIBILD.xml:S3:2380:3	O
patient	STRIBILD.xml:S3:2384:7	O
who	STRIBILD.xml:S3:2392:3	O
develops	STRIBILD.xml:S3:2396:8	O
clinical	STRIBILD.xml:S3:2405:8	O
or	STRIBILD.xml:S3:2414:2	O
laboratory	STRIBILD.xml:S3:2417:10	O
findings	STRIBILD.xml:S3:2428:8	O
suggestive	STRIBILD.xml:S3:2437:10	O
of	STRIBILD.xml:S3:2448:2	O
lactic	STRIBILD.xml:S3:2451:6	O
acidosis	STRIBILD.xml:S3:2458:8	O
or	STRIBILD.xml:S3:2467:2	O
pronounced	STRIBILD.xml:S3:2470:10	O
hepatotoxicity	STRIBILD.xml:S3:2481:14	O
(	STRIBILD.xml:S3:2496:1	O
which	STRIBILD.xml:S3:2497:5	O
may	STRIBILD.xml:S3:2503:3	O
include	STRIBILD.xml:S3:2507:7	O
hepatomegaly	STRIBILD.xml:S3:2515:12	O
and	STRIBILD.xml:S3:2528:3	O
steatosis	STRIBILD.xml:S3:2532:9	O
even	STRIBILD.xml:S3:2542:4	O
in	STRIBILD.xml:S3:2547:2	O
the	STRIBILD.xml:S3:2550:3	O
absence	STRIBILD.xml:S3:2554:7	O
of	STRIBILD.xml:S3:2562:2	O
marked	STRIBILD.xml:S3:2565:6	O
transaminase	STRIBILD.xml:S3:2572:12	O
elevations	STRIBILD.xml:S3:2585:10	O
)	STRIBILD.xml:S3:2595:1	O
.	STRIBILD.xml:S3:2596:1	O

5.2	STRIBILD.xml:S3:2605:3	O
Patients	STRIBILD.xml:S3:2609:8	O
Coinfected	STRIBILD.xml:S3:2618:10	O
with	STRIBILD.xml:S3:2629:4	O
HIV	STRIBILD.xml:S3:2634:3	O
-	STRIBILD.xml:S3:2637:1	O
1	STRIBILD.xml:S3:2638:1	O
and	STRIBILD.xml:S3:2640:3	O
HBV	STRIBILD.xml:S3:2644:3	O

It	STRIBILD.xml:S3:2653:2	O
is	STRIBILD.xml:S3:2656:2	O
recommended	STRIBILD.xml:S3:2659:11	O
that	STRIBILD.xml:S3:2671:4	O
all	STRIBILD.xml:S3:2676:3	O
patients	STRIBILD.xml:S3:2680:8	O
with	STRIBILD.xml:S3:2689:4	O
HIV	STRIBILD.xml:S3:2694:3	O
-	STRIBILD.xml:S3:2697:1	O
1	STRIBILD.xml:S3:2698:1	O
be	STRIBILD.xml:S3:2700:2	O
tested	STRIBILD.xml:S3:2703:6	O
for	STRIBILD.xml:S3:2710:3	O
the	STRIBILD.xml:S3:2714:3	O
presence	STRIBILD.xml:S3:2718:8	O
of	STRIBILD.xml:S3:2727:2	O
chronic	STRIBILD.xml:S3:2730:7	O
hepatitis	STRIBILD.xml:S3:2738:9	O
B	STRIBILD.xml:S3:2748:1	O
virus	STRIBILD.xml:S3:2750:5	O
(	STRIBILD.xml:S3:2756:1	O
HBV	STRIBILD.xml:S3:2757:3	O
)	STRIBILD.xml:S3:2760:1	O
before	STRIBILD.xml:S3:2762:6	O
initiating	STRIBILD.xml:S3:2769:10	O
antiretroviral	STRIBILD.xml:S3:2780:14	O
therapy	STRIBILD.xml:S3:2795:7	O
.	STRIBILD.xml:S3:2802:1	O

STRIBILD	STRIBILD.xml:S3:2804:8	O
is	STRIBILD.xml:S3:2813:2	O
not	STRIBILD.xml:S3:2816:3	O
approved	STRIBILD.xml:S3:2820:8	O
for	STRIBILD.xml:S3:2829:3	O
the	STRIBILD.xml:S3:2833:3	O
treatment	STRIBILD.xml:S3:2837:9	O
of	STRIBILD.xml:S3:2847:2	O
chronic	STRIBILD.xml:S3:2850:7	O
HBV	STRIBILD.xml:S3:2858:3	O
infection	STRIBILD.xml:S3:2862:9	O
and	STRIBILD.xml:S3:2872:3	O
the	STRIBILD.xml:S3:2876:3	O
safety	STRIBILD.xml:S3:2880:6	O
and	STRIBILD.xml:S3:2887:3	O
efficacy	STRIBILD.xml:S3:2891:8	O
of	STRIBILD.xml:S3:2900:2	O
STRIBILD	STRIBILD.xml:S3:2903:8	O
have	STRIBILD.xml:S3:2912:4	O
not	STRIBILD.xml:S3:2917:3	O
been	STRIBILD.xml:S3:2921:4	O
established	STRIBILD.xml:S3:2926:11	O
in	STRIBILD.xml:S3:2938:2	O
patients	STRIBILD.xml:S3:2941:8	O
coinfected	STRIBILD.xml:S3:2950:10	O
with	STRIBILD.xml:S3:2961:4	O
HBV	STRIBILD.xml:S3:2966:3	O
and	STRIBILD.xml:S3:2970:3	O
HIV	STRIBILD.xml:S3:2974:3	O
-	STRIBILD.xml:S3:2977:1	O
1	STRIBILD.xml:S3:2978:1	O
.	STRIBILD.xml:S3:2979:1	O

Severe	STRIBILD.xml:S3:2981:6	O
acute	STRIBILD.xml:S3:2988:5	O
exacerbations	STRIBILD.xml:S3:2994:13	O
of	STRIBILD.xml:S3:3008:2	O
hepatitis	STRIBILD.xml:S3:3011:9	O
B	STRIBILD.xml:S3:3021:1	O
have	STRIBILD.xml:S3:3023:4	O
been	STRIBILD.xml:S3:3028:4	O
reported	STRIBILD.xml:S3:3033:8	O
in	STRIBILD.xml:S3:3042:2	O
patients	STRIBILD.xml:S3:3045:8	O
who	STRIBILD.xml:S3:3054:3	O
are	STRIBILD.xml:S3:3058:3	O
coinfected	STRIBILD.xml:S3:3062:10	O
with	STRIBILD.xml:S3:3073:4	O
HBV	STRIBILD.xml:S3:3078:3	O
and	STRIBILD.xml:S3:3082:3	O
HIV	STRIBILD.xml:S3:3086:3	O
-	STRIBILD.xml:S3:3089:1	O
1	STRIBILD.xml:S3:3090:1	O
and	STRIBILD.xml:S3:3092:3	O
have	STRIBILD.xml:S3:3096:4	O
discontinued	STRIBILD.xml:S3:3101:12	O
emtricitabine	STRIBILD.xml:S3:3114:13	O
or	STRIBILD.xml:S3:3128:2	O
tenofovir	STRIBILD.xml:S3:3131:9	O
DF	STRIBILD.xml:S3:3141:2	O
,	STRIBILD.xml:S3:3143:1	O
two	STRIBILD.xml:S3:3145:3	O
of	STRIBILD.xml:S3:3149:2	O
the	STRIBILD.xml:S3:3152:3	O
components	STRIBILD.xml:S3:3156:10	O
of	STRIBILD.xml:S3:3167:2	O
STRIBILD	STRIBILD.xml:S3:3170:8	O
.	STRIBILD.xml:S3:3178:1	O

In	STRIBILD.xml:S3:3180:2	O
some	STRIBILD.xml:S3:3183:4	O
patients	STRIBILD.xml:S3:3188:8	O
infected	STRIBILD.xml:S3:3197:8	O
with	STRIBILD.xml:S3:3206:4	O
HBV	STRIBILD.xml:S3:3211:3	O
and	STRIBILD.xml:S3:3215:3	O
treated	STRIBILD.xml:S3:3219:7	O
with	STRIBILD.xml:S3:3227:4	O
EMTRIVA	STRIBILD.xml:S3:3232:7	O
,	STRIBILD.xml:S3:3239:1	O
the	STRIBILD.xml:S3:3241:3	O
exacerbations	STRIBILD.xml:S3:3245:13	B-AdverseReaction
of	STRIBILD.xml:S3:3259:2	I-AdverseReaction
hepatitis	STRIBILD.xml:S3:3262:9	I-AdverseReaction
B	STRIBILD.xml:S3:3272:1	I-AdverseReaction
were	STRIBILD.xml:S3:3274:4	O
associated	STRIBILD.xml:S3:3279:10	O
with	STRIBILD.xml:S3:3290:4	O
liver	STRIBILD.xml:S3:3295:5	B-AdverseReaction
decompensation	STRIBILD.xml:S3:3301:14	I-AdverseReaction
and	STRIBILD.xml:S3:3316:3	O
liver	STRIBILD.xml:S3:3320:5	B-AdverseReaction
failure	STRIBILD.xml:S3:3326:7	I-AdverseReaction
.	STRIBILD.xml:S3:3333:1	O

Patients	STRIBILD.xml:S3:3335:8	O
who	STRIBILD.xml:S3:3344:3	O
are	STRIBILD.xml:S3:3348:3	O
coinfected	STRIBILD.xml:S3:3352:10	O
with	STRIBILD.xml:S3:3363:4	O
HIV	STRIBILD.xml:S3:3368:3	O
-	STRIBILD.xml:S3:3371:1	O
1	STRIBILD.xml:S3:3372:1	O
and	STRIBILD.xml:S3:3374:3	O
HBV	STRIBILD.xml:S3:3378:3	O
should	STRIBILD.xml:S3:3382:6	O
be	STRIBILD.xml:S3:3389:2	O
closely	STRIBILD.xml:S3:3392:7	O
monitored	STRIBILD.xml:S3:3400:9	O
with	STRIBILD.xml:S3:3410:4	O
both	STRIBILD.xml:S3:3415:4	O
clinical	STRIBILD.xml:S3:3420:8	O
and	STRIBILD.xml:S3:3429:3	O
laboratory	STRIBILD.xml:S3:3433:10	O
follow	STRIBILD.xml:S3:3444:6	O
-	STRIBILD.xml:S3:3450:1	O
up	STRIBILD.xml:S3:3451:2	O
for	STRIBILD.xml:S3:3454:3	O
at	STRIBILD.xml:S3:3458:2	O
least	STRIBILD.xml:S3:3461:5	O
several	STRIBILD.xml:S3:3467:7	O
months	STRIBILD.xml:S3:3475:6	O
after	STRIBILD.xml:S3:3482:5	O
stopping	STRIBILD.xml:S3:3488:8	O
treatment	STRIBILD.xml:S3:3497:9	O
with	STRIBILD.xml:S3:3507:4	O
STRIBILD	STRIBILD.xml:S3:3512:8	O
.	STRIBILD.xml:S3:3520:1	O

If	STRIBILD.xml:S3:3522:2	O
appropriate	STRIBILD.xml:S3:3525:11	O
,	STRIBILD.xml:S3:3536:1	O
initiation	STRIBILD.xml:S3:3538:10	O
of	STRIBILD.xml:S3:3549:2	O
anti	STRIBILD.xml:S3:3552:4	O
-	STRIBILD.xml:S3:3556:1	O
hepatitis	STRIBILD.xml:S3:3557:9	O
B	STRIBILD.xml:S3:3567:1	O
therapy	STRIBILD.xml:S3:3569:7	O
may	STRIBILD.xml:S3:3577:3	O
be	STRIBILD.xml:S3:3581:2	O
warranted	STRIBILD.xml:S3:3584:9	O
.	STRIBILD.xml:S3:3593:1	O

5.3	STRIBILD.xml:S3:3602:3	O
New	STRIBILD.xml:S3:3606:3	O
Onset	STRIBILD.xml:S3:3610:5	O
or	STRIBILD.xml:S3:3616:2	O
Worsening	STRIBILD.xml:S3:3619:9	O
Renal	STRIBILD.xml:S3:3629:5	O
Impairment	STRIBILD.xml:S3:3635:10	O

Renal	STRIBILD.xml:S3:3651:5	B-AdverseReaction
impairment	STRIBILD.xml:S3:3657:10	I-AdverseReaction
,	STRIBILD.xml:S3:3667:1	O
including	STRIBILD.xml:S3:3669:9	O
cases	STRIBILD.xml:S3:3679:5	O
of	STRIBILD.xml:S3:3685:2	O
acute	STRIBILD.xml:S3:3688:5	B-AdverseReaction
renal	STRIBILD.xml:S3:3694:5	I-AdverseReaction
failure	STRIBILD.xml:S3:3700:7	I-AdverseReaction
and	STRIBILD.xml:S3:3708:3	O
Fanconi	STRIBILD.xml:S3:3712:7	B-AdverseReaction
syndrome	STRIBILD.xml:S3:3720:8	I-AdverseReaction
(	STRIBILD.xml:S3:3729:1	O
renal	STRIBILD.xml:S3:3730:5	B-AdverseReaction
tubular	STRIBILD.xml:S3:3736:7	I-AdverseReaction
injury	STRIBILD.xml:S3:3744:6	I-AdverseReaction
with	STRIBILD.xml:S3:3751:4	O
severe	STRIBILD.xml:S3:3756:6	B-Severity
hypophosphatemia	STRIBILD.xml:S3:3763:16	B-AdverseReaction
)	STRIBILD.xml:S3:3779:1	O
,	STRIBILD.xml:S3:3780:1	O
has	STRIBILD.xml:S3:3782:3	O
been	STRIBILD.xml:S3:3786:4	O
reported	STRIBILD.xml:S3:3791:8	O
with	STRIBILD.xml:S3:3800:4	O
the	STRIBILD.xml:S3:3805:3	O
use	STRIBILD.xml:S3:3809:3	O
of	STRIBILD.xml:S3:3813:2	O
tenofovir	STRIBILD.xml:S3:3816:9	O
DF	STRIBILD.xml:S3:3826:2	O
,	STRIBILD.xml:S3:3828:1	O
a	STRIBILD.xml:S3:3830:1	O
component	STRIBILD.xml:S3:3832:9	O
of	STRIBILD.xml:S3:3842:2	O
STRIBILD	STRIBILD.xml:S3:3845:8	O
,	STRIBILD.xml:S3:3853:1	O
and	STRIBILD.xml:S3:3855:3	O
with	STRIBILD.xml:S3:3859:4	O
the	STRIBILD.xml:S3:3864:3	O
use	STRIBILD.xml:S3:3868:3	O
of	STRIBILD.xml:S3:3872:2	O
STRIBILD	STRIBILD.xml:S3:3875:8	O
[	STRIBILD.xml:S3:3884:1	O
see	STRIBILD.xml:S3:3885:3	O
Adverse	STRIBILD.xml:S3:3890:7	O
Reactions	STRIBILD.xml:S3:3898:9	O
(	STRIBILD.xml:S3:3908:1	O
6.2	STRIBILD.xml:S3:3909:3	O
)	STRIBILD.xml:S3:3912:1	O
]	STRIBILD.xml:S3:3915:1	O
.	STRIBILD.xml:S3:3918:1	O

In	STRIBILD.xml:S3:3925:2	O
the	STRIBILD.xml:S3:3928:3	O
clinical	STRIBILD.xml:S3:3932:8	O
trials	STRIBILD.xml:S3:3941:6	O
of	STRIBILD.xml:S3:3948:2	O
STRIBILD	STRIBILD.xml:S3:3951:8	O
over	STRIBILD.xml:S3:3960:4	O
144	STRIBILD.xml:S3:3965:3	O
weeks	STRIBILD.xml:S3:3969:5	O
,	STRIBILD.xml:S3:3974:1	O
13	STRIBILD.xml:S3:3976:2	O
(	STRIBILD.xml:S3:3979:1	O
1.9%	STRIBILD.xml:S3:3980:4	O
)	STRIBILD.xml:S3:3984:1	O
subjects	STRIBILD.xml:S3:3986:8	O
in	STRIBILD.xml:S3:3995:2	O
the	STRIBILD.xml:S3:3998:3	O
STRIBILD	STRIBILD.xml:S3:4002:8	O
group	STRIBILD.xml:S3:4011:5	O
(	STRIBILD.xml:S3:4017:1	O
N	STRIBILD.xml:S3:4018:1	O
701	STRIBILD.xml:S3:4020:3	O
)	STRIBILD.xml:S3:4023:1	O
,	STRIBILD.xml:S3:4024:1	O
8	STRIBILD.xml:S3:4026:1	O
(	STRIBILD.xml:S3:4028:1	O
2.3%	STRIBILD.xml:S3:4029:4	O
)	STRIBILD.xml:S3:4033:1	O
subjects	STRIBILD.xml:S3:4035:8	O
in	STRIBILD.xml:S3:4044:2	O
the	STRIBILD.xml:S3:4047:3	O
ATV	STRIBILD.xml:S3:4051:3	O
RTV	STRIBILD.xml:S3:4057:3	O
TRUVADA	STRIBILD.xml:S3:4063:7	O
group	STRIBILD.xml:S3:4071:5	O
(	STRIBILD.xml:S3:4077:1	O
N	STRIBILD.xml:S3:4078:1	O
355	STRIBILD.xml:S3:4080:3	O
)	STRIBILD.xml:S3:4083:1	O
and	STRIBILD.xml:S3:4085:3	O
no	STRIBILD.xml:S3:4089:2	O
subjects	STRIBILD.xml:S3:4092:8	O
in	STRIBILD.xml:S3:4101:2	O
the	STRIBILD.xml:S3:4104:3	O
ATRIPLA	STRIBILD.xml:S3:4108:7	O
group	STRIBILD.xml:S3:4116:5	O
(	STRIBILD.xml:S3:4122:1	O
N	STRIBILD.xml:S3:4123:1	O
352	STRIBILD.xml:S3:4127:3	O
)	STRIBILD.xml:S3:4130:1	O
discontinued	STRIBILD.xml:S3:4132:12	O
study	STRIBILD.xml:S3:4145:5	O
drug	STRIBILD.xml:S3:4151:4	O
due	STRIBILD.xml:S3:4156:3	O
to	STRIBILD.xml:S3:4160:2	O
a	STRIBILD.xml:S3:4163:1	O
renal	STRIBILD.xml:S3:4165:5	B-AdverseReaction
adverse	STRIBILD.xml:S3:4171:7	I-AdverseReaction
reaction	STRIBILD.xml:S3:4179:8	I-AdverseReaction
.	STRIBILD.xml:S3:4187:1	O

Of	STRIBILD.xml:S3:4189:2	O
these	STRIBILD.xml:S3:4192:5	O
discontinuations	STRIBILD.xml:S3:4198:16	O
,	STRIBILD.xml:S3:4214:1	O
8	STRIBILD.xml:S3:4216:1	O
in	STRIBILD.xml:S3:4218:2	O
the	STRIBILD.xml:S3:4221:3	O
STRIBILD	STRIBILD.xml:S3:4225:8	O
group	STRIBILD.xml:S3:4234:5	O
and	STRIBILD.xml:S3:4240:3	O
1	STRIBILD.xml:S3:4244:1	O
in	STRIBILD.xml:S3:4246:2	O
the	STRIBILD.xml:S3:4249:3	O
ATV	STRIBILD.xml:S3:4253:3	O
RTV	STRIBILD.xml:S3:4259:3	O
TRUVADA	STRIBILD.xml:S3:4265:7	O
group	STRIBILD.xml:S3:4273:5	O
occurred	STRIBILD.xml:S3:4279:8	O
during	STRIBILD.xml:S3:4288:6	O
the	STRIBILD.xml:S3:4295:3	O
first	STRIBILD.xml:S3:4299:5	O
48	STRIBILD.xml:S3:4305:2	O
weeks	STRIBILD.xml:S3:4308:5	O
.	STRIBILD.xml:S3:4313:1	O

Four	STRIBILD.xml:S3:4315:4	O
(	STRIBILD.xml:S3:4320:1	O
0.6%	STRIBILD.xml:S3:4321:4	O
)	STRIBILD.xml:S3:4325:1	O
subjects	STRIBILD.xml:S3:4327:8	O
who	STRIBILD.xml:S3:4336:3	O
received	STRIBILD.xml:S3:4340:8	O
STRIBILD	STRIBILD.xml:S3:4349:8	O
developed	STRIBILD.xml:S3:4358:9	O
laboratory	STRIBILD.xml:S3:4368:10	O
findings	STRIBILD.xml:S3:4379:8	O
consistent	STRIBILD.xml:S3:4388:10	O
with	STRIBILD.xml:S3:4399:4	O
proximal	STRIBILD.xml:S3:4404:8	B-AdverseReaction
renal	STRIBILD.xml:S3:4413:5	I-AdverseReaction
tubular	STRIBILD.xml:S3:4419:7	I-AdverseReaction
dysfunction	STRIBILD.xml:S3:4427:11	I-AdverseReaction
leading	STRIBILD.xml:S3:4439:7	O
to	STRIBILD.xml:S3:4447:2	O
discontinuation	STRIBILD.xml:S3:4450:15	O
of	STRIBILD.xml:S3:4466:2	O
STRIBILD	STRIBILD.xml:S3:4469:8	O
during	STRIBILD.xml:S3:4478:6	O
the	STRIBILD.xml:S3:4485:3	O
first	STRIBILD.xml:S3:4489:5	O
48	STRIBILD.xml:S3:4495:2	O
weeks	STRIBILD.xml:S3:4498:5	O
of	STRIBILD.xml:S3:4504:2	O
treatment	STRIBILD.xml:S3:4507:9	O
.	STRIBILD.xml:S3:4516:1	O

Two	STRIBILD.xml:S3:4518:3	O
of	STRIBILD.xml:S3:4522:2	O
the	STRIBILD.xml:S3:4525:3	O
four	STRIBILD.xml:S3:4529:4	O
subjects	STRIBILD.xml:S3:4534:8	O
had	STRIBILD.xml:S3:4543:3	O
renal	STRIBILD.xml:S3:4547:5	O
impairment	STRIBILD.xml:S3:4553:10	O
(	STRIBILD.xml:S3:4564:1	O
i	STRIBILD.xml:S3:4565:1	O
.	STRIBILD.xml:S3:4566:1	O
e	STRIBILD.xml:S3:4567:1	O
.	STRIBILD.xml:S3:4568:1	O

estimated	STRIBILD.xml:S3:4570:9	O
creatinine	STRIBILD.xml:S3:4580:10	O
clearance	STRIBILD.xml:S3:4591:9	O
less	STRIBILD.xml:S3:4601:4	O
than	STRIBILD.xml:S3:4606:4	O
70	STRIBILD.xml:S3:4611:2	O
mL	STRIBILD.xml:S3:4614:2	O
per	STRIBILD.xml:S3:4617:3	O
minute	STRIBILD.xml:S3:4621:6	O
)	STRIBILD.xml:S3:4627:1	O
at	STRIBILD.xml:S3:4629:2	O
baseline	STRIBILD.xml:S3:4632:8	O
.	STRIBILD.xml:S3:4640:1	O

The	STRIBILD.xml:S3:4642:3	O
laboratory	STRIBILD.xml:S3:4646:10	O
findings	STRIBILD.xml:S3:4657:8	O
in	STRIBILD.xml:S3:4666:2	O
these	STRIBILD.xml:S3:4669:5	O
4	STRIBILD.xml:S3:4675:1	O
subjects	STRIBILD.xml:S3:4677:8	O
improved	STRIBILD.xml:S3:4686:8	O
but	STRIBILD.xml:S3:4695:3	O
did	STRIBILD.xml:S3:4699:3	O
not	STRIBILD.xml:S3:4703:3	O
completely	STRIBILD.xml:S3:4707:10	O
resolve	STRIBILD.xml:S3:4718:7	O
in	STRIBILD.xml:S3:4726:2	O
all	STRIBILD.xml:S3:4729:3	O
subjects	STRIBILD.xml:S3:4733:8	O
upon	STRIBILD.xml:S3:4742:4	O
discontinuation	STRIBILD.xml:S3:4747:15	O
of	STRIBILD.xml:S3:4763:2	O
STRIBILD	STRIBILD.xml:S3:4766:8	O
.	STRIBILD.xml:S3:4774:1	O

Renal	STRIBILD.xml:S3:4776:5	O
replacement	STRIBILD.xml:S3:4782:11	O
therapy	STRIBILD.xml:S3:4794:7	O
was	STRIBILD.xml:S3:4802:3	O
not	STRIBILD.xml:S3:4806:3	O
required	STRIBILD.xml:S3:4810:8	O
for	STRIBILD.xml:S3:4819:3	O
these	STRIBILD.xml:S3:4823:5	O
subjects	STRIBILD.xml:S3:4829:8	O
.	STRIBILD.xml:S3:4837:1	O

One	STRIBILD.xml:S3:4839:3	O
(	STRIBILD.xml:S3:4843:1	O
0.3%	STRIBILD.xml:S3:4844:4	O
)	STRIBILD.xml:S3:4848:1	O
subject	STRIBILD.xml:S3:4850:7	O
who	STRIBILD.xml:S3:4858:3	O
received	STRIBILD.xml:S3:4862:8	O
ATV	STRIBILD.xml:S3:4871:3	O
RTV	STRIBILD.xml:S3:4877:3	O
TRUVADA	STRIBILD.xml:S3:4883:7	O
developed	STRIBILD.xml:S3:4891:9	O
laboratory	STRIBILD.xml:S3:4901:10	O
findings	STRIBILD.xml:S3:4912:8	O
consistent	STRIBILD.xml:S3:4921:10	O
with	STRIBILD.xml:S3:4932:4	O
proximal	STRIBILD.xml:S3:4937:8	B-AdverseReaction
renal	STRIBILD.xml:S3:4946:5	I-AdverseReaction
tubular	STRIBILD.xml:S3:4952:7	I-AdverseReaction
dysfunction	STRIBILD.xml:S3:4960:11	I-AdverseReaction
leading	STRIBILD.xml:S3:4972:7	O
to	STRIBILD.xml:S3:4980:2	O
discontinuation	STRIBILD.xml:S3:4983:15	O
of	STRIBILD.xml:S3:4999:2	O
ATV	STRIBILD.xml:S3:5002:3	O
RTV	STRIBILD.xml:S3:5008:3	O
TRUVADA	STRIBILD.xml:S3:5014:7	O
after	STRIBILD.xml:S3:5022:5	O
Week	STRIBILD.xml:S3:5028:4	O
96	STRIBILD.xml:S3:5033:2	O
.	STRIBILD.xml:S3:5035:1	O

STRIBILD	STRIBILD.xml:S3:5043:8	O
should	STRIBILD.xml:S3:5052:6	O
be	STRIBILD.xml:S3:5059:2	O
avoided	STRIBILD.xml:S3:5062:7	O
with	STRIBILD.xml:S3:5070:4	O
concurrent	STRIBILD.xml:S3:5075:10	O
or	STRIBILD.xml:S3:5086:2	O
recent	STRIBILD.xml:S3:5089:6	O
use	STRIBILD.xml:S3:5096:3	O
of	STRIBILD.xml:S3:5100:2	O
a	STRIBILD.xml:S3:5103:1	O
nephrotoxic	STRIBILD.xml:S3:5105:11	O
agent	STRIBILD.xml:S3:5117:5	O
.	STRIBILD.xml:S3:5122:1	O

(	STRIBILD.xml:S3:5124:1	O
e	STRIBILD.xml:S3:5125:1	O
.	STRIBILD.xml:S3:5126:1	O
g	STRIBILD.xml:S3:5127:1	O
.	STRIBILD.xml:S3:5128:1	O
,	STRIBILD.xml:S3:5129:1	O
high	STRIBILD.xml:S3:5131:4	O
-	STRIBILD.xml:S3:5135:1	O
dose	STRIBILD.xml:S3:5136:4	O
or	STRIBILD.xml:S3:5141:2	O
multiple	STRIBILD.xml:S3:5144:8	O
non	STRIBILD.xml:S3:5153:3	O
-	STRIBILD.xml:S3:5156:1	O
steroidal	STRIBILD.xml:S3:5157:9	O
anti	STRIBILD.xml:S3:5167:4	O
-	STRIBILD.xml:S3:5171:1	O
inflammatory	STRIBILD.xml:S3:5172:12	O
drugs	STRIBILD.xml:S3:5185:5	O
(	STRIBILD.xml:S3:5191:1	O
NSAIDs	STRIBILD.xml:S3:5192:6	O
))	STRIBILD.xml:S3:5198:2	O
[	STRIBILD.xml:S3:5201:1	O
see	STRIBILD.xml:S3:5202:3	O
Drug	STRIBILD.xml:S3:5207:4	O
Interactions	STRIBILD.xml:S3:5212:12	O
(	STRIBILD.xml:S3:5225:1	O
7.4	STRIBILD.xml:S3:5226:3	O
)	STRIBILD.xml:S3:5229:1	O
]	STRIBILD.xml:S3:5232:1	O
.	STRIBILD.xml:S3:5235:1	O

Cases	STRIBILD.xml:S3:5237:5	O
of	STRIBILD.xml:S3:5243:2	O
acute	STRIBILD.xml:S3:5246:5	O
renal	STRIBILD.xml:S3:5252:5	O
failure	STRIBILD.xml:S3:5258:7	O
after	STRIBILD.xml:S3:5266:5	O
initiation	STRIBILD.xml:S3:5272:10	O
of	STRIBILD.xml:S3:5283:2	O
high	STRIBILD.xml:S3:5286:4	O
dose	STRIBILD.xml:S3:5291:4	O
or	STRIBILD.xml:S3:5296:2	O
multiple	STRIBILD.xml:S3:5299:8	O
NSAIDs	STRIBILD.xml:S3:5308:6	O
have	STRIBILD.xml:S3:5315:4	O
been	STRIBILD.xml:S3:5320:4	O
reported	STRIBILD.xml:S3:5325:8	O
in	STRIBILD.xml:S3:5334:2	O
HIV	STRIBILD.xml:S3:5337:3	O
-	STRIBILD.xml:S3:5340:1	O
infected	STRIBILD.xml:S3:5341:8	O
patients	STRIBILD.xml:S3:5350:8	O
with	STRIBILD.xml:S3:5359:4	O
risk	STRIBILD.xml:S3:5364:4	O
factors	STRIBILD.xml:S3:5369:7	O
for	STRIBILD.xml:S3:5377:3	O
renal	STRIBILD.xml:S3:5381:5	O
dysfunction	STRIBILD.xml:S3:5387:11	O
who	STRIBILD.xml:S3:5399:3	O
appeared	STRIBILD.xml:S3:5403:8	O
stable	STRIBILD.xml:S3:5412:6	O
on	STRIBILD.xml:S3:5419:2	O
tenofovir	STRIBILD.xml:S3:5422:9	O
DF	STRIBILD.xml:S3:5432:2	O
.	STRIBILD.xml:S3:5434:1	O

Some	STRIBILD.xml:S3:5436:4	O
patients	STRIBILD.xml:S3:5441:8	O
required	STRIBILD.xml:S3:5450:8	O
hospitalization	STRIBILD.xml:S3:5459:15	O
and	STRIBILD.xml:S3:5475:3	O
renal	STRIBILD.xml:S3:5479:5	O
replacement	STRIBILD.xml:S3:5485:11	O
therapy	STRIBILD.xml:S3:5497:7	O
.	STRIBILD.xml:S3:5504:1	O

Alternatives	STRIBILD.xml:S3:5506:12	O
to	STRIBILD.xml:S3:5519:2	O
NSAIDs	STRIBILD.xml:S3:5522:6	O
should	STRIBILD.xml:S3:5529:6	O
be	STRIBILD.xml:S3:5536:2	O
considered	STRIBILD.xml:S3:5539:10	O
,	STRIBILD.xml:S3:5549:1	O
if	STRIBILD.xml:S3:5551:2	O
needed	STRIBILD.xml:S3:5554:6	O
,	STRIBILD.xml:S3:5560:1	O
in	STRIBILD.xml:S3:5562:2	O
patients	STRIBILD.xml:S3:5565:8	O
at	STRIBILD.xml:S3:5574:2	O
risk	STRIBILD.xml:S3:5577:4	O
for	STRIBILD.xml:S3:5582:3	O
renal	STRIBILD.xml:S3:5586:5	O
dysfunction	STRIBILD.xml:S3:5592:11	O
.	STRIBILD.xml:S3:5603:1	O

Persistent	STRIBILD.xml:S3:5609:10	O
or	STRIBILD.xml:S3:5620:2	O
worsening	STRIBILD.xml:S3:5623:9	O
bone	STRIBILD.xml:S3:5633:4	O
pain	STRIBILD.xml:S3:5638:4	O
,	STRIBILD.xml:S3:5642:1	O
pain	STRIBILD.xml:S3:5644:4	O
in	STRIBILD.xml:S3:5649:2	O
extremities	STRIBILD.xml:S3:5652:11	O
,	STRIBILD.xml:S3:5663:1	O
fractures	STRIBILD.xml:S3:5665:9	O
and	STRIBILD.xml:S3:5675:3	O
or	STRIBILD.xml:S3:5679:2	O
muscular	STRIBILD.xml:S3:5682:8	O
pain	STRIBILD.xml:S3:5691:4	O
or	STRIBILD.xml:S3:5696:2	O
weakness	STRIBILD.xml:S3:5699:8	O
may	STRIBILD.xml:S3:5708:3	O
be	STRIBILD.xml:S3:5712:2	O
manifestations	STRIBILD.xml:S3:5715:14	O
of	STRIBILD.xml:S3:5730:2	O
proximal	STRIBILD.xml:S3:5733:8	O
renal	STRIBILD.xml:S3:5742:5	O
tubulopathy	STRIBILD.xml:S3:5748:11	O
and	STRIBILD.xml:S3:5760:3	O
should	STRIBILD.xml:S3:5764:6	O
prompt	STRIBILD.xml:S3:5771:6	O
an	STRIBILD.xml:S3:5778:2	O
evaluation	STRIBILD.xml:S3:5781:10	O
of	STRIBILD.xml:S3:5792:2	O
renal	STRIBILD.xml:S3:5795:5	O
function	STRIBILD.xml:S3:5801:8	O
in	STRIBILD.xml:S3:5810:2	O
at	STRIBILD.xml:S3:5813:2	O
-	STRIBILD.xml:S3:5815:1	O
risk	STRIBILD.xml:S3:5816:4	O
patients	STRIBILD.xml:S3:5821:8	O
.	STRIBILD.xml:S3:5829:1	O

Estimated	STRIBILD.xml:S3:5835:9	O
creatinine	STRIBILD.xml:S3:5845:10	O
clearance	STRIBILD.xml:S3:5856:9	O
,	STRIBILD.xml:S3:5865:1	O
urine	STRIBILD.xml:S3:5867:5	O
glucose	STRIBILD.xml:S3:5873:7	O
and	STRIBILD.xml:S3:5881:3	O
urine	STRIBILD.xml:S3:5885:5	O
protein	STRIBILD.xml:S3:5891:7	O
should	STRIBILD.xml:S3:5899:6	O
be	STRIBILD.xml:S3:5906:2	O
documented	STRIBILD.xml:S3:5909:10	O
in	STRIBILD.xml:S3:5920:2	O
all	STRIBILD.xml:S3:5923:3	O
patients	STRIBILD.xml:S3:5927:8	O
prior	STRIBILD.xml:S3:5936:5	O
to	STRIBILD.xml:S3:5942:2	O
initiating	STRIBILD.xml:S3:5945:10	O
therapy	STRIBILD.xml:S3:5956:7	O
.	STRIBILD.xml:S3:5963:1	O

Initiation	STRIBILD.xml:S3:5965:10	O
of	STRIBILD.xml:S3:5976:2	O
STRIBILD	STRIBILD.xml:S3:5979:8	O
in	STRIBILD.xml:S3:5988:2	O
patients	STRIBILD.xml:S3:5991:8	O
with	STRIBILD.xml:S3:6000:4	O
estimated	STRIBILD.xml:S3:6005:9	O
creatinine	STRIBILD.xml:S3:6015:10	O
clearance	STRIBILD.xml:S3:6026:9	O
below	STRIBILD.xml:S3:6036:5	O
70	STRIBILD.xml:S3:6042:2	O
mL	STRIBILD.xml:S3:6045:2	O
per	STRIBILD.xml:S3:6048:3	O
minute	STRIBILD.xml:S3:6052:6	O
is	STRIBILD.xml:S3:6059:2	O
not	STRIBILD.xml:S3:6062:3	O
recommended	STRIBILD.xml:S3:6066:11	O
.	STRIBILD.xml:S3:6077:1	O

Routine	STRIBILD.xml:S3:6083:7	O
monitoring	STRIBILD.xml:S3:6091:10	O
of	STRIBILD.xml:S3:6102:2	O
estimated	STRIBILD.xml:S3:6105:9	O
creatinine	STRIBILD.xml:S3:6115:10	O
clearance	STRIBILD.xml:S3:6126:9	O
,	STRIBILD.xml:S3:6135:1	O
urine	STRIBILD.xml:S3:6137:5	O
glucose	STRIBILD.xml:S3:6143:7	O
,	STRIBILD.xml:S3:6150:1	O
and	STRIBILD.xml:S3:6152:3	O
urine	STRIBILD.xml:S3:6156:5	O
protein	STRIBILD.xml:S3:6162:7	O
should	STRIBILD.xml:S3:6170:6	O
be	STRIBILD.xml:S3:6177:2	O
performed	STRIBILD.xml:S3:6180:9	O
during	STRIBILD.xml:S3:6190:6	O
STRIBILD	STRIBILD.xml:S3:6197:8	O
therapy	STRIBILD.xml:S3:6206:7	O
in	STRIBILD.xml:S3:6214:2	O
all	STRIBILD.xml:S3:6217:3	O
patients	STRIBILD.xml:S3:6221:8	O
.	STRIBILD.xml:S3:6229:1	O

Additionally	STRIBILD.xml:S3:6231:12	O
,	STRIBILD.xml:S3:6243:1	O
serum	STRIBILD.xml:S3:6245:5	O
phosphorus	STRIBILD.xml:S3:6251:10	O
should	STRIBILD.xml:S3:6262:6	O
be	STRIBILD.xml:S3:6269:2	O
measured	STRIBILD.xml:S3:6272:8	O
in	STRIBILD.xml:S3:6281:2	O
patients	STRIBILD.xml:S3:6284:8	O
at	STRIBILD.xml:S3:6293:2	O
risk	STRIBILD.xml:S3:6296:4	O
for	STRIBILD.xml:S3:6301:3	O
renal	STRIBILD.xml:S3:6305:5	O
impairment	STRIBILD.xml:S3:6311:10	O
.	STRIBILD.xml:S3:6321:1	O

Although	STRIBILD.xml:S3:6323:8	O
cobicistat	STRIBILD.xml:S3:6332:10	O
(	STRIBILD.xml:S3:6343:1	O
a	STRIBILD.xml:S3:6344:1	O
component	STRIBILD.xml:S3:6346:9	O
of	STRIBILD.xml:S3:6356:2	O
STRIBILD	STRIBILD.xml:S3:6359:8	O
)	STRIBILD.xml:S3:6367:1	O
may	STRIBILD.xml:S3:6369:3	B-Factor
cause	STRIBILD.xml:S3:6373:5	O
modest	STRIBILD.xml:S3:6379:6	B-Severity
increases	STRIBILD.xml:S3:6386:9	B-AdverseReaction
in	STRIBILD.xml:S3:6396:2	I-AdverseReaction
serum	STRIBILD.xml:S3:6399:5	I-AdverseReaction
creatinine	STRIBILD.xml:S3:6405:10	I-AdverseReaction
and	STRIBILD.xml:S3:6416:3	O
modest	STRIBILD.xml:S3:6420:6	B-Severity
declines	STRIBILD.xml:S3:6427:8	B-AdverseReaction
in	STRIBILD.xml:S3:6436:2	I-AdverseReaction
estimated	STRIBILD.xml:S3:6439:9	I-AdverseReaction
creatinine	STRIBILD.xml:S3:6449:10	I-AdverseReaction
clearance	STRIBILD.xml:S3:6460:9	I-AdverseReaction
without	STRIBILD.xml:S3:6470:7	O
affecting	STRIBILD.xml:S3:6478:9	O
renal	STRIBILD.xml:S3:6488:5	O
glomerular	STRIBILD.xml:S3:6494:10	O
function	STRIBILD.xml:S3:6505:8	O
[	STRIBILD.xml:S3:6514:1	O
see	STRIBILD.xml:S3:6515:3	O
Adverse	STRIBILD.xml:S3:6520:7	O
Reactions	STRIBILD.xml:S3:6528:9	O
(	STRIBILD.xml:S3:6538:1	O
6.1	STRIBILD.xml:S3:6539:3	O
)	STRIBILD.xml:S3:6542:1	O
]	STRIBILD.xml:S3:6545:1	O
,	STRIBILD.xml:S3:6548:1	O
patients	STRIBILD.xml:S3:6550:8	O
who	STRIBILD.xml:S3:6559:3	O
experience	STRIBILD.xml:S3:6563:10	O
a	STRIBILD.xml:S3:6574:1	O
confirmed	STRIBILD.xml:S3:6576:9	O
increase	STRIBILD.xml:S3:6586:8	O
in	STRIBILD.xml:S3:6595:2	O
serum	STRIBILD.xml:S3:6598:5	O
creatinine	STRIBILD.xml:S3:6604:10	O
of	STRIBILD.xml:S3:6615:2	O
greater	STRIBILD.xml:S3:6618:7	O
than	STRIBILD.xml:S3:6626:4	O
0.4	STRIBILD.xml:S3:6631:3	O
mg	STRIBILD.xml:S3:6635:2	O
per	STRIBILD.xml:S3:6638:3	O
dL	STRIBILD.xml:S3:6642:2	O
from	STRIBILD.xml:S3:6645:4	O
baseline	STRIBILD.xml:S3:6650:8	O
should	STRIBILD.xml:S3:6659:6	O
be	STRIBILD.xml:S3:6666:2	O
closely	STRIBILD.xml:S3:6669:7	O
monitored	STRIBILD.xml:S3:6677:9	O
for	STRIBILD.xml:S3:6687:3	O
renal	STRIBILD.xml:S3:6691:5	O
safety	STRIBILD.xml:S3:6697:6	O
.	STRIBILD.xml:S3:6703:1	O

The	STRIBILD.xml:S3:6709:3	O
emtricitabine	STRIBILD.xml:S3:6713:13	O
and	STRIBILD.xml:S3:6727:3	O
tenofovir	STRIBILD.xml:S3:6731:9	O
DF	STRIBILD.xml:S3:6741:2	O
components	STRIBILD.xml:S3:6744:10	O
of	STRIBILD.xml:S3:6755:2	O
STRIBILD	STRIBILD.xml:S3:6758:8	O
are	STRIBILD.xml:S3:6767:3	O
primarily	STRIBILD.xml:S3:6771:9	O
excreted	STRIBILD.xml:S3:6781:8	O
by	STRIBILD.xml:S3:6790:2	O
the	STRIBILD.xml:S3:6793:3	O
kidney	STRIBILD.xml:S3:6797:6	O
.	STRIBILD.xml:S3:6803:1	O

STRIBILD	STRIBILD.xml:S3:6805:8	O
should	STRIBILD.xml:S3:6814:6	O
be	STRIBILD.xml:S3:6821:2	O
discontinued	STRIBILD.xml:S3:6824:12	O
if	STRIBILD.xml:S3:6837:2	O
estimated	STRIBILD.xml:S3:6840:9	O
creatinine	STRIBILD.xml:S3:6850:10	O
clearance	STRIBILD.xml:S3:6861:9	O
declines	STRIBILD.xml:S3:6871:8	O
below	STRIBILD.xml:S3:6880:5	O
50	STRIBILD.xml:S3:6886:2	O
mL	STRIBILD.xml:S3:6889:2	O
per	STRIBILD.xml:S3:6892:3	O
minute	STRIBILD.xml:S3:6896:6	O
as	STRIBILD.xml:S3:6903:2	O
dose	STRIBILD.xml:S3:6906:4	O
interval	STRIBILD.xml:S3:6911:8	O
adjustment	STRIBILD.xml:S3:6920:10	O
required	STRIBILD.xml:S3:6931:8	O
for	STRIBILD.xml:S3:6940:3	O
emtricitabine	STRIBILD.xml:S3:6944:13	O
and	STRIBILD.xml:S3:6958:3	O
tenofovir	STRIBILD.xml:S3:6962:9	O
DF	STRIBILD.xml:S3:6972:2	O
cannot	STRIBILD.xml:S3:6975:6	O
be	STRIBILD.xml:S3:6982:2	O
achieved	STRIBILD.xml:S3:6985:8	O
with	STRIBILD.xml:S3:6994:4	O
the	STRIBILD.xml:S3:6999:3	O
fixed	STRIBILD.xml:S3:7003:5	O
-	STRIBILD.xml:S3:7008:1	O
dose	STRIBILD.xml:S3:7009:4	O
combination	STRIBILD.xml:S3:7014:11	O
tablet	STRIBILD.xml:S3:7026:6	O
.	STRIBILD.xml:S3:7032:1	O

5.4	STRIBILD.xml:S3:7041:3	O
Avoid	STRIBILD.xml:S3:7045:5	O
Use	STRIBILD.xml:S3:7051:3	O
with	STRIBILD.xml:S3:7055:4	O
Other	STRIBILD.xml:S3:7060:5	O
Antiretroviral	STRIBILD.xml:S3:7066:14	O
Products	STRIBILD.xml:S3:7081:8	O

STRIBILD	STRIBILD.xml:S3:7095:8	O
is	STRIBILD.xml:S3:7104:2	O
indicated	STRIBILD.xml:S3:7107:9	O
for	STRIBILD.xml:S3:7117:3	O
use	STRIBILD.xml:S3:7121:3	O
as	STRIBILD.xml:S3:7125:2	O
a	STRIBILD.xml:S3:7128:1	O
complete	STRIBILD.xml:S3:7130:8	O
regimen	STRIBILD.xml:S3:7139:7	O
for	STRIBILD.xml:S3:7147:3	O
the	STRIBILD.xml:S3:7151:3	O
treatment	STRIBILD.xml:S3:7155:9	O
of	STRIBILD.xml:S3:7165:2	O
HIV	STRIBILD.xml:S3:7168:3	O
-	STRIBILD.xml:S3:7171:1	O
1	STRIBILD.xml:S3:7172:1	O
infection	STRIBILD.xml:S3:7174:9	O
and	STRIBILD.xml:S3:7184:3	O
coadministration	STRIBILD.xml:S3:7188:16	O
with	STRIBILD.xml:S3:7205:4	O
other	STRIBILD.xml:S3:7210:5	O
antiretroviral	STRIBILD.xml:S3:7216:14	O
products	STRIBILD.xml:S3:7231:8	O
is	STRIBILD.xml:S3:7240:2	O
not	STRIBILD.xml:S3:7243:3	O
recommended	STRIBILD.xml:S3:7247:11	O
.	STRIBILD.xml:S3:7258:1	O

STRIBILD	STRIBILD.xml:S3:7264:8	O
is	STRIBILD.xml:S3:7273:2	O
not	STRIBILD.xml:S3:7276:3	O
recommended	STRIBILD.xml:S3:7280:11	O
for	STRIBILD.xml:S3:7292:3	O
coadministration	STRIBILD.xml:S3:7296:16	O
with	STRIBILD.xml:S3:7313:4	O
the	STRIBILD.xml:S3:7318:3	O
following	STRIBILD.xml:S3:7322:9	O
:	STRIBILD.xml:S3:7331:1	O

cobicistat	STRIBILD.xml:S3:7341:10	O
(	STRIBILD.xml:S3:7352:1	O
TYBOST	STRIBILD.xml:S3:7353:6	O
)	STRIBILD.xml:S3:7359:1	O
;	STRIBILD.xml:S3:7360:1	O

elvitegravir	STRIBILD.xml:S3:7369:12	O
(	STRIBILD.xml:S3:7382:1	O
VITEKTA	STRIBILD.xml:S3:7383:7	O
)	STRIBILD.xml:S3:7390:1	O
;	STRIBILD.xml:S3:7391:1	O

products	STRIBILD.xml:S3:7400:8	O
containing	STRIBILD.xml:S3:7409:10	O
emtricitabine	STRIBILD.xml:S3:7420:13	O
or	STRIBILD.xml:S3:7434:2	O
tenofovir	STRIBILD.xml:S3:7437:9	O
DF	STRIBILD.xml:S3:7447:2	O
(	STRIBILD.xml:S3:7450:1	O
ATRIPLA	STRIBILD.xml:S3:7451:7	O
,	STRIBILD.xml:S3:7458:1	O
COMPLERA	STRIBILD.xml:S3:7460:8	O
,	STRIBILD.xml:S3:7468:1	O
EMTRIVA	STRIBILD.xml:S3:7470:7	O
,	STRIBILD.xml:S3:7477:1	O
TRUVADA	STRIBILD.xml:S3:7479:7	O
,	STRIBILD.xml:S3:7486:1	O
VIREAD	STRIBILD.xml:S3:7488:6	O
)	STRIBILD.xml:S3:7494:1	O
;	STRIBILD.xml:S3:7495:1	O

products	STRIBILD.xml:S3:7504:8	O
containing	STRIBILD.xml:S3:7513:10	O
lamivudine	STRIBILD.xml:S3:7524:10	O
(	STRIBILD.xml:S3:7535:1	O
COMBIVIR	STRIBILD.xml:S3:7536:8	O
,	STRIBILD.xml:S3:7544:1	O
EPIVIR	STRIBILD.xml:S3:7546:6	O
,	STRIBILD.xml:S3:7552:1	O
EPIVIR	STRIBILD.xml:S3:7554:6	O
-	STRIBILD.xml:S3:7560:1	O
HBV	STRIBILD.xml:S3:7561:3	O
,	STRIBILD.xml:S3:7564:1	O
EPZICOM	STRIBILD.xml:S3:7566:7	O
,	STRIBILD.xml:S3:7573:1	O
TRIUMEQ	STRIBILD.xml:S3:7575:7	O
,	STRIBILD.xml:S3:7582:1	O
TRIZIVIR	STRIBILD.xml:S3:7584:8	O
)	STRIBILD.xml:S3:7592:1	O
;	STRIBILD.xml:S3:7593:1	O

adefovir	STRIBILD.xml:S3:7602:8	O
dipivoxil	STRIBILD.xml:S3:7611:9	O
(	STRIBILD.xml:S3:7621:1	O
HEPSERA	STRIBILD.xml:S3:7622:7	O
)	STRIBILD.xml:S3:7629:1	O
;	STRIBILD.xml:S3:7630:1	O

products	STRIBILD.xml:S3:7639:8	O
containing	STRIBILD.xml:S3:7648:10	O
ritonavir	STRIBILD.xml:S3:7659:9	O
(	STRIBILD.xml:S3:7669:1	O
NORVIR	STRIBILD.xml:S3:7670:6	O
,	STRIBILD.xml:S3:7676:1	O
KALETRA	STRIBILD.xml:S3:7678:7	O
)	STRIBILD.xml:S3:7685:1	O

5.5	STRIBILD.xml:S3:7696:3	O
Risk	STRIBILD.xml:S3:7700:4	O
of	STRIBILD.xml:S3:7705:2	O
Adverse	STRIBILD.xml:S3:7708:7	O
Reactions	STRIBILD.xml:S3:7716:9	O
or	STRIBILD.xml:S3:7726:2	O
Loss	STRIBILD.xml:S3:7729:4	O
of	STRIBILD.xml:S3:7734:2	O
Virologic	STRIBILD.xml:S3:7737:9	O
Response	STRIBILD.xml:S3:7747:8	O
Due	STRIBILD.xml:S3:7756:3	O
to	STRIBILD.xml:S3:7760:2	O
Drug	STRIBILD.xml:S3:7763:4	O
Interactions	STRIBILD.xml:S3:7768:12	O

The	STRIBILD.xml:S3:7787:3	O

concomitant	STRIBILD.xml:S3:7791:11	O
use	STRIBILD.xml:S3:7803:3	O
of	STRIBILD.xml:S3:7807:2	O
STRIBILD	STRIBILD.xml:S3:7810:8	O
and	STRIBILD.xml:S3:7819:3	O
other	STRIBILD.xml:S3:7823:5	O
drugs	STRIBILD.xml:S3:7829:5	O
may	STRIBILD.xml:S3:7835:3	O
result	STRIBILD.xml:S3:7839:6	O
in	STRIBILD.xml:S3:7846:2	O
known	STRIBILD.xml:S3:7849:5	O
or	STRIBILD.xml:S3:7855:2	O
potentially	STRIBILD.xml:S3:7858:11	O
significant	STRIBILD.xml:S3:7870:11	O
drug	STRIBILD.xml:S3:7882:4	O
interactions	STRIBILD.xml:S3:7887:12	O
,	STRIBILD.xml:S3:7899:1	O
some	STRIBILD.xml:S3:7901:4	O
of	STRIBILD.xml:S3:7906:2	O
which	STRIBILD.xml:S3:7909:5	O
may	STRIBILD.xml:S3:7915:3	O
lead	STRIBILD.xml:S3:7919:4	O
to	STRIBILD.xml:S3:7924:2	O
[	STRIBILD.xml:S3:7927:1	O
see	STRIBILD.xml:S3:7928:3	O
Contraindications	STRIBILD.xml:S3:7933:17	O
(	STRIBILD.xml:S3:7951:1	O
4	STRIBILD.xml:S3:7952:1	O
)	STRIBILD.xml:S3:7953:1	O
,	STRIBILD.xml:S3:7956:1	O
Drug	STRIBILD.xml:S3:7959:4	O
Interactions	STRIBILD.xml:S3:7964:12	O
(	STRIBILD.xml:S3:7977:1	O
7.5	STRIBILD.xml:S3:7978:3	O
)	STRIBILD.xml:S3:7981:1	O
]	STRIBILD.xml:S3:7984:1	O
:	STRIBILD.xml:S3:7985:1	O

Loss	STRIBILD.xml:S3:7999:4	O
of	STRIBILD.xml:S3:8004:2	O
therapeutic	STRIBILD.xml:S3:8007:11	O
effect	STRIBILD.xml:S3:8019:6	O
of	STRIBILD.xml:S3:8026:2	O
STRIBILD	STRIBILD.xml:S3:8029:8	O
and	STRIBILD.xml:S3:8038:3	O
possible	STRIBILD.xml:S3:8042:8	O
development	STRIBILD.xml:S3:8051:11	O
of	STRIBILD.xml:S3:8063:2	O
resistance	STRIBILD.xml:S3:8066:10	O
.	STRIBILD.xml:S3:8076:1	O

Possible	STRIBILD.xml:S3:8085:8	O
clinically	STRIBILD.xml:S3:8094:10	O
significant	STRIBILD.xml:S3:8105:11	O
adverse	STRIBILD.xml:S3:8117:7	O
reactions	STRIBILD.xml:S3:8125:9	O
from	STRIBILD.xml:S3:8135:4	O
greater	STRIBILD.xml:S3:8140:7	O
exposures	STRIBILD.xml:S3:8148:9	O
of	STRIBILD.xml:S3:8158:2	O
concomitant	STRIBILD.xml:S3:8161:11	O
drugs	STRIBILD.xml:S3:8173:5	O
.	STRIBILD.xml:S3:8178:1	O

See	STRIBILD.xml:S3:8187:3	O
Table	STRIBILD.xml:S3:8192:5	O
6	STRIBILD.xml:S3:8198:1	O
for	STRIBILD.xml:S3:8201:3	O
steps	STRIBILD.xml:S3:8205:5	O
to	STRIBILD.xml:S3:8211:2	O
prevent	STRIBILD.xml:S3:8214:7	O
or	STRIBILD.xml:S3:8222:2	O
manage	STRIBILD.xml:S3:8225:6	O
these	STRIBILD.xml:S3:8232:5	O
possible	STRIBILD.xml:S3:8238:8	O
and	STRIBILD.xml:S3:8247:3	O
known	STRIBILD.xml:S3:8251:5	O
significant	STRIBILD.xml:S3:8257:11	O
drug	STRIBILD.xml:S3:8269:4	O
interactions	STRIBILD.xml:S3:8274:12	O
,	STRIBILD.xml:S3:8286:1	O
including	STRIBILD.xml:S3:8288:9	O
dosing	STRIBILD.xml:S3:8298:6	O
recommendations	STRIBILD.xml:S3:8305:15	O
[	STRIBILD.xml:S3:8321:1	O
see	STRIBILD.xml:S3:8322:3	O
Drug	STRIBILD.xml:S3:8327:4	O
Interactions	STRIBILD.xml:S3:8332:12	O
(	STRIBILD.xml:S3:8345:1	O
7.5	STRIBILD.xml:S3:8346:3	O
)	STRIBILD.xml:S3:8349:1	O
]	STRIBILD.xml:S3:8352:1	O
.	STRIBILD.xml:S3:8355:1	O

Consider	STRIBILD.xml:S3:8357:8	O
the	STRIBILD.xml:S3:8366:3	O
potential	STRIBILD.xml:S3:8370:9	O
for	STRIBILD.xml:S3:8380:3	O
drug	STRIBILD.xml:S3:8384:4	O
interactions	STRIBILD.xml:S3:8389:12	O
prior	STRIBILD.xml:S3:8402:5	O
to	STRIBILD.xml:S3:8408:2	O
and	STRIBILD.xml:S3:8411:3	O
during	STRIBILD.xml:S3:8415:6	O
STRIBILD	STRIBILD.xml:S3:8422:8	O
therapy	STRIBILD.xml:S3:8431:7	O
;	STRIBILD.xml:S3:8438:1	O
review	STRIBILD.xml:S3:8440:6	O
concomitant	STRIBILD.xml:S3:8447:11	O
medications	STRIBILD.xml:S3:8459:11	O
during	STRIBILD.xml:S3:8471:6	O
STRIBILD	STRIBILD.xml:S3:8478:8	O
therapy	STRIBILD.xml:S3:8487:7	O
;	STRIBILD.xml:S3:8494:1	O
and	STRIBILD.xml:S3:8496:3	O
monitor	STRIBILD.xml:S3:8500:7	O
for	STRIBILD.xml:S3:8508:3	O
the	STRIBILD.xml:S3:8512:3	O
adverse	STRIBILD.xml:S3:8516:7	O
reactions	STRIBILD.xml:S3:8524:9	O
associated	STRIBILD.xml:S3:8534:10	O
with	STRIBILD.xml:S3:8545:4	O
the	STRIBILD.xml:S3:8550:3	O
concomitant	STRIBILD.xml:S3:8554:11	O
drugs	STRIBILD.xml:S3:8566:5	O
.	STRIBILD.xml:S3:8571:1	O

5.6	STRIBILD.xml:S3:8582:3	O

Bone	STRIBILD.xml:S3:8586:4	O
Effects	STRIBILD.xml:S3:8591:7	O
of	STRIBILD.xml:S3:8599:2	O
Tenofovir	STRIBILD.xml:S3:8602:9	O
DF	STRIBILD.xml:S3:8612:2	O

Bone	STRIBILD.xml:S3:8621:4	O
Mineral	STRIBILD.xml:S3:8626:7	O
Density	STRIBILD.xml:S3:8634:7	O
:	STRIBILD.xml:S3:8641:1	O

In	STRIBILD.xml:S3:8649:2	O
clinical	STRIBILD.xml:S3:8652:8	O
trials	STRIBILD.xml:S3:8661:6	O
in	STRIBILD.xml:S3:8668:2	O
HIV	STRIBILD.xml:S3:8671:3	O
-	STRIBILD.xml:S3:8674:1	O
1	STRIBILD.xml:S3:8675:1	O
infected	STRIBILD.xml:S3:8677:8	O
adults	STRIBILD.xml:S3:8686:6	O
,	STRIBILD.xml:S3:8692:1	O
tenofovir	STRIBILD.xml:S3:8694:9	O
DF	STRIBILD.xml:S3:8704:2	O
(	STRIBILD.xml:S3:8707:1	O
a	STRIBILD.xml:S3:8708:1	O
component	STRIBILD.xml:S3:8710:9	O
of	STRIBILD.xml:S3:8720:2	O
STRIBILD	STRIBILD.xml:S3:8723:8	O
)	STRIBILD.xml:S3:8731:1	O
was	STRIBILD.xml:S3:8733:3	O
associated	STRIBILD.xml:S3:8737:10	O
with	STRIBILD.xml:S3:8748:4	O
slightly	STRIBILD.xml:S3:8753:8	O
greater	STRIBILD.xml:S3:8762:7	O
decreases	STRIBILD.xml:S3:8770:9	B-AdverseReaction
in	STRIBILD.xml:S3:8780:2	I-AdverseReaction
bone	STRIBILD.xml:S3:8783:4	I-AdverseReaction
mineral	STRIBILD.xml:S3:8788:7	I-AdverseReaction
density	STRIBILD.xml:S3:8796:7	I-AdverseReaction
(	STRIBILD.xml:S3:8804:1	O
BMD	STRIBILD.xml:S3:8805:3	I-AdverseReaction
)	STRIBILD.xml:S3:8808:1	O
and	STRIBILD.xml:S3:8810:3	O
increases	STRIBILD.xml:S3:8814:9	B-AdverseReaction
in	STRIBILD.xml:S3:8824:2	I-AdverseReaction
biochemical	STRIBILD.xml:S3:8827:11	I-AdverseReaction
markers	STRIBILD.xml:S3:8839:7	I-AdverseReaction
of	STRIBILD.xml:S3:8847:2	I-AdverseReaction
bone	STRIBILD.xml:S3:8850:4	I-AdverseReaction
metabolism	STRIBILD.xml:S3:8855:10	I-AdverseReaction
,	STRIBILD.xml:S3:8865:1	O
suggesting	STRIBILD.xml:S3:8867:10	O
increased	STRIBILD.xml:S3:8878:9	B-AdverseReaction
bone	STRIBILD.xml:S3:8888:4	I-AdverseReaction
turnover	STRIBILD.xml:S3:8893:8	I-AdverseReaction
relative	STRIBILD.xml:S3:8902:8	O
to	STRIBILD.xml:S3:8911:2	O
comparators	STRIBILD.xml:S3:8914:11	O
.	STRIBILD.xml:S3:8925:1	O

Serum	STRIBILD.xml:S3:8927:5	O
parathyroid	STRIBILD.xml:S3:8933:11	O
hormone	STRIBILD.xml:S3:8945:7	O
levels	STRIBILD.xml:S3:8953:6	O
and	STRIBILD.xml:S3:8960:3	O
1.25	STRIBILD.xml:S3:8964:4	O
Vitamin	STRIBILD.xml:S3:8969:7	O
D	STRIBILD.xml:S3:8977:1	O
levels	STRIBILD.xml:S3:8979:6	O
were	STRIBILD.xml:S3:8986:4	O
also	STRIBILD.xml:S3:8991:4	O
higher	STRIBILD.xml:S3:8996:6	O
in	STRIBILD.xml:S3:9003:2	O
subjects	STRIBILD.xml:S3:9006:8	O
receiving	STRIBILD.xml:S3:9015:9	O
tenofovir	STRIBILD.xml:S3:9025:9	O
DF	STRIBILD.xml:S3:9035:2	O
.	STRIBILD.xml:S3:9037:1	O

For	STRIBILD.xml:S3:9039:3	O
additional	STRIBILD.xml:S3:9043:10	O
information	STRIBILD.xml:S3:9054:11	O
,	STRIBILD.xml:S3:9065:1	O
see	STRIBILD.xml:S3:9067:3	O
Adverse	STRIBILD.xml:S3:9071:7	O
Reactions	STRIBILD.xml:S3:9079:9	O
(	STRIBILD.xml:S3:9089:1	O
6.1	STRIBILD.xml:S3:9090:3	O
)	STRIBILD.xml:S3:9093:1	O
and	STRIBILD.xml:S3:9095:3	O
consult	STRIBILD.xml:S3:9099:7	O
the	STRIBILD.xml:S3:9107:3	O
VIREAD	STRIBILD.xml:S3:9111:6	O
prescribing	STRIBILD.xml:S3:9118:11	O
information	STRIBILD.xml:S3:9130:11	O
.	STRIBILD.xml:S3:9141:1	O

The	STRIBILD.xml:S3:9147:3	O
effects	STRIBILD.xml:S3:9151:7	O
of	STRIBILD.xml:S3:9159:2	O
tenofovir	STRIBILD.xml:S3:9162:9	O
DF	STRIBILD.xml:S3:9172:2	O
-	STRIBILD.xml:S3:9174:1	O
associated	STRIBILD.xml:S3:9175:10	O
changes	STRIBILD.xml:S3:9186:7	O
in	STRIBILD.xml:S3:9194:2	O
BMD	STRIBILD.xml:S3:9197:3	O
and	STRIBILD.xml:S3:9201:3	O
biochemical	STRIBILD.xml:S3:9205:11	O
markers	STRIBILD.xml:S3:9217:7	O
on	STRIBILD.xml:S3:9225:2	O
long	STRIBILD.xml:S3:9228:4	O
-	STRIBILD.xml:S3:9232:1	O
term	STRIBILD.xml:S3:9233:4	O
bone	STRIBILD.xml:S3:9238:4	O
health	STRIBILD.xml:S3:9243:6	O
and	STRIBILD.xml:S3:9250:3	O
future	STRIBILD.xml:S3:9254:6	O
fracture	STRIBILD.xml:S3:9261:8	O
risk	STRIBILD.xml:S3:9270:4	O
are	STRIBILD.xml:S3:9275:3	O
unknown	STRIBILD.xml:S3:9279:7	O
.	STRIBILD.xml:S3:9286:1	O

Assessment	STRIBILD.xml:S3:9288:10	O
of	STRIBILD.xml:S3:9299:2	O
BMD	STRIBILD.xml:S3:9302:3	O
should	STRIBILD.xml:S3:9306:6	O
be	STRIBILD.xml:S3:9313:2	O
considered	STRIBILD.xml:S3:9316:10	O
for	STRIBILD.xml:S3:9327:3	O
HIV	STRIBILD.xml:S3:9331:3	O
-	STRIBILD.xml:S3:9334:1	O
1	STRIBILD.xml:S3:9335:1	O
infected	STRIBILD.xml:S3:9337:8	O
patients	STRIBILD.xml:S3:9346:8	O
who	STRIBILD.xml:S3:9355:3	O
have	STRIBILD.xml:S3:9359:4	O
a	STRIBILD.xml:S3:9364:1	O
history	STRIBILD.xml:S3:9366:7	O
of	STRIBILD.xml:S3:9374:2	O
pathologic	STRIBILD.xml:S3:9377:10	O
bone	STRIBILD.xml:S3:9388:4	O
fracture	STRIBILD.xml:S3:9393:8	O
or	STRIBILD.xml:S3:9402:2	O
other	STRIBILD.xml:S3:9405:5	O
risk	STRIBILD.xml:S3:9411:4	O
factors	STRIBILD.xml:S3:9416:7	O
for	STRIBILD.xml:S3:9424:3	O
osteoporosis	STRIBILD.xml:S3:9428:12	O
or	STRIBILD.xml:S3:9441:2	O
bone	STRIBILD.xml:S3:9444:4	O
loss	STRIBILD.xml:S3:9449:4	O
.	STRIBILD.xml:S3:9453:1	O

Although	STRIBILD.xml:S3:9455:8	O
the	STRIBILD.xml:S3:9464:3	O
effect	STRIBILD.xml:S3:9468:6	O
of	STRIBILD.xml:S3:9475:2	O
supplementation	STRIBILD.xml:S3:9478:15	O
with	STRIBILD.xml:S3:9494:4	O
calcium	STRIBILD.xml:S3:9499:7	O
and	STRIBILD.xml:S3:9507:3	O
vitamin	STRIBILD.xml:S3:9511:7	O
D	STRIBILD.xml:S3:9519:1	O
was	STRIBILD.xml:S3:9521:3	O
not	STRIBILD.xml:S3:9525:3	O
studied	STRIBILD.xml:S3:9529:7	O
,	STRIBILD.xml:S3:9536:1	O
such	STRIBILD.xml:S3:9538:4	O
supplementation	STRIBILD.xml:S3:9543:15	O
may	STRIBILD.xml:S3:9559:3	O
be	STRIBILD.xml:S3:9563:2	O
beneficial	STRIBILD.xml:S3:9566:10	O
in	STRIBILD.xml:S3:9577:2	O
all	STRIBILD.xml:S3:9580:3	O
patients	STRIBILD.xml:S3:9584:8	O
.	STRIBILD.xml:S3:9592:1	O

If	STRIBILD.xml:S3:9594:2	O
bone	STRIBILD.xml:S3:9597:4	O
abnormalities	STRIBILD.xml:S3:9602:13	O
are	STRIBILD.xml:S3:9616:3	O
suspected	STRIBILD.xml:S3:9620:9	O
,	STRIBILD.xml:S3:9629:1	O
then	STRIBILD.xml:S3:9631:4	O
appropriate	STRIBILD.xml:S3:9636:11	O
consultation	STRIBILD.xml:S3:9648:12	O
should	STRIBILD.xml:S3:9661:6	O
be	STRIBILD.xml:S3:9668:2	O
obtained	STRIBILD.xml:S3:9671:8	O
.	STRIBILD.xml:S3:9679:1	O

Mineralization	STRIBILD.xml:S3:9688:14	O
Defects	STRIBILD.xml:S3:9703:7	O
:	STRIBILD.xml:S3:9710:1	O

Cases	STRIBILD.xml:S3:9718:5	O
of	STRIBILD.xml:S3:9724:2	O
osteomalacia	STRIBILD.xml:S3:9727:12	B-AdverseReaction
associated	STRIBILD.xml:S3:9740:10	O
with	STRIBILD.xml:S3:9751:4	O
proximal	STRIBILD.xml:S3:9756:8	B-AdverseReaction
renal	STRIBILD.xml:S3:9765:5	I-AdverseReaction
tubulopathy	STRIBILD.xml:S3:9771:11	I-AdverseReaction
,	STRIBILD.xml:S3:9782:1	O
manifested	STRIBILD.xml:S3:9784:10	O
as	STRIBILD.xml:S3:9795:2	O
bone	STRIBILD.xml:S3:9798:4	B-AdverseReaction
pain	STRIBILD.xml:S3:9803:4	I-AdverseReaction
or	STRIBILD.xml:S3:9808:2	O
pain	STRIBILD.xml:S3:9811:4	B-AdverseReaction
in	STRIBILD.xml:S3:9816:2	I-AdverseReaction
extremities	STRIBILD.xml:S3:9819:11	I-AdverseReaction
and	STRIBILD.xml:S3:9831:3	O
which	STRIBILD.xml:S3:9835:5	O
may	STRIBILD.xml:S3:9841:3	B-Factor
contribute	STRIBILD.xml:S3:9845:10	O
to	STRIBILD.xml:S3:9856:2	O
fractures	STRIBILD.xml:S3:9859:9	B-AdverseReaction
,	STRIBILD.xml:S3:9868:1	O
have	STRIBILD.xml:S3:9870:4	O
been	STRIBILD.xml:S3:9875:4	O
reported	STRIBILD.xml:S3:9880:8	O
in	STRIBILD.xml:S3:9889:2	O
association	STRIBILD.xml:S3:9892:11	O
with	STRIBILD.xml:S3:9904:4	O
the	STRIBILD.xml:S3:9909:3	O
use	STRIBILD.xml:S3:9913:3	O
of	STRIBILD.xml:S3:9917:2	O
tenofovir	STRIBILD.xml:S3:9920:9	O
DF	STRIBILD.xml:S3:9930:2	O
[	STRIBILD.xml:S3:9933:1	O
see	STRIBILD.xml:S3:9934:3	O
Adverse	STRIBILD.xml:S3:9939:7	O
Reactions	STRIBILD.xml:S3:9947:9	O
(	STRIBILD.xml:S3:9957:1	O
6.2	STRIBILD.xml:S3:9958:3	O
)	STRIBILD.xml:S3:9961:1	O
]	STRIBILD.xml:S3:9964:1	O
.	STRIBILD.xml:S3:9967:1	O

Arthralgias	STRIBILD.xml:S3:9969:11	B-AdverseReaction
and	STRIBILD.xml:S3:9981:3	O
muscle	STRIBILD.xml:S3:9985:6	B-AdverseReaction
pain	STRIBILD.xml:S3:9992:4	I-AdverseReaction
or	STRIBILD.xml:S3:9997:2	O
weakness	STRIBILD.xml:S3:10000:8	I-AdverseReaction
have	STRIBILD.xml:S3:10009:4	O
also	STRIBILD.xml:S3:10014:4	O
been	STRIBILD.xml:S3:10019:4	O
reported	STRIBILD.xml:S3:10024:8	O
in	STRIBILD.xml:S3:10033:2	O
cases	STRIBILD.xml:S3:10036:5	O
of	STRIBILD.xml:S3:10042:2	O
proximal	STRIBILD.xml:S3:10045:8	B-AdverseReaction
renal	STRIBILD.xml:S3:10054:5	I-AdverseReaction
tubulopathy	STRIBILD.xml:S3:10060:11	I-AdverseReaction
.	STRIBILD.xml:S3:10071:1	O

Hypophosphatemia	STRIBILD.xml:S3:10073:16	O
and	STRIBILD.xml:S3:10090:3	O
osteomalacia	STRIBILD.xml:S3:10094:12	O
secondary	STRIBILD.xml:S3:10107:9	O
to	STRIBILD.xml:S3:10117:2	O
proximal	STRIBILD.xml:S3:10120:8	O
renal	STRIBILD.xml:S3:10129:5	O
tubulopathy	STRIBILD.xml:S3:10135:11	O
should	STRIBILD.xml:S3:10147:6	O
be	STRIBILD.xml:S3:10154:2	O
considered	STRIBILD.xml:S3:10157:10	O
in	STRIBILD.xml:S3:10168:2	O
patients	STRIBILD.xml:S3:10171:8	O
at	STRIBILD.xml:S3:10180:2	O
risk	STRIBILD.xml:S3:10183:4	O
of	STRIBILD.xml:S3:10188:2	O
renal	STRIBILD.xml:S3:10191:5	O
dysfunction	STRIBILD.xml:S3:10197:11	O
who	STRIBILD.xml:S3:10209:3	O
present	STRIBILD.xml:S3:10213:7	O
with	STRIBILD.xml:S3:10221:4	O
persistent	STRIBILD.xml:S3:10226:10	O
or	STRIBILD.xml:S3:10237:2	O
worsening	STRIBILD.xml:S3:10240:9	O
bone	STRIBILD.xml:S3:10250:4	O
or	STRIBILD.xml:S3:10255:2	O
muscle	STRIBILD.xml:S3:10258:6	O
symptoms	STRIBILD.xml:S3:10265:8	O
while	STRIBILD.xml:S3:10274:5	O
receiving	STRIBILD.xml:S3:10280:9	O
products	STRIBILD.xml:S3:10290:8	O
containing	STRIBILD.xml:S3:10299:10	O
tenofovir	STRIBILD.xml:S3:10310:9	O
DF	STRIBILD.xml:S3:10320:2	O
[	STRIBILD.xml:S3:10323:1	O
see	STRIBILD.xml:S3:10324:3	O
Warnings	STRIBILD.xml:S3:10329:8	O
and	STRIBILD.xml:S3:10338:3	O
Precautions	STRIBILD.xml:S3:10342:11	O
(	STRIBILD.xml:S3:10354:1	O
5.3	STRIBILD.xml:S3:10355:3	O
)	STRIBILD.xml:S3:10358:1	O
]	STRIBILD.xml:S3:10361:1	O
.	STRIBILD.xml:S3:10364:1	O

5.7	STRIBILD.xml:S3:10373:3	O
Fat	STRIBILD.xml:S3:10377:3	O
Redistribution	STRIBILD.xml:S3:10381:14	O

Redistribution	STRIBILD.xml:S3:10401:14	B-AdverseReaction
accumulation	STRIBILD.xml:S3:10416:12	B-AdverseReaction
of	STRIBILD.xml:S3:10429:2	I-AdverseReaction
body	STRIBILD.xml:S3:10432:4	I-AdverseReaction
fat	STRIBILD.xml:S3:10437:3	I-AdverseReaction
including	STRIBILD.xml:S3:10441:9	O
central	STRIBILD.xml:S3:10451:7	B-AdverseReaction
obesity	STRIBILD.xml:S3:10459:7	I-AdverseReaction
,	STRIBILD.xml:S3:10466:1	O
dorsocervical	STRIBILD.xml:S3:10468:13	B-AdverseReaction
fat	STRIBILD.xml:S3:10482:3	I-AdverseReaction
enlargement	STRIBILD.xml:S3:10486:11	I-AdverseReaction
(	STRIBILD.xml:S3:10498:1	O
buffalo	STRIBILD.xml:S3:10499:7	B-AdverseReaction
hump	STRIBILD.xml:S3:10507:4	I-AdverseReaction
)	STRIBILD.xml:S3:10511:1	O
,	STRIBILD.xml:S3:10512:1	O
peripheral	STRIBILD.xml:S3:10514:10	I-AdverseReaction
wasting	STRIBILD.xml:S3:10525:7	I-AdverseReaction
,	STRIBILD.xml:S3:10532:1	O
facial	STRIBILD.xml:S3:10534:6	B-AdverseReaction
wasting	STRIBILD.xml:S3:10541:7	I-AdverseReaction
,	STRIBILD.xml:S3:10548:1	O
breast	STRIBILD.xml:S3:10550:6	B-AdverseReaction
enlargement	STRIBILD.xml:S3:10557:11	I-AdverseReaction
,	STRIBILD.xml:S3:10568:1	O
and	STRIBILD.xml:S3:10570:3	O
"	STRIBILD.xml:S3:10574:1	O
cushingoid	STRIBILD.xml:S3:10575:10	B-AdverseReaction
appearance	STRIBILD.xml:S3:10586:10	I-AdverseReaction
"	STRIBILD.xml:S3:10596:1	O
have	STRIBILD.xml:S3:10598:4	O
been	STRIBILD.xml:S3:10603:4	O
observed	STRIBILD.xml:S3:10608:8	O
in	STRIBILD.xml:S3:10617:2	O
patients	STRIBILD.xml:S3:10620:8	O
receiving	STRIBILD.xml:S3:10629:9	O
antiretroviral	STRIBILD.xml:S3:10639:14	O
therapy	STRIBILD.xml:S3:10654:7	O
.	STRIBILD.xml:S3:10661:1	O

The	STRIBILD.xml:S3:10663:3	O
mechanism	STRIBILD.xml:S3:10667:9	O
and	STRIBILD.xml:S3:10677:3	O
long	STRIBILD.xml:S3:10681:4	O
-	STRIBILD.xml:S3:10685:1	O
term	STRIBILD.xml:S3:10686:4	O
consequences	STRIBILD.xml:S3:10691:12	O
of	STRIBILD.xml:S3:10704:2	O
these	STRIBILD.xml:S3:10707:5	O
events	STRIBILD.xml:S3:10713:6	O
are	STRIBILD.xml:S3:10720:3	O
currently	STRIBILD.xml:S3:10724:9	O
unknown	STRIBILD.xml:S3:10734:7	O
.	STRIBILD.xml:S3:10741:1	O

A	STRIBILD.xml:S3:10743:1	O
causal	STRIBILD.xml:S3:10745:6	O
relationship	STRIBILD.xml:S3:10752:12	O
has	STRIBILD.xml:S3:10765:3	O
not	STRIBILD.xml:S3:10769:3	O
been	STRIBILD.xml:S3:10773:4	O
established	STRIBILD.xml:S3:10778:11	O
.	STRIBILD.xml:S3:10789:1	O

5.8	STRIBILD.xml:S3:10798:3	O
Immune	STRIBILD.xml:S3:10802:6	O
Reconstitution	STRIBILD.xml:S3:10809:14	O
Syndrome	STRIBILD.xml:S3:10824:8	O

Immune	STRIBILD.xml:S3:10838:6	B-AdverseReaction
reconstitution	STRIBILD.xml:S3:10845:14	I-AdverseReaction
syndrome	STRIBILD.xml:S3:10860:8	I-AdverseReaction
has	STRIBILD.xml:S3:10869:3	O
been	STRIBILD.xml:S3:10873:4	O
reported	STRIBILD.xml:S3:10878:8	O
in	STRIBILD.xml:S3:10887:2	O
patients	STRIBILD.xml:S3:10890:8	O
treated	STRIBILD.xml:S3:10899:7	O
with	STRIBILD.xml:S3:10907:4	O
combination	STRIBILD.xml:S3:10912:11	O
antiretroviral	STRIBILD.xml:S3:10924:14	O
therapy	STRIBILD.xml:S3:10939:7	O
,	STRIBILD.xml:S3:10946:1	O
including	STRIBILD.xml:S3:10948:9	O
STRIBILD	STRIBILD.xml:S3:10958:8	O
.	STRIBILD.xml:S3:10966:1	O

During	STRIBILD.xml:S3:10968:6	O
the	STRIBILD.xml:S3:10975:3	O
initial	STRIBILD.xml:S3:10979:7	O
phase	STRIBILD.xml:S3:10987:5	O
of	STRIBILD.xml:S3:10993:2	O
combination	STRIBILD.xml:S3:10996:11	O
antiretroviral	STRIBILD.xml:S3:11008:14	O
treatment	STRIBILD.xml:S3:11023:9	O
,	STRIBILD.xml:S3:11032:1	O
patients	STRIBILD.xml:S3:11034:8	O
whose	STRIBILD.xml:S3:11043:5	O
immune	STRIBILD.xml:S3:11049:6	O
system	STRIBILD.xml:S3:11056:6	O
responds	STRIBILD.xml:S3:11063:8	O
may	STRIBILD.xml:S3:11072:3	B-Factor
develop	STRIBILD.xml:S3:11076:7	O
an	STRIBILD.xml:S3:11084:2	O
inflammatory	STRIBILD.xml:S3:11087:12	O
response	STRIBILD.xml:S3:11100:8	O
to	STRIBILD.xml:S3:11109:2	O
indolent	STRIBILD.xml:S3:11112:8	O
or	STRIBILD.xml:S3:11121:2	O
residual	STRIBILD.xml:S3:11124:8	B-AdverseReaction
opportunistic	STRIBILD.xml:S3:11133:13	I-AdverseReaction
infections	STRIBILD.xml:S3:11147:10	I-AdverseReaction
[	STRIBILD.xml:S3:11158:1	O
such	STRIBILD.xml:S3:11159:4	O
as	STRIBILD.xml:S3:11164:2	O
Mycobacterium	STRIBILD.xml:S3:11167:13	B-AdverseReaction
avium	STRIBILD.xml:S3:11181:5	I-AdverseReaction
infection	STRIBILD.xml:S3:11188:9	I-AdverseReaction
,	STRIBILD.xml:S3:11197:1	O
cytomegalovirus	STRIBILD.xml:S3:11199:15	B-AdverseReaction
,	STRIBILD.xml:S3:11214:1	O
Pneumocystis	STRIBILD.xml:S3:11216:12	B-AdverseReaction
jirovecii	STRIBILD.xml:S3:11229:9	I-AdverseReaction
pneumonia	STRIBILD.xml:S3:11240:9	I-AdverseReaction
(	STRIBILD.xml:S3:11250:1	O
PCP	STRIBILD.xml:S3:11251:3	B-AdverseReaction
)	STRIBILD.xml:S3:11254:1	O
,	STRIBILD.xml:S3:11255:1	O
or	STRIBILD.xml:S3:11257:2	O
tuberculosis	STRIBILD.xml:S3:11260:12	B-AdverseReaction
]	STRIBILD.xml:S3:11272:1	O
,	STRIBILD.xml:S3:11273:1	O
which	STRIBILD.xml:S3:11275:5	O
may	STRIBILD.xml:S3:11281:3	O
necessitate	STRIBILD.xml:S3:11285:11	O
further	STRIBILD.xml:S3:11297:7	O
evaluation	STRIBILD.xml:S3:11305:10	O
and	STRIBILD.xml:S3:11316:3	O
treatment	STRIBILD.xml:S3:11320:9	O
.	STRIBILD.xml:S3:11329:1	O

Autoimmune	STRIBILD.xml:S3:11335:10	B-AdverseReaction
disorders	STRIBILD.xml:S3:11346:9	I-AdverseReaction
(	STRIBILD.xml:S3:11356:1	O
such	STRIBILD.xml:S3:11357:4	O
as	STRIBILD.xml:S3:11362:2	O
Graves	STRIBILD.xml:S3:11365:6	B-AdverseReaction
disease	STRIBILD.xml:S3:11373:7	I-AdverseReaction
,	STRIBILD.xml:S3:11380:1	O
polymyositis	STRIBILD.xml:S3:11382:12	B-AdverseReaction
,	STRIBILD.xml:S3:11394:1	O
and	STRIBILD.xml:S3:11396:3	O
Guillain	STRIBILD.xml:S3:11400:8	B-AdverseReaction
-	STRIBILD.xml:S3:11408:1	I-AdverseReaction
Barre	STRIBILD.xml:S3:11409:5	I-AdverseReaction
syndrome	STRIBILD.xml:S3:11415:8	I-AdverseReaction
)	STRIBILD.xml:S3:11423:1	O
have	STRIBILD.xml:S3:11425:4	O
also	STRIBILD.xml:S3:11430:4	O
been	STRIBILD.xml:S3:11435:4	O
reported	STRIBILD.xml:S3:11440:8	O
to	STRIBILD.xml:S3:11449:2	O
occur	STRIBILD.xml:S3:11452:5	O
in	STRIBILD.xml:S3:11458:2	O
the	STRIBILD.xml:S3:11461:3	O
setting	STRIBILD.xml:S3:11465:7	O
of	STRIBILD.xml:S3:11473:2	O
immune	STRIBILD.xml:S3:11476:6	O
reconstitution	STRIBILD.xml:S3:11483:14	O
,	STRIBILD.xml:S3:11497:1	O
however	STRIBILD.xml:S3:11499:7	O
,	STRIBILD.xml:S3:11506:1	O
the	STRIBILD.xml:S3:11508:3	O
time	STRIBILD.xml:S3:11512:4	O
to	STRIBILD.xml:S3:11517:2	O
onset	STRIBILD.xml:S3:11520:5	O
is	STRIBILD.xml:S3:11526:2	O
more	STRIBILD.xml:S3:11529:4	O
variable	STRIBILD.xml:S3:11534:8	O
,	STRIBILD.xml:S3:11542:1	O
and	STRIBILD.xml:S3:11544:3	O
can	STRIBILD.xml:S3:11548:3	O
occur	STRIBILD.xml:S3:11552:5	O
many	STRIBILD.xml:S3:11558:4	O
months	STRIBILD.xml:S3:11563:6	O
after	STRIBILD.xml:S3:11570:5	O
initiation	STRIBILD.xml:S3:11576:10	O
of	STRIBILD.xml:S3:11587:2	O
treatment	STRIBILD.xml:S3:11590:9	O
.	STRIBILD.xml:S3:11599:1	O
